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In studies presented in this thesis, we used a robust cell viability assay to conduct two screens of 
commercially available plant extract libraries in search of plant extracts that can delay chronological 
aging and prolong the longevity of the budding yeast S. cerevisiae. Many of the plant extracts in the 
library have been used for centuries in traditional Chinese and other herbal medicines or the 
Mediterranean and other customary diets. None of these plant extracts, however, were previously 
tested for their ability to slow aging and extend the longevity of any organism. Our screens have 
allowed us to discover twenty-one plant extracts that significantly prolong the longevity of 
chronologically aging yeast cells that are not limited in calorie supply. We provided evidence that 
each of these longevity-extending plant extracts is a geroprotector that lowers the rate of yeast 
chronological aging and elicits a hormetic stress response. Our findings demonstrated that the 
efficiencies of aging delay and longevity extension by many of these geroprotective plant extracts 
significantly exceed those for any of the chemical compounds previously known for their abilities to 
slow aging and prolong lifespan in yeasts, filamentous fungi, nematodes, fruit flies, daphnias, 
mosquitoes, honey bees, fish, mammals and cultured human cells. Our findings also revealed that 
each of the twenty-one geroprotective plant extracts mimics in limited in calorie supply yeast cells 
 
iv 
that are not the aging-delaying, longevity-extending, stress-protecting, metabolic and physiological 
effects of a caloric restriction diet. We also demonstrated that the discovered geroprotective plant 
extracts elicit partially overlapping effects on a distinct set of longevity-defining cellular processes. 
Such processes include the coupled mitochondrial respiration, maintenance of the electrochemical 
potential across the inner mitochondrial membrane, preservation of the cellular homeostasis of 
reactive oxygen species, protection of cellular macromolecules from reactive oxygen species-
inflicted oxidative damage, maintenance of cell resistance to oxidative and thermal stresses, the 
efficiency of the lipolytic cleavage of neutral lipids deposited and stored in lipid droplets. We 
provided evidence that some of the discovered geroprotective plant extracts slow yeast chronological 
aging because they target different hubs, nodes and/or links of the longevity-defining network 
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            The budding yeast Saccharomyces cerevisiae is a unicellular eukaryote with a sequenced 
genome [1, 2]. Advanced methods for biochemical, genetic, cell biological, chemical biological, 
system biological and microfluidic dissection analyses have been developed to elucidate 
mechanisms underlying many cellular processes in this yeast [1-10]. After these mechanisms have 
been characterized by studies with yeast, they appeared to operate in the same way in many 
multicellular eukaryotes [1-4, 10-13]. Due to the availability of comprehensive molecular analyses 
and because both the chronological and replicative lifespans of S. cerevisiae are short and easy to 
measure, this yeast has been successfully used as a model organism in aging research [5-8, 11-20]. 
This research provided evidence that the basic principles and molecular mechanisms of cellular 
aging and its delay by specific genetic, dietary and chemical interventions are evolutionarily 
conserved [5-8, 11-31]. 
1.1 Two different modes of cellular aging in S. cerevisiae 
            Two different modes of aging exist in budding yeast. They are known as the replicative 
and chronological modes (Figure 1.1). These two modes of yeast aging are usually examined 
separately from each other, using robust laboratory assays [32-35]. 
            Because budding yeast reproduction occurs by asymmetric cell divisions, the replicative 
mode of yeast aging in the laboratory is measured by using a micromanipulator to remove every 
new daughter cell formed by budding [33, 35]. The total number of daughter buds that each mother 
cell can make is then calculated (Figure 1.1) [33, 35]. The replicative mode of yeast aging is 
believed to imitate the aging of mitotic human cell types capable of dividing [14, 15, 18, 36, 37]. 
However, recent findings suggest that replicative aging in yeast may also serve as a suitable model 
for the aging of post-mitotic tissues and the aging of the whole organism in the nematode 
Caenorhabditis elegans and in humans [37-39].     
            The chronological mode of yeast aging is measured as the length of time during which a 
yeast cell remains viable after an arrest of its growth and division [32, 40, 41]. A simple clonogenic 
assay is used to measure yeast chronological aging in the laboratory. This assay assesses the 
percentage of yeast cells that remain viable in liquid cultures at different time points after a cell 
population enters the stationary (ST), non-proliferative phase (Figure 1.1) [15, 34, 40]. To assess 
cell viability in the clonogenic assay, the ability of a yeast cell to form a colony after being 
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transferred from liquid culture to the surface of a solid nutrient-rich medium is measured [15, 34, 
40]. The chronological mode of yeast aging is likely to mimic the aging of post-mitotic human cell 
types incapable of dividing [14, 15, 17, 42, 43]. However, there is evidence that yeast 
chronological aging may converge with yeast replicative aging into a single aging process (44-49). 
 
 
Figure 1.1. The replicative and chronological modes of aging in the budding yeast  
Saccharomyces cerevisiae. Replicative aging is studied by measuring the maximum number of  
daughter cells (buds) that a mother cell can produce before becoming senescent (i.e., being unable  
to reproduce by budding on the surface of a fresh solid medium. Chronological aging is studied by  
measuring the length of time during which a cell remains viable (i.e., can form a colony if placed  
on the surface of a fresh solid medium) after an arrest of its growth and division. From: Consortium  
for the Determination of Public Pathways Regulating Longevity  
(http://www.uwaging.org/ellison/).  
 
1.2 Several nutrient-responsive and energy-sensing signaling pathways and protein 
kinases converge into a network that controls the rate of yeast chronological aging 
            One of the major aspects of cellular aging that been conserved in evolution is the 
integration of specific signaling pathways and protein kinases into a network; this network controls 
the rate of cellular aging and regulates the longevity of the entire organism [11, 17, 23, 28, 30, 50-
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59]. In chronologically aging yeast, this longevity regulation network integrates the following 
signaling pathways and protein kinases (Figure 1.2): 1) the pro-aging TORC1 (target of rapamycin 
complex 1) pathway [60-63], 2) the pro-aging PKA (protein kinase A) pathway [64-68], 3) the 
pro-aging PKH1/2 (Pkb-activating kinase homolog) pathway [69-73], 4) the anti-aging SNF1 
(sucrose non-fermenting) pathway [74-79], 5) the anti-aging ATG (autophagy) pathway [80-88], 
and 6) the pro-aging protein kinase Sch9, which is stimulated by the TORC1 and PKH1/2 
pathways [15, 89-94], and 7) the anti-aging protein kinase Rim15, which is inhibited by the 
TORC1, PKA and PKH1/2 pathways [15, 66, 68, 94-96]. This network of signaling pathways and 
protein kinases coordinates specific longevity-defining cellular processes. Among these processes 
are stress responses, protein synthesis in the cytosol and mitochondria, maintenance of nuclear and 
mitochondrial genomes, autophagy, mitochondrial respiration, peroxisome biogenesis, 
gluconeogenesis, lipid metabolism, glyoxylate cycle,  glycogen synthesis and degradation, and the 
synthesis of amino acids and fatty acids (Figure 1.2) [11, 15, 17, 51, 55, 59, 62, 73, 94-107]. 
Information flow along this network in yeast is controlled by such aging-delaying chemical 
compounds as resveratrol, rapamycin, caffeine, spermidine, myriocin, methionine sulfoxide, 
lithocholic acid and cryptotanshinone [11, 14, 32, 72, 84, 108-116]. 
 
 
Figure 1.2. Several nutrient-responsive and energy-sensing signaling pathways and protein 
kinases converge into a network that controls the rate of chronological aging in S. cerevisiae. 
This network coordinates longevity-defining cellular processes named in the boxes. Activation 
arrows and inhibition bars denote pro-aging processes (displayed in blue color) or anti-aging 
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processes (shown in red color). Pro-aging or anti-aging signaling pathways and protein kinases are 
displayed in blue or red color, respectively. Please see text for additional details. Abbreviations: 
ATG, autophagy; PKA, protein kinase A; PKH1/2, Pkb-activating kinase homologs 1 and 2; 
Rim15, an anti-aging protein kinase; Sch9, a pro-aging protein kinase; SNF1, sucrose non-
fermenting protein 1; TORC1, the target of rapamycin complex 1. 
 
1.3 Spatiotemporal organization and regulation of cellular processes controlled by the 
longevity signaling network define yeast chronological lifespan  
            Recent findings provided evidence that specific cellular processes occurring early in the 
life of a yeast cell, before its proliferation in a liquid medium is arrested, define the chronological 
lifespan (CLS) of this cell [15, 17, 32, 55, 59, 62, 87, 98, 100-102, 117-134]. These cellular 
processes are under the control of the longevity regulation signaling network schematically 
depicted above (Figure 1.2). These cellular processes are known for their essential roles in 
metabolism, growth and division, stress protection, cellular homeostasis maintenance, survival and 
regulated death of chronologically aging yeast [15, 17, 32, 55, 59, 62, 87, 98, 100-102, 117-134].   
1.3.1 Age-related changes in the concentrations of certain intermediates in glycolytic and 
non-glycolytic pathways of carbohydrate metabolism define the CLS of S. cerevisiae   
            Longevity of a chronologically aging yeast cell depends on the relative rates of coordinated 
metabolite flows through glycolytic and non-glycolytic pathways of carbohydrate metabolism 
early in life (i.e., when it still actively grows and divides) [6, 15, 32, 42, 43, 45, 59, 98, 123, 126-
129, 131, 135, 140-142]. It has been shown that specific mutations, diets or chemicals can prolong 
yeast CLS because they alter such coordinated metabolite flows in yeast that still actively 
proliferates [32, 42, 43, 45, 128, 129, 131, 135, 139, 140-142]. Based on these findings, our 
laboratory proposed a model to explain the mechanistic links that may exist between glycolytic 
and non-glycolytic pathways of carbohydrate metabolism, longevity-defining cellular processes, 
and the CLS of yeast. This model is shown in Figure 1.3.  
            The available data indicate that glucose (the only exogenous carbon source used in most 
laboratory studies of yeast chronological aging) enters both glycolysis and the pentose phosphate 
pathway (PPP) in yeast cells that actively proliferate during logarithmic (L) growth phase (Figure 
1.3) [32, 34, 40, 59, 128]. During the L phase, the glycolytic pathway yields pyruvate, whereas the 
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PPP produces ribose-5-phosphate and NADPH (Figure 1.3). Ribose-5-phosphate is consumed for 
nucleic acid synthesis while NADPH provides reducing equivalents needed to synthesize fatty 
acids, sterols and amino acids (Figure 1.3) [124, 126, 128, 143]. NADPH produced in the PPP also 
donates electrons to the thioredoxin and glutathione reductase systems, both of which are 
indispensable for the maintenance of cellular redox homeostasis (Figure 1.3) [126, 128, 143]. The 
thioredoxin and glutathione reductase systems are essential for the ability of a caloric restriction 
(CR) diet to prolong yeast CLS [126, 128]. This is because these two NADPH-supported systems 
protect many thiol-containing proteins in the cytosol, nucleus and mitochondria from oxidative 
damage, especially in yeast cells that advance through the L phase of cell culturing (Figure 1.3) 
[126, 128].   
            A culture of chronologically aging yeast exits the L phase of rapid growth and enters the 
diauxic (D) and then post-diauxic (PD) phases of slow growth when it consumes glucose 
exogenously added to the medium at the beginning of cell culturing [30, 32, 34, 138]. Pyruvate, 
the final product of the glycolytic glucose metabolism, can enter several carbon metabolism 
pathways during D and PD phases of culturing. As described below, all these pathways yield 
metabolites playing essential roles in regulating cellular processes that define the longevity of 
chronologically aging yeast [6, 15, 32, 42, 43, 45, 59, 98, 119, 123, 127-129, 131, 135, 136, 138, 
139, 140].     
            One of these pathways of carbon metabolism is fermentation, which generates ethanol 
and/or acetic acid (depending on the type of growth medium and aeration conditions used for cell 
culturing) in the cytosol of yeast cells that advance through D and PD phases of culturing (Figure 
1.3) [6, 15, 42, 43, 45, 32, 119, 135, 138, 140]. The steady-state concentration of ethanol is defined 
by the relative enzymatic activities of Adh1p (an enzyme involved in ethanol synthesis) and Adh2p 
(an enzyme involved in the oxidative degradation of ethanol) (Figure 1.3) [15, 119, 135, 138, 140]. 
The steady-state concentration of ethanol is an essential contributor to longevity regulation of 
chronologically aging yeast because this product of glucose fermentation inhibits the β-oxidation 
of fatty acids in peroxisomes, which is an anti-aging process that extends yeast CLS (Figure 1.3) 
[32, 110].           
            Another product of glucose fermentation in the cytosol of yeast cells that advance through 
D and PD phases of culturing is acetic acid, a product of the Ald6p-dependent acetaldehyde 
dehydrogenase reaction. The steady-state concentration of acetic acid contributes to longevity 
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regulation of chronologically aging yeast because acetic acid promotes an age-related mode of 
apoptotic programmed cell death (PCD), a process that shortens yeast CLS (Figure 1.3) [15, 42, 
43, 45, 141]. Acetic acid is not the only product of the Ald6p-dependent acetaldehyde 
dehydrogenase reaction. NADPH is another product of this enzymatic reaction (Figure 1.3) [124, 
128, 143]. Like the NADPH generated in the PPP, NADPH produced in the Ald6p-dependent 
reaction allows the thioredoxin and glutathione reductase systems to protect many thiol-containing 
proteins from oxidative damage. Because such NADPH-driven protection enables the maintenance 
of cellular redox homeostasis, it is an essential longevity assurance process (Figure 1.3) [126, 128, 
143].    
            Acetic acid formed in the cytosol as a product of glucose fermentation can be further 
converted to acetyl-CoA in an enzymatic reaction catalyzed by Acs2p, a protein that resides in the 
cytosol and nucleus (Figure 1.3) [139, 143]. A nuclear pool of acetyl-CoA generated in the Acs2p-
dependent reaction can be used for the hyperacetylation of histone H3 [139]. Because such 
hyperacetylation selectively inhibits transcription of the ATG5, ATG7, ATG11 and ATG14 genes 
(all of which encode proteins involved in the anti-aging process of autophagy), it shortens yeast 
CLS (Figure 1.3) [139].  
            In addition to being fermented to ethanol and/or acetic acid, glucose fermentation can also 
yield glycerol in yeast cells that advance through D and PD phases of culturing [119]. It has been 
proposed that glucose fermentation to glycerol in these cells and glycerol itself may extend yeast 
CLS through three different mechanisms. First, glucose fermentation to glycerol slows the flow of 
metabolites into glucose fermentation to ethanol and/or acetic acid, thus lowering the 
concentrations of these two glucose fermentation products exhibiting strong pro-aging potential 
(Figure 1.3) [42, 119]. Because glucose fermentation to glycerol decelerates the formation of 
ethanol and acetic acid, it is called a “phantom carbon source” [119]. Second, glycerol is known 
as a potent inducer of yeast cell resistance to chronic oxidative, thermal and osmotic stresses [119]. 
Such stress-protecting ability of glycerol may also contribute to the extension of yeast CLS (Figure 
1.3) [119]. Third, it has been proposed that glucose fermentation to glycerol may help to maintain 
an NAD+/NADH ratio at a level that allows the extension of yeast CLS (Figure 1.3) [119].   
            Pyruvate, the final product of the glycolytic glucose metabolism, can also enter the 
gluconeogenesis pathway that yields glucose (Figure 1.3) [32, 101, 125, 140]. The pool of glucose 
formed gluconeogenetically can be used for the synthesis of trehalose (Figure 1.3) [32, 101, 125, 
8 
 
140]. In yeast cells that advance through the D and PD phases of culturing, trehalose prolongs 
yeast CLS because it enhances the maintenance of cellular proteostasis (see next section of the 
Thesis) [32, 101]. In contrast, in yeast cells that enter the ST phase of culturing, trehalose shortens 
yeast CLS because it interferes with the refolding of misfolded, partially folded and unfolded 
cellular proteins (see next section of the Thesis) [32, 101]. 
 
Figure 1.3. The longevity of chronologically aging S. cerevisiae depends on the intensity of 
metabolic flow through glycolytic and non-glycolytic pathways of carbohydrate metabolism. 
A model shown here explains how glycolytic and non-glycolytic pathways of glucose metabolism 
influence specific cellular processes essential for longevity assurance in chronologically “young” 
(proliferating) and chronologically “old” (non-proliferating) yeast. Activation arrows and 
inhibition bars signify pro-aging processes (shown in blue color) or anti-aging processes 
(presented in red color). Please see text for additional details. Ac-CoA, acetyl-CoA; DHAP, 
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dihydroxyacetone phosphate; EtOH, ethanol; GA-3-P, glyceraldehyde-3-phosphate; GLR, 
glutathione reductase; PCD, programmed cell death; TCA, tricarboxylic acid; TORC1, the target 
of rapamycin complex 1; TRR, thioredoxin reductase. 
 
            In addition to the essential roles that pyruvate, acetaldehyde and acetic acid play in 
regulating yeast longevity by affecting some cellular processes in the cytosol, they also define 
yeast CLS because they influence several longevity-defining processes confined to or coordinated 
by mitochondria (Figure 1.3).  
            As described below, the mitochondrial tricarboxylic acid (TCA) cycle is the central hub 
coordinating these processes.  
            The malate and isocitrate intermediates of the TCA cycle are the substrates for the Mae1p- 
and Idp1p-dependent (respectively) synthesis of NADPH in mitochondria (Figure 1.3) [124, 128, 
143]. The acetaldehyde and NADP+ pools in mitochondria also serve as the substrates for NADPH 
synthesis in these organelles via Ald4p-dependent and Pos5p-dependent (respectively) reactions 
(Figure 1.3) [124, 128, 143]. After being formed in mitochondria, NADPH is exported into the 
cytosol where it can be used (akin to the cytosolic pool of NADPH generated in the PPP and the 
Ald6p-dependent reaction) to help the thioredoxin and glutathione reductase systems in sustaining 
cellular redox homeostasis and extending yeast CLS (see above in my Thesis).  
            Oxaloacetate and α-ketoglutarate (two other intermediates of the mitochondrial TCA cycle) 
are the substrates for the synthesis of amino acids in mitochondria (Figure 1.3) [124, 143, 144]. 
Following their synthesis in mitochondria and exit into the cytosol, some of these amino acids (i.e., 
aspartate, asparagine, glutamate and glutamine) stimulate the protein kinase activity of TORC1 on 
the surface of vacuoles (Figure 1.3) [55, 61, 94, 96, 144-146]. After being stimulated by the amino 
acids, TORC1 shortens yeast CLS because it phosphorylates and alters the activities of many 
proteins implicated in longevity-defining cellular processes (Figure 1.3). The following four 
longevity-shortening effects of such TORC1-dependent protein phosphorylation are known: 1) the 
pro-aging process of protein synthesis in the cytosol is activated, 2) the anti-aging process of 
autophagy in vacuoles is inhibited, 3) the anti-aging process of transcription of many nuclear genes 
involved in stress protection is also inhibited, and 4) the anti-aging process of mitochondrial 
protein synthesis is inhibited as well (Figure 1.3) [53, 61, 62, 94, 96, 118, 144-146].      
            In sum, the intensity of metabolic flow through glycolytic and non-glycolytic pathways of 
carbohydrate metabolism defines the longevity of chronologically aging S. cerevisiae because it 
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orchestrates many pro-aging and anti-aging cellular processes in various cellular locations. The 
relative impacts of the critical intermediates of these metabolic pathways in regulating longevity 
of chronologically aging budding yeast remain to be determined.  
1.3.2 The intracellular concentration of trehalose is an essential contributor to longevity 
regulation in S. cerevisiae because trehalose controls cellular protein homeostasis 
            A body of evidence indicates that trehalose is indispensable for sustaining cellular protein 
homeostasis (proteostasis) because this non-reducing disaccharide regulates protein folding, 
misfolding, unfolding, refolding, oxidative damage, solubility and aggregation in vivo and in vitro 
[101, 147-151].  
          The involvement of trehalose in cellular proteostasis maintenance underlies its essential 
roles in regulating the longevity of chronologically aging budding yeast. It needs to be emphasized 
that trehalose regulates yeast CLS differently in chronologically “young” and chronologically 
“old” yeast (Figure 1.4).   
            Trehalose has an anti-aging role in chronologically “young” yeast cells that advance 
through the D and PD phases of culturing because it is present at the concentrations that elicit the 
following three effects on cellular proteostasis. First, trehalose binding to newly formed cellular 
proteins increases the stability of their native folding conformations and slows their conversion 
into abnormally folded and/or unfolded protein forms (Figure 1.4) [32, 101]. Second, trehalose 
suppresses the formation of insoluble protein aggregates because it protects the extensive regions 
of hydrophobic side chain amino acids from the aqueous environment; such regions can be found 
in misfolded, partially folded and unfolded proteins (Figure 1.4) [32, 101]. Third, trehalose 
indirectly inhibits the aggregation of oxidatively damaged proteins because it prevents the 
oxidative damage of abnormally folded proteins (Figure 1.4) [32, 101].   
            Trehalose has a pro-aging role in chronologically “old” yeast cells that enter the ST (non-
proliferative) phase of culturing because it suppresses the chaperone-assisted refolding of 
misfolded, partially folded and unfolded proteins (Figure 1.4) [101, 152-155]. Such a pro-aging 
role of trehalose in chronologically “old” yeast is due to its high affinity to exposed stretches of 
hydrophobic amino acid residues that are abundant in aberrantly folded proteins. Because trehalose 
binds to these stretches of hydrophobic amino acid residues, it prevents their interaction with 
molecular chaperones needed for protein folding (Figure 1.4) [101, 152-155]. 
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            In sum, these findings provide evidence that, depending on the trehalose concentration in 
chronologically aging yeast cells, it can play a dual role in regulating longevity. 
 
 
Figure 1.4. Trehalose contributes to the chronological aging of S. cerevisiae because trehalose 
controls cellular proteostasis. A model for molecular mechanisms through which trehalose 
controls the process of cellular aging in yeast because it regulates protein folding, misfolding, 
unfolding, refolding, oxidative damage, solubility and aggregation. Trehalose controls cellular 
aging differently in chronologically “young” and chronologically “old” yeast. Activation arrows 
and inhibition bars signify pro-aging processes (shown in blue color) or anti-aging processes 
(presented in red color). Please see text for additional details.  
1.3.3 Mitochondrial functionality and reactive oxygen species (ROS) production in 
mitochondria contribute to longevity regulation in S. cerevisiae because they orchestrate 
many cellular processes outside of these organelles 
            Growing evidence supports the notion that the functional state of mitochondria and their 
ROS producing capacity in chronologically “young” yeast cells advancing through D and PD 
phases of culturing define yeast CLS [15, 32, 41, 62, 87, 102, 103, 110, 117, 118, 120-122, 129-
132, 134, 156-158]. Two major aspects of mitochondrial functionality contribute to longevity 
regulation in budding yeast. They include the capability of electron transport chain (ETC) coupled 
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to ATP synthesis [15, 32, 62, 87, 102, 103, 110, 117, 118, 125, 133, 134, 157] and the value of 
mitochondrial membrane potential across the inner mitochondrial membrane (IMM), which 
depends on the efficiency of the ETC-dependent proton exchange between the matrix to the 
intermembrane space (IMS) [15, 32, 62, 87, 102, 110, 118, 122]. Mitochondrial ROS producing 
capacity, which also contributes to longevity regulation in budding yeast, is defined by the extent 
of coupling between the ETC and oxidative phosphorylation (OXPHOS) system in mitochondria 
[62, 118].  
            Based on the effects on the mitochondrial ETC, OXPHOS system and ROS production of 
certain longevity-extending mutations, dietary regimens and chemicals in chronologically “young” 
yeast cells [15, 32, 41, 62, 87, 102, 103, 110, 117, 118, 120-122, 125, 130-134, 156-158], a model 
can be proposed to explain how coupled mitochondrial respiration, mitochondrial membrane 
potential maintenance and mitochondrial ROS production in these cells define yeast CLS. The 
model is shown in Figure 1.5. 
            According to the model, the capacities of the above mitochondrial processes in 
chronologically “young” yeast cells cultured under non-CR conditions on 2% glucose are below a 
critical threshold; as a result, these cells acquire and sustain a pro-aging pattern of longevity-
defining processes (Figure 1.5; these capacities are shown in green) [32, 120, 125, 133, 134]. The 
model also posits that the capacities of these mitochondrial processes in chronologically “young” 
yeast cells cultured under so-called “mild” CR conditions on 0.5% glucose are above the critical 
threshold; because of that, these cells develop and maintain an anti-aging pattern of longevity-
defining processes taking place not only inside of mitochondria but also outside of these organelles 
(Figure 1.5; these capacities are shown in red color) [32, 62, 87, 102, 103, 110, 118, 122, 125, 
134]. The model further suggests that the capacities of coupled mitochondrial respiration, 
mitochondrial membrane potential maintenance and mitochondrial ROS production significantly 
exceed the critical threshold in chronologically “young” yeast cells cultured under so-called 
“strong” CR conditions on 0.2% glucose; consequently, the longevity of these cells is lower than 
that of cells cultured under mild CR conditions (Figure 1.5; these capacities are shown in blue 
color) [32, 102, 103, 110]. 
            Five major longevity regulation pathways control the capacities of coupled mitochondrial 
respiration, mitochondrial membrane potential maintenance and mitochondrial ROS production in 
chronologically “young” yeast cells (Figure 1.5). Each of these pathways is described below. The 
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nutrient-responsive and energy-sensing TOR signaling pathway uses the rapamycin-sensitive 
protein kinase Tor1p to suppress the mitochondrial synthesis of the OXPHOS enzymes encoded 
by mitochondrial DNA (mtDNA) (Figure 1.5) [62, 110, 118, 122, 125]. A CR pathway inhibits 
Tor1p and also operates in a Tor1p-independent manner to sustain the coupled mitochondrial 
respiration, mitochondrial membrane potential and mitochondrial ROS at an optimal for longevity 
extension level in chronologically “young” yeast cells (Figure 1.5) [15, 32, 62, 110, 118, 119, 122, 
125, 138]. The mitochondrial base-excision repair enzyme Ntg1p orchestrates a pathway for the 
maintenance of mitochondrial genome integrity (Figure 1.5) [158]. The receptor protein Atg32p 
on the mitochondrial surface for selective autophagic degradation of aged, dysfunctional or 
damaged mitochondria is a crucial player in the mitophagy pathway of mitochondrial quality 
control (Figure 1.5) [87]. Exogenously added lithocholic acid (LCA) enters yeast cells [102, 103], 
amasses mainly in the IMM and initiates a pathway for specific, longevity-extending remodeling 
of the mitochondrial membrane lipidome (Figure 1.5) [102, 103]. The TOR and CR pathways [15, 
32, 62, 110, 118, 119, 122, 125, 138], as well as the TOR and Ntg1p pathways [158], partially 
overlap and act together to orchestrate coordinated control of the coupled mitochondrial 
respiration, mitochondrial membrane potential maintenance and mitochondrial ROS production in 
chronologically “young” yeast cells (Figure 1.5). This is in contrast to a CR pathway and an LCA-
dependent pathway for mitochondrial membrane lipidome remodeling [102, 103], as well as with 
a CR pathway and the Ntg1p-dependent pathway [158]; these pathways do not overlap and act 
independently to elicit a synergistic stimulation of the above mitochondrial processes.  
            The efficiency of the coupled mitochondrial respiration, the value of mitochondrial 
membrane potential and the concentration of mitochondrially produced ROS in chronologically 
“young” yeast cells control many “downstream” longevity-defining processes in several cellular 
locations (Figure 1.5). These processes are essential contributors to longevity regulation in 
chronologically aging yeast and are described below. One of the downstream processes is the 
maintenance of the homeostasis of trehalose, which (as described above in my Thesis) sustains 
cellular proteostasis in both chronologically “young” and chronologically “old” yeast cells (Figure 
1.5) [32, 101]. The maintenance of the high concentrations of glycogen, a reserve carbohydrate, in 
chronologically “young” and “old” yeast cells under CR conditions [32] is another downstream 
process (Figure 1.5). The maintenance of neutral lipid homeostasis within the endoplasmic 
reticulum (ER) and lipid droplets (LD) [32, 110, 159, 160] is also a downstream process (Figure 
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1.5). Downstream processes include fatty acid oxidation in peroxisomes (Figure 1.5) [32, 110, 159, 
160] 
 
Figure 1.5. A model for how the coupled mitochondrial respiration, mitochondrial 
membrane potential maintenance and mitochondrial ROS production in chronologically 
“young” yeast cells that advance through D and PD phases of culturing define their CLS. 
Activation arrows and inhibition bars denote pro-aging processes (shown in blue color) or anti-
aging processes (shown in red color). Please see text for additional details. CR, caloric restriction; 
D, diauxic growth phase; DAG, diacylglycerol; EtOH, ethanol; FFA, non-esterified (“free”) fatty 
acids; IMM, inner mitochondrial membrane; L, logarithmic growth phase; LCA, lithocholic acid; 
LD, lipid droplet; PD, post-diauxic growth phase; PS, phosphatidylserine; ROS, reactive oxygen 




Another downstream process is the maintenance of the homeostasis of non-esterified (“free”) fatty 
acids (FFA) and diacylglycerol (DAG), both of which cause an age-related form of the liponecrotic 
PCD in chronologically aging yeast (Figure 1.5) [32, 110, 161]. Downstream processes include 
the regulation of intracellular ethanol concentration by coordinating the relative rates of glycolysis 
and gluconeogenesis (see above in my Thesis) (Figure 1.5) [32, 110]. The mitochondrial 
translation is a downstream process that contributes to longevity assurance in chronologically 
aging yeast (Figure 1.5) [32, 62, 118, 122]. Another downstream process is the maintenance of a 
proper balance between the fusion of mitochondria and their fission; this process is an essential 
contributor to preserving mitochondrial size and number, sustaining the extended length of 
mitochondrial cristae, and synthesizing elevated levels of ATP (Figure 1.5) [32, 87, 102, 110]. 
Downstream processes include the establishment and maintenance of cell resistance to chronic 
oxidative, thermal and osmotic stresses (Figure 1.5) [15, 32, 62, 100, 110, 122, 125, 138]. Another 
downstream process is an age-related commitment to apoptotic PCD through the fragmentation of 
a tubular mitochondrial network, the exit of cytochrome c from fragmented mitochondria into the 
cytosol and phosphatidylserine (PS) externalization within the plasma membrane (Figure 1.5) [32, 
110]. Among downstream processes are also the development and maintenance of cell resistance 
to age-related modes of apoptotic and liponecrotic PCD in response to a rise in the concentrations 
of hydrogen peroxide (a form of ROS) or palmitoleic acid, respectively (Figure 1.5) [32, 100, 110, 
161]. 
            Mitochondrially generated ROS in chronologically “young” yeast cells contribute to 
longevity regulation via two mitochondria-to-nucleus retrograde signaling pathways [95, 99, 130, 
132, 158, 162]. One of these pathways of retrograde signaling consists in the ability of 
mitochondrially generated ROS, if present in hormetic concentrations, to activate transcriptional 
factors Gis1p, Msn2p and Msn4p in the nucleus; once activated by ROS, Gis1p, Msn2p and Msn4p 
stimulate transcription of many genes essential for stress resistance, stationary phase survival, 
carbohydrate metabolism, nutrient sensing and longevity assurance [95, 99, 162]. In another 
pathway of retrograde signaling, hormetic concentrations of mitochondrially produced ROS 
promote the ability of the DNA damage response (DDR) kinase Tel1p to phosphorylate and 
activate the DDR kinase Rad53p [158]. After being activated by the Tel1p-dependent 
phosphorylation, Rad53p phosphorylates and inactivates the histone demethylase Rph1p bound to 
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sub-telomeric chromatin regions [158]. The resulting inactivation of Rph1p suppresses the 
transcription of sub-telomeric chromatin regions, lowers telomeric DNA damage and eventually 
prolongs the longevity of chronologically aging yeast [158]. 
           In sum, these findings imply that the coupled mitochondrial respiration, mitochondrial 
membrane potential maintenance and mitochondrial ROS production in chronologically “young” 
cells that advance through D and PD phases of culturing play essential roles in regulating longevity 
of chronologically aging yeast. 
1.3.4 Peroxisomal protein import in chronologically aging yeast affects the longevity-
defining processes outside of peroxisomes, thus contributing to longevity regulation in S. 
cerevisiae  
            The import of proteins into the peroxisome of a eukaryotic cell is known to depend on the 
cytosolic shuttling receptor Pex5p for proteins containing the peroxisomal targeting signal type 1 
(PTS1) and on the cytosolic shuttling receptor Pex7p for proteins containing PTS2 [163-165]. It 
has been shown that the efficiency with which proteins are imported into the peroxisome in yeast 
and other eukaryotes declines with the chronological age of their cells [59, 123, 166, 167]. It has 
also been shown that the efficiency of peroxisomal protein import influences two types of cellular 
processes, namely: 1) fatty acid oxidation, hydrogen peroxide formation and decomposition, and 
anaplerotic metabolism in the peroxisome and 2) the unidirectional and bidirectional types of flow 
of soluble metabolites and lipids between the peroxisome and other cellular compartments [55, 59, 
123, 127, 168-172]. The available data also indicate that the unidirectional and bidirectional 
communications between the peroxisome and several other cellular compartments contribute to 
longevity regulation because they affect some longevity-defining processes taking place in these 
other compartments [55, 59, 98, 123, 127, 168-173]. 
            Based on these findings, our laboratory proposed a model to explain the mechanistic links 
that may exist between the age-related efficiency of peroxisomal protein import, peroxisomal 
functionality, communications between peroxisomes and other cellular compartments, and 
longevity of chronologically aging S. cerevisiae.  This model is shown in Figure 1.6.    
            According to the model, three groups of proteins are efficiently imported into peroxisomes 
within chronologically “young” yeast cells that advance through D and PD phases of culturing. 
These three groups of proteins are described below. First, enzymes that catalyze the decomposition 
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of hydrogen peroxide and other ROS within the peroxisome; these enzymes include the catalase 
Cta1p and peroxiredoxin Pmp20p [55, 59, 110, 123, 159, 160, 174]. Second, enzymes involved in 
the β-oxidation of fatty acids to acetyl-CoA within the peroxisome; these enzymes include the 
fatty-acyl coenzyme A oxidase Fox1p, the 3-hydroxyacyl-CoA dehydrogenase and enoyl-CoA 
hydratase Fox2p, and the 3-ketoacyl-CoA thiolase Fox3p [55, 59, 110, 123, 159, 160, 174]. Third, 
enzymes catalyzing the anaplerotic conversion of acetyl-CoA to citrate and acetyl-carnitine to 
facilitate the replenishment of TCA cycle intermediates destined for mitochondria; these enzymes 
include the citrate synthase Cit2p and acetyl-carnitine synthase Cat2p (respectively) [55, 59, 110, 
123, 159, 160, 174]. 
            The model further posits that the efficient peroxisomal import of all these enzymes within 
chronologically “young” yeast cells promotes three groups of longevity-extending processes 
confined to peroxisomes and other cellular compartments. These three groups of longevity-
extending processes are described below. First, the extent of oxidative damage to peroxisomal 
proteins and membrane lipids declines (Figure 1.6) [32, 55, 59, 123, 127, 160]. Second, so-called 
stress-response hormesis is established because chronologically “young” yeast cells can sustain 
peroxisomally produced hydrogen peroxide at a threshold concentration that is insufficient to elicit 
oxidative damage to cellular molecules but sufficient to activate transcription of nuclear genes 
essential for cell survival (Figure 1.6) [32, 55, 59, 123, 127, 160]. Third, the TCA cycle and ETC 
in mitochondria are stimulated to help chronologically “young” cells in sustaining mitochondrially 
produced ROS at a non-toxic level that can promote transcription of nuclear genes coding for many 
stress-protecting proteins (Figure 1.6) [32, 55, 59, 123, 127, 160]. 
            The model also envisions that the peroxisomal import of the polyamine oxidase Fms1p, an 
enzyme involved in the synthesis of the natural polyamine called spermidine [111, 175], may 
contribute to the ability of the peroxisome to stimulate pro-longevity processes outside of this 
organelle (Figure 1.6). Spermidine prolongs the longevity of chronologically aging yeast because 
it activates autophagy, a pro-longevity cytoprotective process of degrading damaged and 
dysfunctional macromolecules and organelles within the vacuole [83, 84, 176]. It has been shown 
that the intracellular concentration of spermidine in chronologically “young” yeast is substantially 
higher than that in chronologically “old” yeast [83]. Therefore, the model suggests that Fms1p 
import into peroxisomes of chronologically “young” yeast is more efficient than that into 
peroxisomes of chronologically “old” yeast (Figure 1.6). As a result, the chronologically “young” 
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yeast cells can develop and maintain a cellular pattern that allows them to age slower and survive 
longer because they more proficiently eliminate damaged and dysfunctional macromolecules and 
organelles (Figure 1.6).       
            According to the model, the Pex5p- and Pex7p-dependent peroxisomal import of Cta1p, 
Pmp20p, Fox1p, Fox2p, Fox3p, Cit2p, Cat2p and Fms1p deteriorates within chronologically “old” 
yeast cells (Figure 1.6). Because of that, four groups of longevity-shortening processes are 
accelerated in these cells. These four groups of longevity-shortening processes are described 
below. First, the intracellular concentration of peroxisomally produced hydrogen peroxide is 
increased above a cytotoxic level, thereby promoting the oxidative damage to cellular 
macromolecules (Figure 1.6) [32, 55, 59, 98, 110, 123, 127, 136, 159-161, 177-183]. Second, the 
efficiency of peroxisomal oxidation of fatty acids originated from the neutral lipids triacylglycerols 
(TAG) that are synthesized in the ER and deposited within LD is decreased; as a result, the 
concentrations of FFA and DAG rise above a critical threshold to cause an age-related form of 
liponecrotic PCD (Figure 1.6) [32, 55, 59, 98, 110, 123, 127, 136, 159-161, 177-183]. Third, the 
replenishment of TCA cycle intermediates in peroxisomes intended for the TCA cycle in 
mitochondria deteriorates; because of that, the mitochondrial ETC and electrochemical potential 
across the IMM decline, mitochondrial network undergoes fragmentation, cytochrome c and other 
pro-apoptotic proteins exit fragmented mitochondria, and an age-related form of apoptotic PCD is 
stimulated (Figure 1.6) [32, 55, 59, 98, 110, 123, 127, 136, 159-161, 177-183]. Fourth, the 
peroxisome-dependent synthesis of spermidine is decreased, thus attenuating the pro-longevity 
process of autophagy (Figure 1.6) [83, 84, 111,175, 176]. 
            The model also reflects that chronologically “young” and “old” yeast cells cultured in a 
nutrient-rich medium under longevity-shortening non-CR conditions amass ethanol, a product of 
glucose fermentation [32, 136]. Ethanol has been shown to slow down Fox1p-, Fox2p- and Fox3p-
dependent peroxisomal oxidation of FFA because it represses the synthesis of Fox1p, Fox2p and 
Fox3p (Figure 1.6) [174, 184]. The ethanol-dependent decline in peroxisomal oxidation of FFA 
under non-CR conditions elicits the following two responses. First, it suppresses the pro-longevity 
process of the replenishment of TCA cycle intermediates intended for mitochondria because it 
decelerates peroxisomal oxidation of FFA to acetyl-CoA, thus weakening the anaplerotic 
conversion of acetyl-CoA to citrate and acetyl-carnitine (Figure 1.6) [59, 123, 174, 184]. Second, 
it promotes an age-related form of liponecrotic PCD because it causes a buildup of the non-
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oxidized FFA and DAG inducers of such PCD (Figure 1.6) [32, 59, 98, 110, 123, 136, 161]. None 
of these effects of ethanol has been observed in chronologically “young” or chronologically “old” 
yeast cells cultured under longevity-extending CR conditions because these cells do not amass 
ethanol (Figure 1.6) [32, 59, 98, 110, 123, 136, 161]. Thus, the inability of these cells to accumulate 
ethanol is an essential contributing factor to yeast CLS extension by CR. 
 
Figure 1.6. A model for how the age-related efficiency of peroxisomal protein import in 
chronologically aging yeast cells define their CLS by influencing a distinct set of processes 
inside and outside of peroxisomes. Activation arrows and inhibition bars signify pro-aging 
processes (shown in blue color) or anti-aging processes (shown in red color). Please see text for 
additional details. Ac-Carnitine, acetyl-carnitine; Ac-CoA, acetyl-CoA; DAG, diacylglycerol; ER, 
endoplasmic reticulum; ETC, electron transport chain; EtOH, ethanol; FFA, non-esterified (ʺfreeʺ) 
fatty acids; LD, lipid droplet; ROS, reactive oxygen species; TAG, triacylglycerols; TCA, 
tricarboxylic acid cycle; ΔΨm, the electrochemical potential across the inner mitochondrial 
membrane. 
 
            Collectively, these findings provide evidence that the upregulated peroxisomal protein 
import in chronologically “young” cells that advance through D and PD phases of culturing play 
essential roles in prolonging the longevity of chronologically aging yeast.  
1.4 Spatiotemporal dynamics of intercompartmental communications define the 
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chronology of cellular aging in yeast 
            New evidence implies that various organelle-organelle and organelle-cytosol 
communications play essential roles in chronological aging of S. cerevisiae. The molecular 
mechanisms underlying the vital roles of intercompartmental communications in yeast 
chronological aging have begun to emerge. The scope of this section of my Thesis is to analyze 
recent progress in understanding such mechanisms critically. My analysis suggests a model for 
how temporally and spatially coordinated movements of specific metabolites between various 
cellular compartments impact yeast chronological aging. In my model, diverse changes in these 
key metabolites are restricted to critical longevity-defining periods of chronological lifespan 
(CLS). In each of these periods, a limited set of proteins responds to such changes of the 
metabolites by altering the rate and efficiency of a particular cellular process essential for longevity 
regulation. Spatiotemporal dynamics of alterations in these longevity-defining cellular processes 
orchestrate the development and maintenance of a pro- or anti-aging cellular pattern. 
            Recent studies have revealed that various intercompartmental communications (i.e., 
organelle-organelle and organelle-cytosol) play essential roles in chronological aging of yeast 
cultured in media with glucose as the only carbon source [55, 98, 107, 123]. A model for how such 
communications impact yeast chronological aging is depicted schematically in Figure 1.7. The 
model includes the notion that the longevity-defining intercompartmental communications involve 
unidirectional and bidirectional movements of a distinct set of metabolites between mitochondria 
and the cytosol, mitochondria and peroxisomes, mitochondria and the nucleus, peroxisomes and 
the nucleus, mitochondria and vacuoles, the ER and the plasma membrane (PM), the ER and the 
cytosol, the PM and the cytosol, the PM and vacuoles, the ER and LD, and LD and peroxisomes 
(Figure 1.7). The intracellular concentrations of such metabolites and/or the rates of their 
movement between cellular compartments undergo age-related changes. In the proposed model, 
different changes of the key metabolites are temporally restricted to several longevity-defining 
periods; the term “checkpoints” has been coined to describe these critical periods in yeast CLS 
(Figure 1.7).  [17, 100, 101, 106]. Most of these checkpoints occur early in the life of 
chronologically aging yeast cells, during D and PD growth phases. Some of the checkpoints are 
late-life checkpoints that exist in the non-proliferative ST phase of culturing. At each of these 
checkpoints, the changes of the key metabolites are detected by a distinct set of checkpoint-specific 
proteins called “master regulators” [17, 185]. The model further posits that each of these master 
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regulators can respond to a change of the detected key metabolite by altering the rate and efficiency 
of a certain cellular process essential for longevity regulation (Figure 1.7). By establishing the rates 
and efficiencies of different longevity-defining cellular processes throughout the CLS, the 
checkpoint-specific master regulators set up a pro- or anti-aging cellular pattern [17, 185]. 
            At checkpoint 1, which exists early in the D growth phase, two oxidative reactions of the 
pentose phosphate pathway (PPP) in the cytosol and four enzymatic reactions in mitochondria 
create NADPH (Figure 1.7) [17, 124, 126, 128]. NADPH provides reducing equivalents for the 
synthesis of amino acids, fatty acids, and sterols [124, 143]. NADPH is also a donor of electrons 
for thioredoxin and glutathione reductase systems. As mentioned above, both these reductase 
systems contribute to the establishment and maintenance of an anti-aging cellular pattern because 
they protect many thiol-containing proteins from oxidative damage; such thiol-containing proteins 
reside in the nucleus, mitochondria and cytosol (Figure 1.7) [126, 128]. 
            Glycerol is produced by glucose fermentation in the cytosol [143]. At checkpoint 2, 
glycerol plays an essential role in the establishment and maintenance of an anti-aging cellular 
pattern by affecting the following three cellular processes: 1) glucose fermentation to glycerol 
weakens its fermentation to ethanol and acetic acid, both known to be pro-aging metabolites in 
yeast, 2) glucose fermentation to glycerol enables to sustain the NAD+/NADH ratio that slows 
yeast chronological aging, and 3) glycerol increases resistance to acute oxidative, thermal, and 
osmotic stresses that accelerate yeast chronological aging (Figure 1.7) [17, 42, 119]. 
            As mentioned above, the non-reducing disaccharide trehalose is synthesized from glucose 
in the cytosol of chronologically “young” yeast cells that advance through D and PD phases of 
culturing [32, 101]. The rate of such synthesis sustains cellular trehalose homeostasis and is 
modulated by the efficiency of coupled mitochondrial respiration [125]. The effectiveness of such 
respiration is, in turn, modulated by the rate of peroxisome-to-mitochondria transfer of citrate and 
acetyl-carnitine [17, 59, 174, 186, 187]. At checkpoint 3, trehalose is essential for maintaining an 
anti-aging pattern of cellular proteostasis because it attenuates the misfolding, aggregation and 
oxidative damage of newly synthesized polypeptides (Figure 1.7) [17, 32, 101]. 
            During D and PD growth phases, the intracellular concentration of hydrogen peroxide 
(H2O2) in chronologically aging yeast depends on the efficiencies with which this major ROS is 
produced by and released from mitochondria and peroxisomes [110, 130, 132, 158]. If the 
concentration of H2O2 at checkpoint 4 is sustained at a sub-lethal (“hormetic”) level, it elicits the 
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establishment of an anti-aging cellular pattern by stimulating the master regulators Gis1, Msn2, 
and Msn4. In the nucleus, these three transcriptional factors activate expression of genes that 
encode proteins involved in heat-shock and DNA-damage responses, ROS decomposition, cell 
cycle progression and transition to quiescence, autophagy, maintenance of cell wall integrity, 
trehalose synthesis and degradation, glycogen synthesis and degradation, glycolysis and 
gluconeogenesis, the pentose phosphate pathway, glycerol and amino acid synthesis, ergosterol 
synthesis, maintenance of glutathione and thioredoxin homeostasis, methylglyoxal detoxification, 
maintenance of heavy metal ion homeostasis, potassium transport, and mitochondrial electron 
transport; these proteins are needed for resistance to thermal, oxidative, osmotic, low pH, carbon 
source starvation, sorbic acid, high ethanol concentration, and DNA-damage stresses (Figure 1.7) 
[66, 188-191]. 
            At checkpoint 5, H2O2 produced by and released from mitochondria and peroxisomes 
modulates a signaling pathway, which includes the DNA damage response kinases Tel1 and Rad53 
(both of which are anti-aging master regulators) and the histone demethylase Rph1 (a pro-aging 
master regulator) (Figure 1.7) [130]. If the concentration of H2O2 at this checkpoint is sustained at 
a hormetic level, it stimulates the Tel1-dependent phosphorylation/activation of Rad53, which in 
response phosphorylates and inactivates Rph1 (Figure 1.7) [132, 158]. The resulting inactivation 
of Rph1 establishes an anti-aging cellular pattern because it allows to attenuate the Rph1-
dependent transcription of sub-telomeric chromatin regions in the nucleus, thereby lessening the 
extent of telomeric DNA damage (Figure 1.7) [130, 132, 158].  
            During D and PD growth phases, the amino acids aspartate, asparagine, glutamate, and 
glutamine are synthesized from intermediates of the TCA cycle in mitochondria [124, 143]. After 
being released into the cytosol, these amino acids stimulate protein kinase (PK) activity of the 
TOR complex 1 (TORC1) at the surface of vacuoles (Figure 1.7) [61, 94, 96, 144, 145, 146]. 
Following its activation, TORC1 acts as a pro-aging master regulator at checkpoint 6 by 
phosphorylating the nutrient-sensory PK Sch9 and the Tap42 protein. Once phosphorylated, Sch9 
and Tap42 accelerate the pro-aging process of protein synthesis in the cytosol by stimulating 
ribosome biogenesis and augmenting translation initiation (Figure 1.7) [94, 96, 192-194]. The 
TOR complex 2 (TORC2) at the PM also functions as a pro-aging master regulator at checkpoint 
6. If activated, TORC2 phosphorylates the PK Ypk1. After being phosphorylated, Ypk1 stimulates 
the synthesis of complex sphingolipids in the ER. These sphingolipids then stimulate the PKs Pkh1 
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and Pkh2, both of which in response phosphorylate Sch9 to intensify the pro-aging process of 
protein synthesis in the cytosol (Figure 1.7) [72, 73, 89, 194-196]. 
           At checkpoint 7, the amino acids aspartate, asparagine, glutamate, and glutamine are 
released from mitochondria and activate TORC1 at the surface of vacuoles. Active TORC1 sets 
off a pro-aging cellular pattern by phosphorylating Sch9, which then attenuates the anti-aging 
process of protein synthesis in mitochondria (Figure 1.7) [62, 94, 96, 118, 146].  
            At checkpoint 8, the efflux of the amino acids aspartate, asparagine, glutamate and 
glutamine from mitochondria, the resulting activation of TORC1 at the vacuolar surface and 
subsequent phosphorylation of Sch9 cause retention of the nutrient-sensory PK Rim15 in the 
cytosol (Figure 1.7) [97, 197]. Because under such conditions Rim15 cannot enter the nucleus, it 
is unable to stimulate Msn2, Msn4 and Gis1; these three transcriptional activators can orchestrate 
an anti-aging transcriptional program in the nucleus only if Rim15 stimulates them (Figure 1.7) 
[96, 97, 146, 197, 198]. Furthermore, protein kinase A (PKA) activity at the cytosolic leaflet of 
the PM also contributes to the establishment of a pro-aging cellular pattern at checkpoint 8. This 
PK activity inhibits nuclear import of Msn2 and Msn4, thus turning off an anti-aging 
transcriptional program driven - in a Rim15-dependent manner - by these two transcriptional 
activators (Figure 1.7) [63, 96, 97, 199]. Moreover, a study on a methionine restriction-induced 
delay of yeast chronological aging implies that excess of methionine can elicit a pro-aging cellular 
pattern at checkpoint 8 by activating the tRNA methyltransferase Ncl1 in the cytosol (Figure 1.7) 
[200]. This decreases the concentration of non-methylated tRNAs, attenuates the efflux of 
cytochrome c (Cyc1) from mitochondria and mitigates the nuclear import of the cytosolic 
Rtg1/Rtg2/Rtg3 heterotrimeric transcriptional factor, which is required for the stimulation of an 
anti-aging transcriptional program in the nucleus (Figure 1.7) [200]. 
            If TORC1 at the surface of vacuoles is activated by the release of the amino acids aspartate, 
asparagine, glutamate, and glutamine from mitochondria at checkpoint 9, active TORC1 
phosphorylates the autophagy-initiating protein Atg13 (Figure 1.7) [94, 96, 146, 201]. At this 
checkpoint, Atg13 can also be phosphorylated by PKA kinase activity confined to the cytosolic 
face of the PM (Figure 1.7) [146, 202-204]. The TORC1- and PKA-driven phosphorylation of 
Atg13 at checkpoint 9 inhibits autophagosome formation in the cytosol, thus suppressing the anti-
aging process of autophagy (Figure 1.7) [146, 202-204]. Furthermore, a study on the methionine 
restriction-induced delay of yeast chronological aging revealed that the excess of methionine in 
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the cytosol could trigger a pro-aging cellular pattern at checkpoint 9 because it weakens autophagy, 
either by stimulating TORC1 at the vacuolar surface or by attenuating autophagosome formation 
in the cytosol (Figure 1.7) [205]. Such methionine-driven weakening of autophagy accelerates 
aging by decreasing the extent of vacuolar acidification and by increasing acetic acid accumulation 
in cultural medium (Figure 1.7) [200, 206]. Moreover, mitochondria, peroxisomes and the cytosol 
house individual reactions for the synthesis of the polyamine spermidine (Figure 1.7) [111, 127, 
175]. At checkpoint 9, spermidine inhibits the histone acetyltransferases Iki3 and Sas3 (Figure 1.7) 
[83]. Although such spermidine-driven inhibition of Iki3 and Sas3 causes a global decline in the 
acetylation of histone H3 and silencing of numerous genes in the nucleus, histones in the promoter 
regions of several ATG (autophagy) genes get acetylated under these conditions [83, 84, 176, 207]. 
The resulting selective activation of transcription of these genes at checkpoint 9 promotes the anti-
aging process of autophagy (Figure 1.7). Also, a fraction of acetic acid in the cytosol can be 
imported into the nucleus and then converted into acetyl-CoA in the Acs2-dependent reaction 
[139]. At checkpoint 9, this acetyl-CoA selectively represses the transcription of nuclear ATG 
genes, thus suppressing the anti-aging process of autophagy (Figure 1.7) [139, 208]. 
            Chronologically aging yeast cells produce acetic acid as follows: 1) it is generated as the 
alternative product of glucose fermentation in the cytosol and 2) it is formed in the Ald4-dependent 
reaction in mitochondria, from which acetic acid can be released into the cytosol (Figure 1.7) [15, 
17, 42, 143]. At the late-life checkpoint 10 in the ST phase, a pool of acetic acid in the cytosol 
accelerates yeast chronological aging because it elicits an age-related form of apoptotic PD (Figure 
1.7) [15, 17, 42, 43, 45]. 
            While at the early-life checkpoint 3, trehalose is essential for maintaining an anti-aging 
pattern of cellular proteostasis (see above in my Thesis), this non-reducing disaccharide sets off a 
pro-aging cellular pattern at the late-life checkpoint 11 in ST phase. This is because in 
chronologically “old” yeast cells, which do not grow or divide, trehalose covers hydrophobic 
amino acid side chains of misfolded and unfolded proteins (Figure 1.7) [17, 32, 101]. Such side 
chains are needed to be recognized by a group of molecular chaperones that help to refold these 
misfolded and unfolded proteins [152-155]. By competing with molecular chaperones for binding 
to such clusters of hydrophobic amino acids, trehalose attenuates the anti-aging process of 
maintaining cellular proteostasis (Figure 1.7) [17, 32, 101].  




Figure 1.7. A model for how various organelle-organelle and organelle-cytosol 
communications influence yeast chronological aging. These communications involve 
movements of specific metabolites between multiple cellular compartments. Different changes in 
these metabolites are temporally restricted to longevity-defining periods called checkpoints. At 
each checkpoint, the changes of these metabolites are detected by specific master regulator 
proteins. Because each of the master regulator proteins modulates specific longevity-defining 
cellular processes, a coordinated in space and time action of these proteins orchestrates the 
development and maintenance of a pro- or anti-aging cellular pattern. See the text for details. Ac-
Carnitine, acetyl-carnitine; Ac-CoA, acetyl-CoA; AcOH, acetic acid; DAG, diacylglycerol; EtOH, 
ethanol; FFA, free (non-esterified) fatty acids; m5c-tRNAs, 5-methylcytosine tRNAs; PKA, 
protein kinase A; PM, the plasma membrane; ROS, reactive oxygen species; TAG, 
triacylglycerols; TCA, tricarboxylic; TORC, the target of rapamycin complex; tRNAs, transfer 
RNAs. 
 
            At the late-life checkpoint 12 in ST phase, the excessive accumulation of free (non-
esterified) fatty acids (FFA) and diacylglycerol (DAG) in cellular membranes accelerates yeast 
chronological aging because it triggers an age-related form of liponecrotic PD (Figure 1.7) [17, 
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32, 136, 209, 210]. ATP, which is produced mainly in mitochondria, slows age-related liponecrosis 
by providing the energy needed for the detoxification of FFA in the ER through the incorporation 
of FFA into TAG and other neutral lipids (Figure 1.7) [17, 161, 210]. Ethanol, a product of glucose 
fermentation, accelerates age-related liponecrosis by suppressing peroxisomal oxidation of FFA 
that are generated in LD due to lipolysis of TAG and other neutral lipids (Figure 1.7) [17, 
32, 136, 185].  The sirtuin deacetylase Sir2 promotes ethanol accumulation by inactivating the 
Adh2 isoform of alcohol dehydrogenase, which is required for ethanol catabolism (Figure 1.7) 
[135]. 
            In sum, my analysis indicates that intercompartmental communications in yeast cells are 
integrated into a convoluted network involving unidirectional and bidirectional movements of 
specific metabolites between cellular compartments. Different changes in the intracellular 
concentrations and the rates of flow of these metabolites are restricted to critical longevity-defining 
periods of yeast CLS called checkpoints. Specific proteins known as master regulators can detect 
the changes of the key metabolites at each of these checkpoints. The checkpoint-specific master 
regulator proteins contribute to setting up a pro- or anti-aging cellular pattern because each of these 
proteins controls specific longevity-defining cellular processes.  
1.5 Some phytochemicals delay aging and prolong the longevity of budding yeast 
            Plants, and some non-pathogenic endophytic bacteria and fungi living within the plants, 
use an evolutionarily conserved set of primary biochemical pathways to satisfy their fundamental 
metabolic needs in energy and biosynthetic products [211-221]. They also use their secondary 
biochemical pathways to synthesize many secondary metabolites called phytochemicals [211-
221]. Based on chemical nature, phytochemicals belong to several main classes [215, 222-228]. 
All these main classes are listed in Table 1.1. A commonly accepted view is that the biosynthetic 
pathways for phytochemicals have evolved for increasing the chances of plants and non-
pathogenic endophytic microorganisms inhabiting plants to survive and reproduce within their 
natural ecological niches [211-213, 215-223, 229-251]. The survival and reproduction advantages 
that various phytochemicals acting as interspecies chemical signals can provide to the host plant 
autotrophic organisms and their non-pathogenic endophytic microorganismal residents are shown 
in Table 1.2. 
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Table 1.1. The main classes of phytochemicals with respect to their chemical nature. 
Chemical class of phytochemicals Names of chemical compounds 
Phenolic compounds Flavonoids, phenolic acids, hydroxycinnamic 
acids, lignans, tyrosol esters, stilbenoids and 
alkylresorcinols 
Terpenes Carotenoids, monoterpenes, saponins, some 
modified lipid species and triterpenoids 
Betalains Betacyanins and betaxanthins 
Polysulfides Allyl methyl trisulfides  
Organosulfides Diallyl disulfides  
Indoles Indole-3-carbinol and 3,3'-diindolylmethane 
Protease inhibitors Protease inhibitors from soybeans, seeds, 
legumes, potatoes and cereals 
Organic acids Oxalic and anacardic acids 
Modified purines Caffeine and related purine alkaloids  
Quinones Catechin quinones (epigallocatechin gallate 
and gallocatechin gallate) 
Polyamines Putrescine, spermidine and spermine 
 
Table 1.2. The survival and reproduction advantages that phytochemicals provide to plants. 
The survival and reproduction advantage 
Help plants to survive many environmental stresses 
Protect plants from viral, bacterial, yeast and fungal infections 
Defend plants from invading insects, herbivorous animals and competitor plant species 
Protect plants from environmental pollutants 
Attract pollinators and other symbiotes to plants 
Attract the natural predators of herbivorous insects and animals to plants 
  
            Phytochemicals provide survival and reproduction advantages not only to plants. 
Phytochemicals can also decelerate cellular and organismal aging, prolong longevity and improve 
the health of evolutionarily distant heterotrophic organisms [215, 223-228, 231, 232, 237, 249, 
252-270]. The scope of this section of my Thesis is to analyze recent progress in understanding 
mechanisms underlying the aging-delaying (geroprotective), longevity-prolonging and health-
improving effects of phytochemicals on budding yeast. These effects are outlined below in this 
section.  
            The polyamine spermidine extends the longevity of chronologically aging yeast because it 
inhibits histone acetyltransferases, thus eliciting the deacetylation of histone H3 [83]. The resulting 
rise in the abundance of non-acetylated histone H3 stimulates transcription of many autophagy-
related genes, promotes autophagic clearance of dysfunctional macromolecules and organelles, 
and postpones the onset of an age-related form of necrotic PCD [83]. 
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            The quinone compound called cryptotanshinone increases yeast CLS because it suppresses 
the pro-aging protein kinases Tor1, Sch9 and Gcn2 [227]. Cryptotanshinone also stimulates 
mitochondrial superoxide dismutase Sod2, thereby decreasing the concentration of intracellular 
ROS below a toxic threshold [227].   
            The polyphenolic compound called resveratrol is a geroprotector in replicatively aging 
budding yeast because it activates Sir2, a member of the conserved sirtuin family of NAD+-
dependent protein deacetylases, thus lowering the frequency of rDNA recombination and 
increasing DNA stability [271]. 
            The modified purine called caffeine prolongs the longevity of chronologically aging yeast 
because it inhibits specifically the pro-aging PK activity of TORC1, thereby suppressing the 
TORC1-dependent phosphorylation of the anti-aging PK called Rim15 [197].  The ensuing 
dephosphorylation of Rim15 activates it and initiates a Rim15-driven cascade of events that 
ultimately promote transcription of genes encoding heat-shock proteins and molecular chaperones 
[197]. The resulting rise in the abundance of these facilitators of protein folding enhances the anti-
aging process of cellular proteostasis [197].   
            The polyphenolic compound called phloridzin prolongs the replicative lifespan of budding 
yeast because it activates transcription of the genes encoding Sod1 (a cytosolic form of superoxide 
dismutase), Sod2 and Sir2 proteins [272]. The ensuing rise in the enzymatic activities of these 
three proteins lowers intracellular concentrations of ROS, thus increasing cell resistance to 
oxidative stress [272]. 
            The flavonoid compound called quercetin extends yeast CLS because it lowers the 
intracellular concentrations of ROS, reduces the efficacies of glutathione oxidation and lipid 
peroxidation, lessens the extent of protein carbonylation, and decreases cell susceptibility to 
oxidative stress [273]. 
1.6 Certain combinations of the geroprotective chemicals that target different longevity-
defining processes exhibit a synergistic effect on the extent of aging delay and longevity 
extension 
            Different patient-customized combinations of Chinese plants have been for centuries used 
in traditional Chinese herbal medicine to prevent and treat a wide range of human diseases [274-
277]. The recent use of high-throughput “omics,” system biological and bioinformatic approaches 
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in animal models of many human diseases and cultured human cells has revealed that these 
combinations of Chinese plants affect multiple cellular and organismal processes [277-281]. The 
term “network pharmacology” (also known as “Traditional Chinese Medicine [TCM] network 
pharmacology”) has been introduced to describe such systemic effects of various combinations of 
Chinese herbs on the cellular and organismal networks integrating multiple disease-related 
processes [282-292]. The key tenet of the TCM network pharmacology concept is that the high 
therapeutic effectiveness, a multitude of targeted pathologies and limited side effects of Chinese 
herbal medicine are due to the ability of cocktails of plant chemical compounds to affect multiple 
molecular targets through numerous low-affinity interactions [277, 282-295]. A body of evidence 
supports the notion that, by modulating different nodes, edges and modules of these disease-
specific networks, the combined action of Chinese herb mixtures allows to restore cellular and 
organismal homeostasis differently altered in diverse human diseases [277, 281, 288, 292-295]. 
            The two critical conceptual advances in our understanding of the biology of human diseases 
are the following: 1) many (in not all) human diseases are due to various perturbations in complex 
networks that assimilate specific signaling, metabolic and other molecular pathways, and 2) 
rational design of particular combinations of pure drugs and/or natural chemical compounds, each 
targeting different nodes, edges or modules of such networks, may yield potent multicomponent 
therapies with limited side effects and lowered potential of drug resistance development [296-309]. 
An expansion of such multi-component therapies with the help of high-throughput screening 
methods for identifying effective combinations of therapeutic compounds represents an essential 
strategy of modern medicine [296-310]. This strategy has been successfully used for the 
development of multicomponent and multitargeted therapeutics for the treatment of complex 
human diseases, including cancer, infectious diseases, central nervous system disorders, 
Alzheimer’s disease, hypertension, chronic obstructive pulmonary disease, asthma and acquired 
immunodeficiency syndrome [296, 305, 307, 308, 310-322]. The significant progress in 
developing multicomponent and multitargeted therapeutics has been facilitated by the advances in 
mathematical, computational and pharmacological approaches to study compound combination 
effects [310, 322-331]. 
            Incidence rates of many human chronic diseases increase with age [332-336]. Because an 
age-related dysregulation of specific cellular and organismal processes is the primary cause of 
these chronic diseases, they are considered as diseases associated with aging [333, 334, 337-339]. 
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Among these aging-associated human diseases are cardiovascular diseases, chronic obstructive 
pulmonary disease, chronic kidney disease, diabetes, osteoarthritis, osteoporosis, sarcopenia, 
stroke, neurodegenerative diseases (including Parkinson’s, Alzheimer’s and Huntington’s 
diseases), and many forms of cancer [334-343]. The major aspects and underlying mechanisms of 
aging and aging-associated pathology have been conserved throughout evolution; they include the 
following: 1) the hallmark events of aging, such as the age-related accumulation of genomic 
damage, deterioration of telomeres, epigenetic perturbations, impairment of cellular proteostasis, 
deregulation of nutrient-sensing systems, a decline in mitochondrial functionality, accumulation 
of senescent cells, decrease of the abundance and functionality of stem cells, and deterioration of 
intercellular communications [344], and 2) the nutrient- and energy-sensing signaling network of 
longevity regulation, which integrates the insulin/insulin-like growth factor 1 (IGF-1) pathway, 
AMP-activated protein kinase/target of rapamycin (AMPK/TOR) pathway, cAMP/protein kinase 
A (cAMP/PKA) pathway and sirtuin-governed protein deacetylation module [339–341, 344-346]. 
            Some of the known hallmarks of aging and signaling pathways of longevity regulation are 
specifically targeted by certain individually added chemical compounds (either synthetic drugs or 
natural chemicals) that delay the onset and decelerate the progression of the aging process in 
eukaryotes across species [333, 337-343, 347-349]. It needs to be emphasized that none of these 
individually added aging-delaying chemical compounds could affect all hallmarks of aging or 
modulate all signaling pathways of longevity regulation [337-340, 348, 349]. It has been therefore 
proposed that, if two or more aging-delaying chemical compounds each targeting a different 
hallmark and/or signaling pathway of aging are added together, their combination may have an 
additive or a synergistic effect on the extent of aging delay and longevity extension [347-350]. The 
following multicomponent combinations of chemical compounds have been proposed for such 
therapeutic multiplexing of aging delay and longevity extension: 1) a three-component mixture of 
epigallocatechin gallate (an activator of cAMP synthesis), N-acetyl-L-cysteine (an inhibitor of cell 
proliferation pathways) and myricetin (an activator of integrin signaling, DNA repair, cAMP 
synthesis and hypoxia signaling) [347], 2) a seven-component mixture of rapalogs (including 
rapamycin and its synthetic drug analogs, all of which are inhibitors of the pro-aging TOR 
pathway), metformin (an activator of AMPK, which is a primary cellular regulator of glucose and 
lipid metabolism), losartan or lisinopril (both of which are inhibitors of angiotensin II signaling), 
a statin (such as atorvastatin, simvastatin or lovastatin, all of which decrease blood cholesterol 
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levels), propranolol (a non-cardioselective beta-adrenergic antagonist), aspirin (an inhibitor of 
cyclooxygenase) and a phosphodiesterase 5 inhibitor, in combination with physical exercise and 
caloric restriction (CR) diet or intermittent fasting [349, 351], and 3) a three-component mixture 
of rapamycin, acarbose (an a-glucosidase inhibitor) and a cardiolipin-binding peptide [350].  
            Recent studies in mice have supported the notion that a combination of the aging-delaying 
chemical compounds that target different aging-associated processes may exhibit a synergistic 
effect on the extent of aging delay; this combination included rapamycin and metformin [352, 
353]. This notion has also been supported by the following studies in model eukaryotic organisms: 
1) pairwise combinations of rapamycin and wortmannin (an inhibitor of phosphoinositide 3-
kinase), rapamycin and pyrrolidine dithiocarbamates (PDTC; inhibitors of the NF-κB pathway), 
and wortmannin and PDTC have been shown to exhibit synergistic effects on the extent of 
Drosophila melanogaster lifespan extension [354], 2) a pairwise combination of rapamycin and 
an inhibitor of the stress-activated c-Jun N-terminal kinase have been demonstrated to act in 
synergy to prolong the longevity of the coastal marine and salt-lake rotifer Brachionus manjavacas 
[355], 3) some double and triple combinations of synthetic drugs and natural chemicals that target 
the IGF-1, transforming growth factor β and sterol regulatory element-binding protein signaling 
pathways of longevity regulation have been shown to extend the lifespan of the nematode 
Caenorhabditis elegans in a synergistic manner [356], and 4) rapamycin and myriocin (an inhibitor 
of sphingolipid synthesis) act in synergy to extend chronological lifespan in the budding yeast 
Saccharomyces cerevisiae and the fission yeast Schizosaccharomyces pombe [357, 358]. 
1.7 Thesis outline and contributions of colleagues   
 All the research presented in this thesis was performed under the supervision of Dr. 
Vladimir Titorenko at Concordia University. Dr. Titorenko developed the research project 
concepts and outlines, analyzed experimental results and prepared the manuscripts that make-up 
this thesis. I contributed to the execution of experiments, data analysis and preparation of 
manuscripts. 
           Chapter 1 serves as an introduction to the topic of aging in yeast addressed in this thesis.  
In Chapter 2 of my thesis, the objective was to perform a screen for previously unknown aging-
delaying (geroprotective) chemical compounds extracted from various plants. In the described 
screen for geroprotectors, a mixture of chemicals present in a plant extract (PE) was added 
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exogenously to a culture of the budding yeast S. cerevisiae. The ability of each of the tested PEs 
to prolong yeast CLS was assessed with the help of a robust plating assay for monitoring changes 
in an age-related survival (clonogenicity) of yeast cells. The screen revealed six PEs that prolong 
yeast CLS much more efficiently than any of the longevity-extending geroprotectors yet described. 
We provided evidence that each of these PEs is a geroprotector that postpones the onset and 
decelerates the advancement of yeast chronological aging by promoting a hormetic stress response. 
We demonstrated that each of these geroprotective PEs affects several cellular processes known 
to regulate longevity in evolutionarily distant organisms. I performed experiments presented in 
figures 2.9, 2.10, 2.12, 2.18, 2.19 and 2.20, and prepared these figures. I also prepared figure 2.24. 
The experiments shown in figures 2.1-2.8, 2.11, 2.13-2.17 were carried out by Vicky Lutchman, 
Mélissa McAuley, Younes Medkour and me. The experiments shown in figures 2.21-2.23 were 
carried out by Mélissa McAuley and Younes Medkour. All data presented in Chapter 2 were 
published in Oncotarget. 2016; 7:16542-16566. Dr. Titorenko provided the intellectual leadership 
of this project. He also edited the first draft of Chapter 2 of my thesis and the entire manuscript of 
the above article. 
            Because studies presented in Chapter 2 led to the discovery of six geroprotective PEs and 
revealed a distinct set of longevity-defining cellular processes controlled by each of them, the 
objective of studies presented in Chapter 3 was to examine how each of the six PEs influences the 
information flow through a signaling network that regulates longevity in yeast and other 
eukaryotes; this evolutionarily conserved network integrates several signaling pathways and 
protein kinases. To attain the above objective, in Chapter 3 we investigated how single-gene-
deletion mutations eliminating each of these signaling pathways and kinases influence the aging-
delaying efficiency of each of the six geroprotective PEs. We provided evidence that each of the 
six geroprotective PEs targets a different hub, node and/or link of the signaling network governing 
longevity regulation in chronologically aging S. cerevisiae. I performed experiments presented in 
figures 3.2-3.4, 3.8-3.10 and 3.14-3.16, and prepared these figures. I also prepared figures 3.1 and 
3.20. The experiments shown in tables 3.2 and 3.3, figures 3.5-3.7, 3.11-3.13 and 3.17-3.19 were 
carried out by Vicky Lutchman, Mélissa McAuley, Berly Cortes and me. All data presented in 
Chapter 3 were published in Oncotarget. 2016; 7:50845-50863. Dr. Titorenko intellectually 
directed this project. He also corrected the first draft of Chapter 3 of my thesis and the entire 
manuscript of the above article. 
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            Because studies described in Chapter 3 of my Thesis revealed that the six geroprotective 
plant extracts target different signaling pathways and protein kinases integrated into a signaling 
network of longevity regulation, we hypothesized that a combination of two of them or a 
combination of one of them and spermidine or resveratrol (two other geroprotectors) might have 
a synergistic effect on the extent of aging delay only if each component of this combination targets 
a different element of the network. The objective of the studies presented in Chapter 4 was to test 
the hypothesis. To attain this objective, we investigated longevity-extending efficiencies of all 
possible pairwise combinations of the six geroprotective plant extracts or one of them and 
spermidine or resveratrol in chronologically aging yeast. Our investigation supported the above 
hypothesis and provided evidence that only pairwise combinations of geroprotective chemicals 
that delay aging because they target different elements of the network slow aging synergistically. 
I carried out experiments presented in figures 4.2-4.6, 4.11-4.13 and 4.23-4.28, and prepared these 
figures. I also prepared figure 4.1 and table 4.1. The experiments shown in figures 4.7-4.10 and 
4.14-4.22 were performed by Monica Lozano Rodriguez, Mélissa McAuley, Vicky Lutchman and 
Berly Cortes. All data presented in Chapter 4 were published in Oncotarget. 2019; 10:313-338. Dr. 
Titorenko provided the intellectual leadership of this project. He also corrected the first draft of 
Chapter 4 of my thesis and the entire manuscript of the above article. 
            The objective of studies described in Chapter 5 of my thesis was to search for commercially 
available plant extracts that can substantially prolong the chronological lifespan of budding yeast. 
We aimed at discovering previously unknown geroprotective natural chemicals. Our search for 
new geroprotective compounds led to a discovery of fifteen plant extracts that prolong the 
longevity of chronologically aging yeast not limited in calorie supply. We provided evidence that 
each of these plant extracts is a geroprotector that decreases the rate of yeast chronological aging 
and promotes a hormetic stress response. We also demonstrated that each of the fifteen 
geroprotective plant extracts mimics the longevity-extending, stress-protecting, metabolic and 
physiological effects of a caloric restriction diet in yeast not limited in calorie supply. We revealed 
that the fifteen geroprotective plant extracts elicit partially overlapping effects on specific 
longevity-defining cellular processes. I carried out experiments presented in figures 5.1-5.3, 5.7, 
5.8, 5.11, 5.13, 5.14, 5.16, 5.20 and 5.21, and prepared these figures. I also made table 5.1. The 
experiments shown in figures 5.4-5.6, 5.9, 5.10, 5.12, 5.15, 5.17-5.19 and 5.22 were conducted by 
Monica Lozano Rodriguez, Jennifer Anne Baratang Junio, Darya Mitrofanova, Tala Tafakori, 
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Tarek Taifour, Vicky Lutchman and Eugenie Samson. All findings described in Chapter 5 have 
been submitted for publication as a manuscript of a research paper. Dr. Titorenko intellectually 
directed this project. He also corrected the first draft of Chapter 5 of my thesis and the entire 






CHAPTER 2  
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2 Discovery of plant extracts that delay yeast chronological aging and have different 
effects on longevity-defining cellular processes 
2.1 Introduction 
            The main goal of our research was to use the budding yeast S. cerevisiae as a model 
organism to uncover novel chemical compounds that can slow aging and postpone the onset of 
aging-associated diseases in evolutionarily distant eukaryotic organisms. Some age-delaying 
(geroprotective) compounds have already been discovered from extractions of certain plants [116, 
225, 258]. Thus, the first step our lab took in order to discover new geroprotectors of plant origin, 
was to conduct a screen of various plant extracts (PEs). We aimed to screen for compounds that 
successfully extended yeast chronological lifespan (CLS). This chapter illustrates the finding of 
six PEs that increase CLS much more efficiently than other known longevity-extending chemicals. 
In addition, it highlights the effects these PEs have on several longevity-defining cellular 
processes. 
2.2 Materials and methods 
2.2.1 Yeast strains, media and culture conditions 
            The wild-type strain Saccharomyces cerevisiae BY4742 (MATa his31 leu2 lys2 
ura3) from Thermo Scientific/Open Biosystems was grown in a synthetic minimal YNB medium 
(0.67% Yeast Nitrogen Base without amino acids) initially containing 2% or 0.5% glucose and 
supplemented with 20 mg/l histidine, 30 mg/l leucine, 30 mg/l lysine and 20 mg/l uracil. Cells 
were cultured at 30°C with rotational shaking at 200 rpm in Erlenmeyer flasks at a “flask 
volume/medium volume” ratio of 5:1. 
2.2.2 CLS assay 
            A sample of cells was taken from a culture at a certain day after cell inoculation and PE 
addition into the medium. A fraction of the sample was diluted to determine the total number of 
cells using a hemacytometer. Another fraction of the cell sample was diluted, and serial dilutions 
of cells were plated in duplicate onto YEP (1% yeast extract, 2% peptone) plates containing 2% 
glucose as carbon source. After 2 d of incubation at 30°C, the number of colony-forming units 
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(CFU) per plate was counted. The number of CFU was considered as the number of viable cells in 
a sample. For each culture, the percentage of viable cells was calculated as follows: (number of 
viable cells per ml/total number of cells per ml) × 100. The percentage of viable cells in the mid-
logarithmic growth phase was set at 100%. 
2.2.3 A screen for PEs that can extend yeast CLS 
            CLS analysis in the presence of diverse PEs was conducted as described above. A 20% 
stock solution of each PE in ethanol was made on the day of adding this PE to cell cultures. For 
each PE, the stock solution was added to the growth medium with 2% glucose immediately 
following cell inoculation into the medium. The final concentration of each PE in the medium was 
0.02%, 0.04%, 0.06%, 0.08%, 0.1%, 0.3%, 0.5% or 1.0%. 
2.2.4 Oxygen consumption assay (cellular respiration measurement) 
            A sample of cells was taken from a culture at a certain time-point. Cells were pelleted by 
centrifugation and resuspended in 1 ml of fresh YP (1% yeast extract, 2% bactopeptone) medium 
containing 0.05% glucose. Oxygen uptake by cells was measured continuously in a 2-ml stirred 
chamber using a custom-designed biological oxygen monitor (Science Technical Center of 
Concordia University) equipped with a Clark-type oxygen electrode. 
2.2.5 Live-cell fluorescence microscopy for measuring the mitochondrial membrane 
potential  
            The mitochondrial membrane potential (m) was measured in live yeast by fluorescence 
microscopy of Rhodamine 123 (R123) staining. For R123 staining, 5 × 106 cells were harvested 
by centrifugation for 1 min at 21,000 × g at room temperature and then resuspended in 100 μl of 
50 mM sodium citrate buffer (pH 5.0) containing 2% glucose. R123 was added to a final 
concentration of 10 μM. Following incubation in the dark for 30 min at room temperature, the cells 
were washed twice in 50 mM sodium citrate buffer (pH 5.0) containing 2% glucose and then 
analyzed by fluorescence microscopy. Images were collected with a Zeiss Axioplan fluorescence 
microscope (Zeiss) mounted with a SPOT Insight 2-megapixel color mosaic digital camera (Spot 
Diagnostic Instruments). For evaluating the percentage of R123-positive cells, the UTHSCSA 
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Image Tool (Version 3.0) software was used to calculate both the total number of cells and the 
number of stained cells. Fluorescence of individual R123-positive cells in arbitrary units was 
determined by using the UTHSCSA Image Tool software (Version 3.0). In each of 3 independent 
experiments, the value of the median fluorescence was calculated by analyzing at least 800-1000 
cells that were collected at each time-point. The median fluorescence values were plotted as a 
function of the number of days cells were cultured. 
2.2.6 Live-cell fluorescence microscopy for measuring the formation of reactive oxygen 
species (ROS)  
            ROS production was measured microscopically by incubating cells with dihydrorhodamine 
123 (DHR). In the cell, this non-fluorescent compound can be oxidized by ROS to form the 
fluorescent chromophore rhodamine 123. DHR was stored in the dark at -20oC as 50 µl aliquots 
of a 1 mg/ml solution in ethanol. The staining of cells with DHR was performed as follows. The 
required amount of the 50 µ DHR aliquot (1 mg/ml) was recovered from the freezer and warmed 
to room temperature. The solution of DHR was then centrifuged at 21,000 × g for 5 min to clear it 
of any aggregates of fluorophores. For cell cultures with a titer of 107 cells/ml, 100 µl was 
recovered from the cell culture for the treatment. If the cell titer was lower, proportionally larger 
volumes were used. Then, 6 µl of the 1 mg/ml DHR was added to each 100 µl aliquot of the culture. 
After a 2-h incubation in the dark at room temperature, the samples were centrifuged at 21,000 × 
g for 5 min. Pellets were resuspended in 10 ml of PBS buffer (20 mM KH2PO4/KOH, pH 7.5, and 
150 mM NaCl). Then, 5 µl of mounting medium was added to a microscope slide with each 
sample, and the slide was overlaid with a coverslip, and sealed using nail polish. Once the slides 
were prepared, they were visualized under the Zeiss Axioplan fluorescence microscope mounted 
with a SPOT Insight 2-megapixel color mosaic digital camera. Fluorescence of individual DHR-
positive cells in arbitrary units was determined by using the UTHSCSA Image Tool software 
(Version 3.0). In each of 3-5 independent experiments, the value of the median fluorescence was 
calculated by analyzing at least 800-1000 cells that were collected at each time point. The median 
fluorescence values were plotted as a function of the number of days cells were cultured. 




            BODIPY 493/503 staining for visualizing neutral lipids deposited in LDs was performed 
as follows. Formaldehyde-fixed cells were permeabilized by treatment with 0.2% Triton X-100 
for 6 min and incubated with 10 μM BODIPY 493/503 in 20 mM Tris-HCl (pH 7.5), 150 mM 
NaCl for 15 min to label LDs. Live imaging was performed on a Leica DM6000B epifluorescence 
microscope equipped with a high-resolution Hamamatsu Orca ER CCD camera using immersion 
oil and a 100X objective. Images were acquired with 20-ms exposures using PerkinElmer Volocity 
software. Image files were exported as TIFFs then opened in ImageJ, where the percentage of cells 
with LDs was counted.  
2.2.8 Measurement of oxidative damage to cellular proteins 
            Yeast cells were harvested by centrifugation for 1 min at 21,000  g at room temperature. 
The cell pellet was resuspended in 1 ml of ice-cold 50 mM KH2PO4/KOH buffer (pH 7.5) + 1 mM 
EDTA. The cells were sonicated on ice, harvested by centrifugation for 5 min at 21,000  g at 4oC 
and then resuspended in 200 µl of ice-cold 50 mM KH2PO4/KOH buffer (pH 7.5) + 1 mM EDTA. 
The Protein Carbonyl Assay Kit (#10005020; Cayman Chemical) was used to measure protein 
carbonylation (i.e., oxidative protein damage) as the amount of protein-hydrazone produced in the 
DNPH (2,4-dinitrophenylhydrazine) reaction at an absorbance of 360 nm.      
2.2.9 Measurement of oxidative damage to cellular membrane lipids 
            Yeast cells were harvested by centrifugation for 3 min at 16,000  g at room temperature. 
The cell pellet was washed with ice-cold ABC buffer (155 mM ammonium bicarbonate, pH 8.0) 
by centrifugation for 3 min at 16,000 × g at 4oC, and then resuspended in 1 ml of ice-cold ABC 
buffer. Then, 200 µl of glass beads were added, and the sample was vortexed for 5 min. After that, 
1 ml of ice-cold nanopore water was added, and the sample was transferred to a 15-ml glass 
centrifuge tube. Then, 3 ml of chloroform/methanol (17:1) mixture was added, and the sample was 
vortexed at 4°C for 2 h. The sample was subjected to centrifugation at 3000 × g for 5 min at room 
temperature to form two phases. The lower organic phase was transferred to a new 15-ml glass 
tube. The solvent was evaporated off under nitrogen flow or in a vacuum evaporator. The lipid 
film was dissolved in 100 µl of methanol/chloroform (2:1) mixture. The PeroXOquant 
Quantitative Peroxide Assay Kit assay kit (#23285; Thermo Scientific Pierce) was used to measure 
lipid hydroperoxides as the Fe3+ complexes with the xylenol orange dye at an absorbance of 595 
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nm.     
2.2.10 Measurement of the frequency of spontaneous mutations in nuclear DNA   
            The frequency of spontaneous point mutations in the CAN1 gene of nuclear DNA was 
evaluated by measuring the frequency of mutations that caused resistance to the antibiotic 
canavanine. A sample of cells was removed from each culture at various time-points. Cells were 
plated in triplicate onto YNB (0.67% Yeast Nitrogen Base without amino acids [#DF0919153; 
Fisher Scientific]) plates containing 2% glucose and supplemented with L-canavanine (50 mg/l), 
histidine, leucine, lysine and uracil (#C1625, #H8125, #L8912, #L5751 and #U0750, respectively; 
all from Sigma). Serial dilutions of each sample were then plated in triplicate onto YP plates 
containing 2% glucose for measuring the number of viable cells. The number of CFU was counted 
after 4 d of incubation at 30oC. For each culture, the frequency of mutations that caused resistance 
to canavanine was calculated as follows: number of CFU per ml on YNB plates containing 2% 
glucose, L-canavanine (50 mg/l), histidine, leucine, lysine and uracil/number of CFU per ml on 
YP plates containing 2% glucose. 
2.2.11 Measurement of the frequency of spontaneous mutations in mitochondrial DNA 
            The frequency of spontaneous point mutations in the rib2 and rib3 loci of mitochondrial 
DNA (mtDNA) was evaluated by measuring the frequency of mtDNA mutations that caused 
resistance to the antibiotic erythromycin. These mutations impair only the mtDNA. A sample of 
cells was removed from each culture at various time-points. Cells were plated in triplicate onto YP 
plates containing 3% glycerol and erythromycin (1 mg/ml) [#227330050; Acros Organics]. Also, 
serial dilutions of each sample were plated in triplicate onto YP plates containing 3% glycerol as 
a carbon source for measuring the number of respiratory-competent (rho+) cells. The number of 
CFU was counted after 6 d of incubation at 30oC. For each culture, the frequency of mutations that 
caused resistance to erythromycin was calculated as follows: the number of CFU per ml on YP 
plates containing 3% glycerol and erythromycin/number of CFU per ml on YP plates containing 
3% glycerol. 
2.2.12 Plating assays for the analysis of resistance to oxidative and thermal stresses 
            For the analysis of hydrogen peroxide (oxidative stress) resistance, serial dilutions (1:100 
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to 1:105) of cells removed from each culture at various time-points were spotted onto two sets of 
plates. One set of plates contained YP medium with 2% glucose alone, whereas the other set 
contained YP medium with 2% glucose supplemented with 5 mM hydrogen peroxide. Pictures 
were taken after a 3-day incubation at 30oC. 
            For the analysis of thermal stress resistance, serial dilutions (1:100 to 1:105) of cells 
removed from each culture at various time-points were spotted onto two sets of plates containing 
YP medium with 2% glucose. One set of plates was incubated at 30oC. The other set of plates was 
initially incubated at 60oC for 60 min and was then transferred to 30oC. Pictures were taken after 
a 3-day incubation at 30oC. 
2.2.13 Miscellaneous procedures 
            The age-specific mortality rate (qx) [359-361], Gompertz slope or mortality rate coefficient 
(α) [360, 361], and mortality rate doubling time (MRDT) [360, 361] were calculated as previously 
described.  
2.2.14 Statistical analysis 
            Statistical analysis was performed using Microsoft Excel’s (2010) Analysis ToolPack-
VBA. All data are presented as mean ± SEM. The p values for comparing the means of two groups 
(using an unpaired two-tailed t test) and survival curves (using a two-tailed t test) were calculated 
with the help of the GraphPad Prism statistics software. 
2.3 Results 
2.3.1 A screen for PEs that can extend the longevity of chronologically aging yeast 
            We began with 35 known plant extracts that we screened for an increase in yeast 
chronological lifespan. The origin and properties of the PEs can be found summarized in tables 
2.1 and 2.2, respectively. We used the wild-type strain BY4742 cultured in a synthetic minimal 
YNB medium with an initial 2% glucose. This is because yeast cells cultured under these 
conditions have been shown to age chronologically under non-caloric restrictions (non-CR) that 
accelerate aging in different yeast genetic backgrounds including BY4742 [14, 15, 17]. The 
chronological life-span assay we used, preformed in a controlled environment, described above 
42 
 




Table 2.1. A list of plant extracts used in this study. 
Abbreviated name  Botanical name Plant part used Commercial source 
PE1 Echinacea purpurea Whole plant Idunn Technologies 
PE2 Astragalus membranaceous Root Idunn Technologies 
PE3 Rhodiola rosea L. Root Idunn Technologies 
PE4 Cimicifuga racemosa Root and rhizome Idunn Technologies 
PE5 Valeriana officinalis L. Root Idunn Technologies 
PE6 Passiflora incarnate L. Whole plant Idunn Technologies 
PE7 Polygonum cuspidatum Root and rhizome Idunn Technologies 
PE8 Ginkgo biloba Leaf Idunn Technologies 
PE9 Zingiber officinale Roscoe Rhizome Idunn Technologies 
PE10 Theobroma cacao L. Cacao nibs Idunn Technologies 
PE11 Camellia sinensis L. Kuntze Leaf Idunn Technologies 
PE12 Apium graveolens L. Seed Idunn Technologies 
PE13 Scutellaria baicalensis Root Idunn Technologies 
PE14 Euterpe oleracea Fruit Idunn Technologies 
PE15 Withania somnifera Root and leaf Idunn Technologies 
PE16 Phyllanthus emblica Fruit Idunn Technologies 
PE17 Camellia sinensis Leaf Idunn Technologies 
PE18 Pueraria lobata Root Idunn Technologies 
PE19 Silybum marianum Seed Idunn Technologies 
PE20 Eleutherococcus senticosus Root and stem Idunn Technologies 
PE21 Salix alba Bark Idunn Technologies 
PE22 Glycine max L. Bean Idunn Technologies 
PE24 Calendula officinalis Flower Idunn Technologies 
PE25 Salvia miltiorrhiza Root Idunn Technologies 
PE27 Panax quinquefolium Root Idunn Technologies 
PE28 Harpagophytum procumbens Root Idunn Technologies 
PE29 Olea europaea L. Leaf Idunn Technologies 
PE30 Gentiana lutea Root Idunn Technologies 
PE31 Piper nigrum Fruit Idunn Technologies 
PE32 Aesculus hippocastanum  Seed Idunn Technologies 
PE33 Mallus pumila Mill. Fruit Idunn Technologies 
PE34 Fragaria spp. Fruit Idunn Technologies 
PE35 Ribes nigrum Leaf Idunn Technologies 
PE36 Dioscorea opposita Root Idunn Technologies 








PE1 Extraction solvent: ethanol (75%)/water (25%). Extract ratio: 4/1. Composition: 
natural extract, maltodextrin. 
PE2 Extraction solvent: denatured ethanol (70%)/water (30%). Extract ratio: 10/1. 
Composition: natural extract (40-50%), gum arabic (50-60%).  
PE3 Extraction solvent: ethanol (60-80%)/water (40-20%). Extract ratio: 15-20/1. 
Composition: natural extract (80-100%), maltodextrin (0-20%). 
PE4 Extract ratio: 6-8/1. Composition: natural extract (28-38%), maltodextrin (60-
70%), tricalcium phosphate (0-5%). 
PE5 Extraction solvent: denatured ethanol/water. Extract ratio: ~ 6/1. Composition: 
natural extract, maltodextrin, silica (0-1%). 
PE6 Extraction solvent: water (100%). Extract ratio: 4/1. Composition: natural 
extract, maltodextrin. 
PE7 Extraction solvent: ethanol (80%)/water (20%). Extract ratio: 40/1. 
Composition: natural extract (90-100%), maltodextrin (0-10%). 
PE8 Extraction solvent: ethanol/water. Extract ratio: 50/1. Composition: natural 
extract.  
PE9 Extraction solvent: ethanol/water. Composition: natural extract (96%), 
gingerols (4%). 
PE10 Natural powder/final product ratio: 2-3/1. Composition: natural powder. 
PE11 Extraction solvent: ethyl acetate (90%)/water (10%). Extract ratio: 6/1. 
Composition: natural extract (100%). 
PE12 Extraction solvent: ethanol (90%)/water (10%). Extract ratio: 8/1. Composition: 
natural extract, maltodextrin, modified starch, silica. 
PE13 Extraction solvent: ethanol/water. Extract ratio: 4/1. Composition: natural 
extract. 
PE14 Extraction solvent: ethanol/water. Extract ratio: 4/1. Composition: natural 
extract. 
PE15 Extraction solvent: water. Extract ratio: 9/1. Composition: withanolide 
glycoside conjugates (10%), oligosaccharides (32%), free withanolides (0.5%). 
PE16 Extraction solvent: water. Composition: hydrolyzable tannins (>60%), 
including Emblicanin-A, Emblicanin-B, Punigluconin, Pedunculagin.  
PE17 Composition: tea polyphenols (>90%), including epigallocatechin gallate 
(>40%). 
PE18 Composition: flavonoids (>40%), including puerarin. 
PE19 Extraction solvent: ethanol/water. Composition: silymarin (>80%). 
PE20 Extraction solvent: water. Composition: eleutheroside B+E (>0.8%). 
PE21 Extraction solvent: ethanol/water. Composition: salicin (>25%). 
PE22 Composition: isoflavones (40%). 
PE24 Composition: lutein (>5%). 
PE25 Composition: tanshinones, isotanshinones, cryptotanshinone, 
isocryptotanshinone, dihydrotanshinone, hydroxytanshinones.  
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PE27 Composition: ginsenosides (10%, by HPLC-UV), quintozene-free. 
PE28 Extraction solvent: ethanol/water. Extract ratio: 40/1. Composition: 
harpagosides (20%, by HPLC-UV). 
PE29 Extraction solvent: ethanol (70%)/water (30%). Extract ratio: 5-10/1. 
Composition: natural extract, maltodextrin, silica (0.2%). 
PE30 Composition: isogentisin (0.04%). 
PE31 Extraction solvent: ethanol. Extract ratio: 10/1. Composition: piperine (>90%). 
PE32 Composition: aescin (20%). 
PE33 Extraction solvent: ethanol (70%)/water (30%). Extract ratio: 120-130/1. 
Composition: natural extract (60-70%), maltodextrin (30-40%). 
PE34 Extract ratio: 5/1. Composition: natural extract, including polyphenols (>2%). 
PE35 Extraction solvent: water. Composition: polyphenols (15%, by HPLC-UV). 
PE36 Composition: diosgenine (>16%, by HPLC-UV). 
PE37 Extraction solvent: water. Composition: polyphenols (25%, by HPLC-UV). 
 
            Initially, we did not know the optimal concentration we would need for each of the PEs in 
order to see potential results. Thus, we decided to test the PEs at multiple plausible final 
concentrations ranging from 0.02% to 1.0% at the time of cell inoculation. Three different 
outcomes were possible, either the plant-extracts had no effect on the lifespan of chronologically 
aging yeast or they in fact managed to either increase or decrease CLS. Indeed, all three outcomes 
were observed. Some of the plant extracts we tested did not change the mean and the maximum 
chronological lifespan of yeast under the specific conditions we set. Such plant extracts included 
PE9, PE13, PE16, PE22, PE28 and PE36 (Figure 2.2-Figure 2.5). We also observed, with other 
plant extracts, the opposite of the desired effect. In said cases, the PEs, at final concentrations 
ranging from 0.08% to 1.0%, reduced the mean and/or maximum CLS of the yeast under non-
caloric restrictions. Among them are PE1-PE3, PE7, PE10, PE11, PE14, PE15, PE17-PE20, PE24, 
PE25, PE27, PE29-PE35 and PE37 (Figure 2.1-Figure 2.5). Lastly, 6 out of the 35 PEs we had in 
our library managed to increase both the mean and maximum CLS of yeast cells grown under non-
CR conditions. It was also made apparent that though, in some cases, multiple final concentrations, 
did increase CLS, one concentration showed better results with a higher effect on CLS increase 
than the others. The names of the PEs and the optimal final concentration are as follows: 1) 0.5% 
PE4 from Cimicifuga racemosa (Figure 2.1, Figure 2.6A, Figure 2.8A and 2.8B); 2) 0.5% PE5 
from Valeriana officinalis L. (Figure 2.1, Figure 2.6B, Figure 2.8A and 2.8B); 3) 1.0% PE6 from 
Passiflora incarnata L. (Figure 2.1, Figure 2.6C, Figure 2.8A and 2.8B); 4) 0.3% PE8 from Ginkgo 
biloba (Figure 2.1, Figure 2.6D, Figure 2.8A and 2.8B); 5) 0.1% PE12 from Apium graveolens L. 
(Figure 2.2, Figure 2.6E, Figure 2.8A and 2.8B); and 6) 0.1% PE21 from Salix alba (Figure 2.3, 
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Figure 2.6F, Figure 2.8A and 2.8B).  
            None of the six lifespan-extending plant extracts affected the growth rates of the yeast cells 
in the logarithmic (L) and post-diauxic (PD) phases or impacted the maximum cell density in the 
stationary (ST) phase of yeast cultures under non-CR conditions on 2% glucose (Figure 2.9). In 
this case, it is unlikely that the results observed from the addition of the 6 PEs, are due to a decrease 
in growth rate or an added resistance to toxic substances that accumulate during culturing in 





Figure 2.1. PE4, PE5, PE6 and PE8, but not PE1, PE2, PE3 or PE7, extend the CLS of WT 
yeast grown under non-CR conditions. WT cells were grown in the synthetic minimal YNB 
medium initially containing 2% glucose (non-CR conditions), in the presence of a PE or its 
absence. The mean and maximum lifespans of chronologically aging WT strain cultured under 
non-CR conditions without a PE or with a PE added at various concentrations are shown; data are 
presented as means ± SEM (n = 6-21; * p < 0.05; the p values for comparing the means of two 
groups were calculated with the help of the GraphPad Prism statistics software using an unpaired 
two-tailed t test). Note that PE1, PE2, PE3 and PE7 can shorten the CLS of WT yeast under non-
CR conditions if added at high concentrations (n = 6; * p < 0.05; the p values for comparing the 
means of two groups were calculated with the help of the GraphPad Prism statistics software using 




Figure 2.2. PE12, but not PE9, PE10, PE11, PE13, PE14, PE15 or PE16, extends the CLS of 
WT yeast grown under non-CR conditions. WT cells were grown in the synthetic minimal YNB 
medium initially containing 2% glucose (non-CR conditions), in the presence of a PE or its 
absence. The mean and maximum lifespans of chronologically aging WT strain cultured under 
non-CR conditions without a PE or with a PE added at various concentrations are shown; data are 
presented as means ± SEM (n = 6-29; * p < 0.05; the p values for comparing the means of two 
groups were calculated with the help of the GraphPad Prism statistics software using an unpaired 
two-tailed t test). Note that PE10, PE11, PE14 and PE15 can shorten the CLS of WT yeast under 
non-CR conditions if added at high concentrations (n = 6; * p < 0.05; the p values for comparing 
the means of two groups were calculated with the help of the GraphPad Prism statistics software 




Figure 2.3. PE21, but not PE17, PE18, PE19, PE20, PE22, PE24 or PE25, extends the CLS 
of WT yeast grown under non-CR conditions. WT cells were grown in the synthetic minimal 
YNB medium initially containing 2% glucose (non-CR conditions), in the presence of a PE or its 
absence. The mean and maximum lifespans of chronologically aging WT strain cultured under 
non-CR conditions without a PE or with a PE added at various concentrations are shown; data are 
presented as means ± SEM (n = 6-35; * p < 0.05; the p values for comparing the means of two 
groups were calculated with the help of the GraphPad Prism statistics software using an unpaired 
two-tailed t test). Note that PE17, PE18, PE19, PE20, PE24 and PE25 can shorten the CLS of WT 
yeast under non-CR conditions if added at high concentrations (n = 6; * p < 0.05; the p values for 
comparing the means of two groups were calculated with the help of the GraphPad Prism statistics 




Figure 2.4. PE27, PE28, PE29, PE30, PE31, PE32, PE33 and PE34 do not extend the CLS of 
WT yeast grown under non-CR conditions. WT cells were grown in the synthetic minimal YNB 
medium initially containing 2% glucose (non-CR conditions), in the presence of a PE or its 
absence. The mean and maximum lifespans of chronologically aging WT strain cultured under 
non-CR conditions without a PE or with a PE added at various concentrations are shown; data are 
presented as means ± SEM (n = 5-6; * p < 0.05; the p values for comparing the means of two 
groups were calculated with the help of the GraphPad Prism statistics software using an unpaired 
two-tailed t test). Note that PE 27, PE29, PE30, PE31, PE32, PE33 and PE34 can shorten the CLS 
of WT yeast under non-CR conditions if added at high concentrations (n = 6; * p < 0.05; the p 
values for comparing the means of two groups were calculated with the help of the GraphPad 




Figure 2.5. PE35, PE36 and PE37 do not extend the CLS of WT yeast grown under non-CR 
conditions. WT cells were grown in the synthetic minimal YNB medium initially containing 2% 
glucose (non-CR conditions), in the presence of a PE or its absence. The mean and maximum 
lifespans of chronologically aging WT strain cultured under non-CR conditions without a PE or 
with a PE added at various concentrations are shown; data are presented as means ± SEM (n = 5-
6; * p < 0.05; the p values for comparing the means of two groups were calculated with the help 
of the GraphPad Prism statistics software using an unpaired two-tailed t test). Note that PE 35 and 
PE37 can shorten the CLS of WT yeast under non-CR conditions if added at high concentrations 
(n = 6; * p < 0.05; the p values for comparing the means of two groups were calculated with the 









Figure 2.6. PE4, PE5, PE6, PE8, PE12 and PE21 extend the chronological lifespan (CLS) of 
yeast grown under non-caloric restriction (non-CR) conditions. Wild-type (WT) cells were 
grown in the synthetic minimal YNB medium (0.67% Yeast Nitrogen Base without amino acids) 
initially containing 2% glucose in the presence of a PE or its absence. Survival curves of 
chronologically aging WT strain cultured with or without 0.5% PE4 (A), 0.5% PE5 (B), 1% PE6 
(C), 0.3% PE8 (D), 0.1% PE12 (E) or 0.1% PE21 (F) are shown. Data are presented as means ± 
SEM (n = 21-35). CLS extension was significant for each of the PEs tested (p < 0.05; the p values 
for comparing survival curves were calculated with the help of the GraphPad Prism statistics 




Figure 2.7. PE5 and PE21, but not PE4, PE6, PE8 or PE12, extend the CLS of yeast grown 
under CR conditions. WT cells were grown in the synthetic minimal YNB medium initially 
containing 0.5% glucose (CR conditions) or 2% glucose (non-CR conditions), in the presence of 
a PE or its absence. Survival curves (A), the mean (B) and maximum (C) lifespans of 
chronologically aging WT strain cultured under CR or non-CR conditions in the absence of a PE 
are shown; data are presented as means ± SEM (n = 5-7). CR caused significant extension of CLS 
(A) (p < 0.05; the p values for comparing survival curves were calculated with the help of the 
GraphPad Prism statistics software). CR extended both the mean (B) and maximum (C) lifespans 
(* p < 0.05; the p values for comparing the means of two groups were calculated with the help of 
the GraphPad Prism statistics software using an unpaired two-tailed t test). Survival curves of 
chronologically aging WT strain cultured under CR on 0.5% glucose with or without 0.5% PE4 
(D), 0.5% PE5 (E), 1% PE6 (F), 0.3% PE8 (G), 0.1% PE12 (H) or 0.1% PE21 (I) are shown; data 
are presented as means ± SEM (n = 5-7). CLS extension under CR on 0.5% glucose was significant 
for PE5 and PE21 (p < 0.05; the p values for comparing survival curves were calculated with the 
help of the GraphPad Prism statistics software). CLS extension under CR on 0.5% glucose was 
not significant for PE4, PE6, PE8 and PE12. Abbreviations: Logarithmic (L), post-diauxic (PD) 




Figure 2.8. The longevity-extending efficacy under non-CR conditions significantly exceeds 
that under CR conditions for each of the six lifespan-prolonging PEs. WT cells were grown in 
the synthetic minimal YNB medium initially containing 0.5% glucose (CR conditions) or 2% 
glucose (non-CR conditions), in the presence of a PE or its absence. The mean (A, C and E) and 
maximum (B, D and F) lifespans of chronologically aging WT strain cultured under CR (C, D, E 
and F) or non-CR (A, B, E and F) conditions in the absence of a PE or in the presence of 0.5% 
PE4, 0.5% PE5, 1% PE6, 0.3% PE8, 0.1% PE12 or 0.1% PE21 are shown; data are presented as 
means ± SEM (n = 5-7; * p < 0.05). The extent to which each of the PE tested increases the mean 
and maximum lifespans under non-CR conditions exceeds that under CR conditions (* p < 0.05; 
the p values for comparing the means of two groups were calculated with the help of the GraphPad 





Figure 2.9. PE4, PE5, PE6, PE8, PE12 and PE21 do not cause significant effects on the growth 
of WT yeast under non-CR conditions. WT cells were grown in the synthetic minimal YNB 
medium initially containing 2% glucose (non-CR conditions), in the absence of a PE or in the 
presence of 0.5% PE4 (A), 0.5% PE5 (B), 1% PE6 (C), 0.3% PE8 (D), 0.1% PE12 (E) or 0.1% 
PE21 (F). Kinetics of cell growth is shown (n = 8-14). Abbreviations: Logarithmic (L), post-
diauxic (PD) or stationary (ST) growth phase. 
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2.3.2 For each of the six lifespan-prolonging PEs, the longevity-extending efficacy under 
CR conditions is significantly lower than that under non-CR conditions 
            It has been previously shown that chronologically aging yeast grown under caloric 
restriction conditions (with 0.5% glucose) are able to live longer than yeast cultured under non-
CR conditions (with 2% glucose). In addition, the capacity of the CR diet has been observed for 
yeast cultured in media of different nutrient compositions [14, 15, 17]. With that in mind, we 
decided to test the efficiency of the CR diet on lifespan extension on yeast cultured in the YNB 
medium with and without six plant extracts. Firstly, our test results (Figure 2.7A-2.7C) showed 
that if we cultured yeast in YNB medium with 0.5% glucose, the CR diet significantly increased 
both the mean and maximum CLS of S. cerevisiae. Secondly, our findings suggested that the 
addition of PEs to yeast grown under CR conditions had various effects. In fact, both 0.5% of PE5 
and 0.1% of PE21 extended the mean CLS of yeast grown under the previously mentioned 
conditions (Figure 2.7D-2.7I, Figure 2.8C). On the other hand, 0.5% PE5, 1.0% PE6 and 0.1% 
PE21 were revealed to extend the maximum CLS of yeast grown under CR conditions (Figure 
2.7D-2.7I, Figure 2.8D). Notably, the growth rates of yeast cultures in the L and PD phases, as 
well as the maximum cell density in the ST phase, remained unaltered under CR conditions similar 
to non-CR conditions (Figure 2.10). After comparing the capacity of PEs to extend mean and 
maximum CLS of yeast, our results (figures 2.8A-2.8F) show that the six PEs were able to extend 
the mean and maximum CLS of yeast cultured under non-CR conditions (2% glucose) to an even 
larger extent than that of yeast under CR (0.5% glucose). This observation indicates that each of 
these PEs could potentially mimic the longevity-extending effect of CR. 
2.3.3 Each of the six longevity-extending PEs is a geroprotector which postpones the onset 
and slows the advancement of yeast chronological aging because it causes a hormetic stress 
response 
            Our previous results indicated that PE4, PE5, PE6, PE8, PE12 and PE21 greatly prolong 
the mean CLS of yeast cultured under non-CR conditions (Figures 2.1-2.3, Figure 2.6A, Figure 
2.8A and 2.8B). When contemplating the aging of an organism, the mean lifespan is said to be 
directly proportional to the survival rates of organisms in the population during the development 
and maturity stages. In addition, the mean lifespan is believed to be influenced by certain 
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environmental factors referred to as extrinsic factors [359, 362-364]. Hence, it is reasonable that 
the six PEs can decrease the extrinsic rate of yeast chronological aging before cell entry into 
quiescence or senescence.  
  Furthermore, we revealed that the same six plant extracts also increase the maximum CLS 
of yeast cultured under non-CR conditions (Figures 2.1-2.3, Figure 2.6A, Figure 2.8A and 2.8B). 
Maximum lifespan is believed to reflect the duration of “healthy” life period (i.e., healthspan) 
during the quiescence/senescence stage of organismal aging; maximum lifespan is likely to be 
controlled by certain intrinsic (cellular and organismal) longevity modifiers [48, 359, 362, 363, 
365, 366]. One could, therefore, conclude that PE4, PE5, PE6, PE8, PE12 and PE21 also decrease 




Figure 2.10. PE4, PE5, PE6, PE8, PE12 and PE21 do not cause significant effects on the 
growth of WT yeast under CR conditions. WT cells were grown in the synthetic minimal YNB 
medium initially containing 0.5% glucose (CR conditions), in the absence of a PE or in the 
presence of 0.5% PE4 (A), 0.5% PE5 (B), 1% PE6 (C), 0.3% PE8 (D), 0.1% PE12 (E) or 0.1% 
PE21 (F). Kinetics of cell growth is shown (n = 6-9). Abbreviations: Logarithmic (L), post-diauxic 
(PD) or stationary (ST) growth phase. 
            
 Our analysis of the Gompertz mortality function further validated the conclusion that PE4, 
PE5, PE6, PE8, PE12 and PE21 considerably decrease the rate of yeast chronological aging. 
Indeed, we found that each of these longevity-extending PEs causes a substantial decline in the 
slope of the Gompertz mortality rate (also known as mortality rate coefficient α) and a considerable 
rise in the mortality rate doubling time (MRDT) (Figure 2.11A-2.11G). Such changes in the values 
of α and MRDT are characteristic of interventions that decrease the rate of progression through 
the process of biological aging [359, 367, 368]. 
 
 
Figure 2.11. Analysis of the Gompertz mortality function indicates that PE4, PE5, PE6, PE8, 
PE12 and PE21 significantly decrease the rate of chronological aging in yeast. WT cells were 
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grown in synthetic minimal YNB medium initially containing 2% glucose in the presence of a PE 
or its absence. Survival curves shown in Figs. 2.6A-2.6F were used to calculate the age-specific 
mortality rates (qx) of chronologically aging WT yeast populations cultured with or without 0.5% 
PE4 (A), 0.5% PE5 (B), 1% PE6 (C), 0.3% PE8 (D), 0.1% PE12 (E) or 0.1% PE21 (F). Each of 
these longevity-extending PEs caused a substantial decrease in the slope of the Gompertz mortality 
rate (also known as mortality rate coefficient α) and a considerable increase in the mortality rate 
doubling time (MRDT) (G). The values of qx, α and MRDT were calculated as described in 
Materials and methods. Abbreviations: Logarithmic (L), post-diauxic (PD) or stationary (ST) 
growth phase. 
          
Of note, our analyses of how different concentrations of PE4, PE5, PE6, PE8, PE12 and 
PE21 influence yeast longevity under non-CR conditions revealed that each of them causes a so-
called “hormetic” stress response in chronologically aging yeast concerning longevity. Indeed, the 
dose-response curves (i.e., the curves that reflect relationships between PE concentrations and 
mean or maximum CLS) for PE4, PE5, PE8, PE12 and PE21 were inverted U-shaped. Besides, 
the dose-response curve for PE6 was J-shaped (Figure 2.1-2.3). Such nonlinear and biphasic dose-
response curves signify a hormetic type of stress response, in which 1) lower (hormetic) 
concentrations of a chemical compound increase the survival of a cell or an organism by 
stimulating biological processes that allow cellular or organismal stress at a level below a threshold 
of toxicity, whereas 2) higher concentrations of this chemical compound decrease the survival of 
a cell or an organism by creating stress that exceeds such threshold [116, 254, 369-371]. 
2.3.4 Each of the six lifespan-extending PEs alters the age-related chronology of 
longevity-defining traits of mitochondrial functionality 
            We hypothesized that PE4, PE5, PE6, PE8, PE12 and PE21 slow yeast chronological aging 
by influencing specific cellular processes. We sought to identify these longevity-defining 
processes. Certain aspects of mitochondrial functionality (such as mitochondrial respiration, 
mitochondrial membrane potential and mitochondrial reactive oxygen species [ROS] homeostasis) 
are known to define the rate of chronological aging in yeast [15, 17, 24, 32, 55, 59, 62, 87, 102, 
103, 106, 110, 118, 122, 125, 132, 134, 158]. We, therefore, assessed how PE4, PE5, PE6, PE8, 
PE12 and PE21 impact these longevity-defining processes in chronologically aging yeast cultures 
under non-CR conditions on 2% glucose. 
            We found that each of the six lifespan-extending PEs stimulates coupled mitochondrial 
respiration, which was assessed by measuring the rate of oxygen consumption by yeast cells. PE4, 
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PE8 and PE12 significantly decreased the extent to which such respiration declined in ST-phase 
cultures (Figure 2.12A, 2.12D and 2.12E), whereas PE5, PE6 and PE21 considerably increased 
the rate of mitochondrial respiration in yeast during the PD and ST phases of culturing (Figure 
2.12B, 2.12C and 2.12F). 
            We also found that each of the six lifespan-extending PEs sustains healthy populations of 
functional mitochondria that have high mitochondrial membrane potential (ΔΨm). PE4, PE8 and 
PE12 substantially decreased the extent to which ΔΨm declined during the PD and ST phases of 
culturing (Figure 2.13A, 2.13D and 2.13E; Figures 2.14 and 2.15), whereas PE5, PE6 and PE21 
prevented such decline (Figure 2.13A, 2.13D and 2.13E; Figures 2.14 and 2.15). 
 
Figure 2.12. PE4, PE5, PE6, PE8, PE12 and PE21 alter the age-related chronology of 
mitochondrial oxygen consumption by yeast grown under non-CR conditions. WT cells were 
60 
 
grown in the synthetic minimal YNB medium initially containing 2% glucose in the presence of a 
PE or its absence. A polarographic assay was used to measure oxygen uptake by live yeast cells, 
as described in Materials and methods. Age-dependent changes in the rate of mitochondrial oxygen 
consumption by chronologically aging WT strain cultured under non-CR conditions on 2% glucose 
with or without 0.5% PE4 (A), 0.5% PE5 (B), 1% PE6 (C), 0.3% PE8 (D), 0.1% PE12 (E) or 0.1% 
PE21 (F) are shown; data are presented as means ± SEM (n = 7-9; * p < 0.05; the p values for 
comparing the means of two groups were calculated with the help of the GraphPad Prism statistics 
software using an unpaired two-tailed t test). Abbreviations: Logarithmic (L), post-diauxic (PD) 
or stationary (ST) growth phase. 
 
 
Figure 2.13. PE4, PE5, PE6, PE8, PE12 and PE21 sustain healthy populations of functional 
mitochondria that exhibit high mitochondrial membrane potential (ΔΨm) in chronologically 
aging yeast grown under non-CR conditions. WT cells were grown in the synthetic minimal 
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YNB medium initially containing 2% glucose in the presence of a PE or its absence. ΔΨm was 
measured in live yeast by fluorescence microscopy of Rhodamine 123 staining, as described in 
Materials and methods. Age-dependent changes in the percentage of WT cells displaying high 
ΔΨm in chronologically aging yeast cultures under non-CR conditions on 2% glucose with or 
without 0.5% PE4 (A), 0.5% PE5 (B), 1% PE6 (C), 0.3% PE8 (D), 0.1% PE12 (E) or 0.1% PE21 
(F) are shown; data are presented as means ± SEM (n = 3-4; * p < 0.05; the p values for comparing 
the means of two groups were calculated with the help of the GraphPad Prism statistics software 
using an unpaired two-tailed t test). Abbreviations: Logarithmic (L), post-diauxic (PD) or 




Figure 2.14. PE4, PE5, PE6, PE8, PE12 and PE21 significantly delay an age-dependent 
decline in the number of WT cells that exhibit high mitochondrial membrane potential under 
non-CR conditions. WT cells were grown in the synthetic minimal YNB medium initially 
containing 2% glucose in the presence of a PE or its absence. Yeast cells were recovered at days 
1 and 2 of culturing, stained with Rhodamine 123 (R123) for visualizing cells displaying high 
mitochondrial membrane potential, and subjected to live-cell fluorescence microscopy and 




Figure 2.15. PE4, PE5, PE6, PE8, PE12 and PE21 significantly delay an age-dependent 
decline in the number of WT cells that exhibit high mitochondrial membrane potential under 
non-CR conditions. WT cells were grown in the synthetic minimal YNB medium initially 
containing 2% glucose in the presence of a PE or its absence. Yeast cells were recovered at days 
3 and 4 of culturing, stained with R123 for visualizing cells displaying high mitochondrial 
membrane potential, and subjected to live-cell fluorescence microscopy and DIC microscopy as 
described in Materials and methods. 
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            PE4, PE5, PE6, PE8, PE12 and PE21 also caused significant changes in the age-related 
chronology of intracellular ROS, which in yeast and other organisms are known to be formed 
mainly as by-products of mitochondrial respiration [66, 179]. Each of these PEs decreased the 
extent to which the intracellular concentration of mitochondrially generated ROS declined during 
the PD and ST phases of culturing (Figure 2.16A-2.16F). On days 3 and 4 of culturing, ROS 
concentrations in yeast exposed to PE4, PE5, PE6, PE8, PE12 or PE21 exceeded those in yeast 
cultured without it (Figure 2.16A-2.16F). 
 
Figure 2.16. In yeast grown under non-CR conditions, PE4, PE5, PE6, PE8, PE12 and PE21 
alter the patterns of age-related changes in intracellular reactive oxygen species (ROS) 
known to be generated mainly as by-products of mitochondrial respiration. WT cells were 
grown in the synthetic minimal YNB medium initially containing 2% glucose in the presence of a 
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PE or its absence. The intracellular concentrations of ROS were measured in live yeast by 
fluorescence microscopy of dihydrorhodamine 123 staining, as described in Materials and 
methods. Age-dependent changes in ROS concentrations within chronologically aging WT cells 
cultured under non-CR conditions on 2% glucose with or without 0.5% PE4 (A), 0.5% PE5 (B), 
1% PE6 (C), 0.3% PE8 (D), 0.1% PE12 (E) or 0.1% PE21 (F) are shown. Data are presented as 
means ± SEM (n = 3-4; * p < 0.05; the p values for comparing the means of two groups were 
calculated with the help of the GraphPad Prism statistics software using an unpaired two-tailed t 
test). Abbreviations: Logarithmic (L), post-diauxic (PD) or stationary (ST) growth phase. 
2.3.5 The six lifespan-extending PEs differently influence the extent of age-related 
oxidative damage to cellular proteins, membrane lipids, mitochondrial and nuclear 
genomes 
            A body of evidence supports the following view on the relationships between cellular ROS, 
oxidative molecular damage and aging in organisms across species: 1) if cellular concentrations 
of ROS exceed a threshold of toxicity, ROS cause oxidative damage to proteins, lipids and DNA, 
2) oxidative damage to these macromolecules accumulates with age, and 3) cumulative oxidative 
damage to the different types of macromolecules is one of the major causes of aging [123, 372-
379]. We, therefore, examined how PE4, PE5, PE6, PE8, PE12 and PE21 influence the extent of 
oxidative damage to proteins, lipids and DNA in chronologically aging yeast cultured under non-
CR conditions on 2% glucose. 
            We found that each of the six lifespan-extending PEs postpones the onset of an age-related 
rise in the extent of oxidative damage to cellular proteins. PE6, PE12 and PE21 decreased oxidative 
carbonylation of proteins in yeast cells advancing through the ST phase of culturing (Figure 2.17C, 
2.17E and 2.17F). PE4, PE5 and PE8 elicited such inhibitory effect on oxidative protein damage 
only later in the ST phase, on day 4 of culturing (Figure 2.17A, 2.17B and 2.17D). 
            Furthermore, PE5, PE6, PE8, PE12 and PE21 (but not PE4) caused a significant decline in 
the levels of oxidatively damaged membrane lipids; such decline was observed late in the ST 
phase, on days 3 and/or 4 of culturing (Figure 2.17H-2.17L). 
            Moreover, PE4, PE5, PE6, PE8, PE12 and PE21 decreased the frequencies of spontaneous 
point mutations in the RIB2 and RIB3 genes of mitochondrial DNA (mtDNA) (Figure 2.18A-
2.18F) - likely due to a reduced extent of oxidative damage to mtDNA in yeast cells exposed to 
any of these PEs. Such inhibitory effects of the six lifespan-extending PEs on oxidative damage to 
mtDNA were observed late in the ST phase, on day 4 of culturing. 
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            We also found that PE12 and PE21 (but not PE4, PE5, PE6 or PE8) caused a significant 
decline in the frequencies of spontaneous point mutations in the CAN1 gene of nuclear DNA 
(nDNA) (Figure 2.18K and 2.18L) - possibly due to a decreased degree of oxidative damage to 
nDNA in yeast cells cultured in the presence of PE12 or PE21. Such inhibitory effects of PE12 or 
PE21 on oxidative damage to nDNA were also observed late in the ST phase, on day 4 of culturing. 
 
Figure 2.17. PE4, PE5, PE6, PE8, PE12 and PE21 delay an age-dependent rise in the extent 
of oxidative damage to cellular proteins in chronologically aging yeast grown under non-CR 
conditions. PE5, PE6, PE8, PE12 and PE21, but not PE4, have similar effects on the extent of 
oxidative damage to membrane lipids. WT cells were grown in the synthetic minimal YNB 
medium initially containing 2% glucose in the presence of a PE or its absence. Carbonylated 
cellular proteins (A – F) and oxidatively damaged membrane lipids (G – L) were determined as 
described in Materials and methods. Age-dependent changes in the concentrations of these 
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oxidatively damaged macromolecules within chronologically aging WT cells cultured under non-
CR conditions on 2% glucose with or without 0.5% PE4 (A and G), 0.5% PE5 (B and H), 1% PE6 
(C and I), 0.3% PE8 (D and J), 0.1% PE12 (E and K) or 0.1% PE21 (F and L) are shown; data are 
presented as means ± SEM (n = 2-4; * p < 0.05; the p values for comparing the means of two 
groups were calculated with the help of the GraphPad Prism statistics software using an unpaired 




Figure 2.18. PE4, PE5, PE6, PE8, PE12 and PE21 slow down an age-dependent rise in the 
frequency of spontaneous point mutations in the RIB2 and RIB3 loci of mitochondrial DNA 
(mtDNA) in chronologically aging yeast cultured under non-CR conditions. PE12 and PE21, 
but not PE4, PE5, PE6 or PE8, have similar effects on the frequency of spontaneous point 
mutations in the CAN1 gene of nuclear DNA (nDNA). WT cells were grown in the synthetic 
minimal YNB medium initially containing 2% glucose in the presence of a PE or its absence. The 
frequency of spontaneous point mutations in the RIB2 and RIB3 loci of mtDNA (A - F), as well as 
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the frequency of spontaneous point mutations in the CAN1 gene of nDNA (G - L), were measured 
as described in Materials and methods. Age-dependent changes in the frequencies of these mtDNA 
and nDNA mutations in chronologically aging WT cells cultured under non-CR conditions on 2% 
glucose with or without 0.5% PE4 (A and G), 0.5% PE5 (B and H), 1% PE6 (C and I), 0.3% PE8 
(D and J), 0.1% PE12 (E and K) or 0.1% PE21 (F and L) are shown; data are presented as means 
± SEM (n = 3-5; * p < 0.05; the p values for comparing the means of two groups were calculated 
with the help of the GraphPad Prism statistics software using an unpaired two-tailed t test). 
Abbreviations: Logarithmic (L), post-diauxic (PD) or stationary (ST) growth phase. 
2.3.6 The six lifespan-extending PEs differently influence the resistance of chronologically 
aging yeast to chronic oxidative and thermal stresses 
A wealth of research has shown that the development of resistance to chronic (long-term) 
oxidative and/or thermal stresses can extend longevity in organisms across species, including yeast 
[11, 14, 15, 17, 32, 68, 178, 179, 254, 370, 371, 380-382]. We, therefore, assessed how PE4, PE5, 
PE6, PE8, PE12 and PE21 influence the abilities of chronologically aging yeast cultured under 
non-CR conditions to resist chronic oxidative and thermal stresses. 
            Chronic oxidative stress was administered by recovering yeast cells advancing through the 
L, PD or ST phases of culturing in liquid YNB medium initially containing 2% glucose, spotting 
these cells on solid YEP medium with 2% glucose and 5 mM hydrogen peroxide, and incubating 
them for 3 days. We found that PE6, PE12 and PE21 significantly increase cell resistance to 
chronic oxidative stress in yeast cultures advancing through the L, PD and ST phases of culturing 
(Figure 2.19A and 2.19B). PE4, PE5 and PE8 enhanced the ability of cells to resist chronic 
oxidative stress only in yeast cultures advancing through the ST phase but did not alter such ability 
during the L and PD phases of culturing (Figure 2.19A and 2.19B). 
            Chronic thermal stress was administered by recovering yeast cells advancing through the 
L, PD or ST phases of culturing in liquid YNB medium initially containing 2% glucose, spotting 
these cells on solid YEP medium with 2% glucose and incubating at 60°C for 60 min, and then 
transferring plates with these cells to 30°C and incubating at this temperature for 3 days. We found 
that PE6, PE8, PE12 and PE21 increase cell resistance to chronic thermal stress only in yeast 
cultures advancing through the ST phase of culturing (Figure 2.20A and 2.20B). In contrast, each 
of these four lifespan-extending PEs weakened the ability of cells to resist chronic thermal stress 
during the L and PD phases of culturing (Figure 2.20A and 2.20B). Furthermore, neither PE4 nor 
PE5 altered cell resistance to chronic thermal stress in yeast cultures advancing through the ST 
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phase of culturing (Figure 2.20A and 2.20B). PE4 did not affect the ability of cells to resist chronic 
thermal stress also during the L and PD phases of culturing, whereas PE5 weakened such ability 
in yeast cultures advancing through these two phases of culturing (Figure 2.20A and 2.20B). 
 
Figure 2.19. PE4, PE5, PE6, PE8, PE12 and PE21 enhance the ability of chronologically 
aging yeast grown under non-CR conditions to resist chronic oxidative stress. WT cells were 
grown in the synthetic minimal YNB medium initially containing 2% glucose in the presence of a 
PE or its absence. (A) Spot assays for monitoring oxidative stress resistance were performed as 
described in Materials and methods. Serial 10-fold dilutions of cells recovered at different days of 
culturing were spotted on plates with solid YEP medium containing 2% glucose as carbon source, 
with or without 5 mM hydrogen peroxide. All pictures were taken after a 3-d incubation at 30oC. 
(B) A model for how 0.5% PE4, 0.5% PE5, 1% PE6, 0.3% PE8, 0.1% PE12 and 0.1% PE21 
influence the resistance of yeast to chronic oxidative stress during the logarithmic (L), post-diauxic 
(PD) or stationary (ST) phases of growth.  or  Denote unaltered or enhanced, respectively, 
cell resistance to chronic oxidative stress during a particular phase of growth. Abbreviations: 




Figure 2.20. PE4, PE5, PE6, PE8, PE12 and PE21 exhibit different effects on the ability of 
chronologically aging yeast grown under non-CR conditions to resist chronic thermal stress. 
WT cells were grown in the synthetic minimal YNB medium initially containing 2% glucose in 
the presence of a PE or its absence. (A) Spot assays for monitoring thermal stress resistance were 
performed as described in Materials and methods. Serial 10-fold dilutions of cells recovered at 
different days of culturing were spotted on plates with solid YEP medium containing 2% glucose 
as carbon source. Plates were initially incubated at 30oC (control) or 60oC for 60 min and were 
then transferred to 30oC. All pictures were taken after a 3-d incubation at 30oC. (B) A model for 
how 0.5% PE4, 0.5% PE5, 1% PE6, 0.3% PE8, 0.1% PE12 and 0.1% PE21 influence the resistance 
of yeast to chronic thermal stress during the logarithmic (L), post-diauxic (PD) or stationary (ST) 
phases of growth.  or  Denote unaltered, reduced or enhanced, respectively, cell resistance 
to chronic thermal stress during a particular phase of growth. Abbreviations: Logarithmic (L), 
post-diauxic (PD) or stationary (ST) growth phase.     
2.3.7 Each of the six lifespan-extending PEs causes rapid degradation of neutral lipids 
deposited in lipid droplets 
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            Triacylglycerols and steryl esters are uncharged (and therefore are called “neutral” or 
“nonpolar”) classes of lipids that can be found in cells of all eukaryotic organisms [183, 383, 384]. 
After being initially synthesized in the endoplasmic reticulum and then deposited in lipid droplets 
(LDs), these two highly hydrophobic lipids can undergo lipolytic degradation to provide substrates 
for the synthesis of phospholipids and sphingolipids [183, 385-388]. New evidence supports the 
view that the biosynthesis, storage and lipolysis of neutral lipids are longevity assurance processes; 
importantly, it has been shown that these processes can be controlled by specific dietary and 
pharmacological interventions known to slow aging in various eukaryotes, including yeast [9, 17, 
32, 98, 110, 113, 127, 136, 161, 210, 388-402]. We, therefore, used live-cell fluorescence 
microscopy to examine how PE4, PE5, PE6, PE8, PE12 and PE21 influence the age-related 
dynamics of changes in the intracellular concentration of neutral lipids confined to LDs in 
chronologically aging yeast grown under non-CR conditions. 
            We found that each of the six lifespan-extending PEs causes a rapid age-related decline in 
the number of yeast cells having LDs (Figures 2.21A–2.21F; Figures 2.22 and 2.23). In contrast, 
no significant changes in the number of cells with LDs were seen in yeast advancing through the 
L, PD and ST phases of culturing in medium without a PE (Figures 2.21A-2.21F; Figures 2.22 and 
2.23). These findings show that in chronologically aging yeast grown under non-CR conditions, 
each of the six lifespan-extending PEs causes rapid lipolytic degradation of neutral lipids stored in 
LDs. 
2.4 Discussion 
            In this study, we performed a screen for PEs capable of extending the longevity of the 
chronologically aging yeast. Our screen uncovered six PEs (which we call PE4, PE5, PE6, PE8, 
PE12 and PE21) that can significantly increase yeast CLS. We demonstrated that each of these 
PEs is a geroprotector postponing the onset and slowing the advancement of yeast chronological 
aging because it causes a hormetic stress response. We provided evidence that each of these 
geroprotective PEs has different effects on cellular processes known to assure longevity in 
organisms across species. Such effects include the following: 1) amplified mitochondrial 
respiration and membrane potential, 2) increased or decreased concentrations of ROS, 3) decreased 
oxidative damage to cellular proteins, membrane lipids, and mitochondrial and nuclear genomes, 
4) enhanced cell resistance to oxidative and thermal stresses, and 5) accelerated degradation of 
72 
 
neutral lipids deposited in LDs (Figure 2.24). These findings provide critical new insights into 
mechanisms through which some chemical compounds of plant origin can slow biological aging. 
 
 
Figure 2.21. PE4, PE5, PE6, PE8, PE12 and PE21 induce rapid consumption of neutral lipids 
deposited in lipid droplets (LDs) of chronologically aging yeast grown under non-CR 
conditions. WT cells were grown in the synthetic minimal YNB medium initially containing 2% 
glucose in the presence of a PE or its absence. Neutral lipids deposited in LDs were measured in 
live yeast by fluorescence microscopy of BODIPY 493/503 staining, as described in Materials and 
methods. Age-dependent changes in the percentage of WT cells exhibiting LDs in chronologically 
aging yeast cultures under non-CR conditions on 2% glucose with or without 0.5% PE4 (A), 0.5% 
PE5 (B), 1% PE6 (C), 0.3% PE8 (D), 0.1% PE12 (E) or 0.1% PE21 (F) are shown; data are 
presented as means ± SEM (n = 3-4; * p < 0.05; the p values for comparing the means of two 
groups were calculated with the help of the GraphPad Prism statistics software using an unpaired 
73 
 
two-tailed t test). Abbreviations: Logarithmic (L), post-diauxic (PD) or stationary (ST) growth 
phase. 
 
Figure 2.22. PE4, PE5, PE6, PE8, PE12 and PE21 significantly accelerate an age-dependent 
decline in the number of WT cells that exhibit LDs under non-CR conditions. WT cells were 
grown in the synthetic minimal YNB medium initially containing 2% glucose in the presence of a 
PE or its absence. Yeast cells were recovered at days 1 and 2 of culturing, stained with BODIPY 
493/503 for visualizing cells displaying neutral lipids deposited in LDs, and subjected to live-cell 
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fluorescence microscopy and differential interference contrast (DIC) microscopy as described in 
Materials and methods. 
 
Figure 2.23. PE4, PE5, PE6, PE8, PE12 and PE21 significantly accelerate an age-dependent 
decline in the number of WT cells that exhibit LDs under non-CR conditions. WT cells were 
grown in the synthetic minimal YNB medium initially containing 2% glucose in the presence of a 
PE or its absence. Yeast cells were recovered at days 3 and 4 of culturing, stained with BODIPY 
493/503 for visualizing cells displaying neutral lipids deposited in LDs, and subjected to live-cell 
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fluorescence microscopy and differential interference contrast (DIC) microscopy as described in 
Materials and methods. 
 
Figure 2.24. PE4, PE5, PE6, PE8, PE12 and PE21 delay yeast chronological aging and have 
different effects on several longevity-defining cellular processes. Arrows pointing at boxes with 
the terms of longevity-defining cellular processes denote activation of these processes, T bars 
denote inhibition of these processes, whereas lines with filled circles denote a change in the age-
related chronology of intracellular ROS. The thickness of such arrows, T bars and lines with filled 
circles correlates with the extent to which a PE activates, inhibits or alters the age-related 
chronology (respectively) of a particular longevity-defining cellular process. Arrows and T bars 
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pointing at boxes with the term “AGING” denote acceleration or deceleration (respectively) of 
yeast chronological aging. 
2.4.1 Each of the six longevity-extending PEs increases lifespan more efficiently than any 
lifespan-prolonging chemical compound presently known 
            Our findings indicate that the efficiency of longevity extension by PE4, PE5, PE6, PE8, 
PE12 or PE21 significantly exceeds that for any of the 42 chemical compounds known to increase 
lifespan in yeasts, filamentous fungi, nematodes, fruit flies, daphnias, mosquitoes, honey bees, 
fishes, mammals and cultured human cells (Table 2.3). Indeed, under non-CR conditions, these 
longevity-extending PEs increase the mean and maximum CLS of yeast by 145%–475% and 80%–
369%, respectively (Figure 2.8A and 2.8B; Table 2.3); the corresponding rows in Table 2.3 are 
highlighted in yellow. In contrast, any of the 42 currently known lifespan-extending chemical 
compounds has been shown to extend cellular and/or organismal lifespan in evolutionarily distant 
eukaryotes much less efficiently, within the 5% to 75% range (Table 2.3) [61-63, 83, 197, 227, 
271, 273, 368, 403-451]. Only two chemical compounds, spermidine under non-CR conditions 
and lithocholic acid under CR-conditions, have been reported to have the lifespan-extending 
efficiencies that are comparable to those for PE4, PE5, PE6, PE8 and PE12 (Table 2.3) [83, 102, 
110]. Specifically, both these pharmacological interventions were demonstrated to increase the 
RLS and/or CLS of yeast and human peripheral blood mononuclear cells by 83%-200%; the 
corresponding rows in Table 2.3 are highlighted in green. Of note, PE21 appears to be the most 
potent longevity-extending pharmacological intervention presently known. It increases the mean 
and maximum CLS of yeast by 475% and 369%, respectively (Figure 2.8A and 2.8B; Table 2.3). 
 
Table 2.3. Percent increase of lifespan by geroprotective PEs in this study and by longevity-
extending chemical compounds that have been previously identified. 
 
PE or chemical 
compound 
% increase of lifespan* [reference] Organism exhibiting 
lifespan increase 
0.5% PE4 195% (mean CLS) [this study] 
100% (max** CLS) [this study] 
S. cerevisiae  
 
0.5% PE5 185% (mean CLS) [this study] 





1.0 % PE6 180% (mean CLS) [this study] 
80% (max CLS) [this study] 
S. cerevisiae 
 
0.3% PE8 145% (mean CLS) [this study] 
104% (max) [this study] 
S. cerevisiae 
 
0.1% PE12 160% (mean CLS) [this study] 
107% (max CLS) [this study] 
S. cerevisiae 
 
0.1% PE21 475% (mean CLS) [this study] 
369% (max CLS) [this study] 
S. cerevisiae 
 
Acteoside  24 - 25% (female); 16 - 18% (male) (mean OLS) [419] 
9 - 13% (female); 9 - 15% (male) (max OLS) [419] 
The fruit fly Drosophila 
melanogaster 
Butein  55% (mean RLS) [271] S. cerevisiae 
Caffeic acid 11% (mean OLS) [440] The nematode 
Caenorhabditis elegans 
Caffeine 8% (median CLS) [197] S. cerevisiae  
46% (mean CLS) [449] 




52% (mean OLS) [438]; 37% (mean OLS) [448] 
29% (median OLS) [438] 
C. elegans 
Catechin  15% (mean OLS) [427] 
14% (median OLS) [427] 
C. elegans 





13% - 39% (mean OLS) [437] C. elegans 
26% (females; mean OLS); 16% (males; mean OLS) [433, 451] 
75% (median OLS) [444] 
D. melanogaster, 
including 5 different 
models of the 
Alzheimer’s disease  
Crocin 37% - 58% (max OLS) [425]  
 
Dalton’s lymphoma 
ascites bearing mice 
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Cryptotanshinone 34% (mean CLS) [227] S. cerevisiae 
Cyanidin 2% - 6% (max RLS; untreated cells); 14 - 21% (max RLS; 
prematurely aging cells pre-treated with H2O2) [431] 
WI-38 human diploid 
fibroblasts  
Diallyl trisulfide 13% (mean OLS) [439] C. elegans 
Ellagic acid 9% (mean OLS); 11% - 13% (median OLS) [442] C. elegans 
Epigallocatechin 
gallate 
10% - 14% (mean OLS) [423]   C. elegans 
Epicatechin 42% (mean OLS) [450] 
3% (max OLS) [450]  
D. melanogaster 
8% (mean OLS) [450] Obese diabetic mice 
Ferulsinaic acid 18% (mean CLS) [441] 
42% (max OLS) [441] 
C. elegans 
Fisetin 31% (mean RLS) [271] S. cerevisiae 
6% (mean OLS) [411] 
6% (median OLS) [411] 
C. elegans 
Fucoxanthin 14% (mean OLS) [368] 
24% (max OLS) [368] 
C. elegans 
33% - 49% (females; median OLS); 33% (males; median OLS) 
[368] 
22% - 27% (females; max OLS); 12% - 17% (males; max OLS) 
[368] 
D. melanogaster 
Gallic acid 12% (mean OLS) [442] 
14% (median OLS) [442] 
C. elegans 
HDTIC-1, HDTIC-2 14% - 38% (max RLS) [405] Human fetal lung 
diploid fibroblasts  
Icariin, icariside II 31% (mean OLS) [436] C. elegans 
Kaempferol  10% (mean OLS) [411] 
6% (median OLS) [411] 
C. elegans 
Lipoic acid 21% (median OLS) [415] C. elegans 





4% (males; average OLS); 4% (males; median OLS) [406] 
Lithocholic acid 146% (mean CLS) [102, 110] 
100% (max CLS) [102, 110] 
S. cerevisiae 
Metformin 40% (median OLS) [434] C. elegans 
38% (mean OLS) [414] 




78% (mean CLS) [61] 
63% (max CLS) [61] 
S. cerevisiae 
Mianserin  25% (mean OLS) [413] C. elegans 
Myricetin  15% (mean OLS) [446] 
17% (median OLS) [446] 




10% (median OLS) [407] 
32% (max OLS) [407] 
Mouse model of 
Alzheimer’s disease 
12% (median OLS) [422] Male mice 
12% (mean OLS) [403] D. melanogaster 
42% - 64% (mean OLS) [404] Mosquitoes  
Oleuropein  15% (max RLS) [412] Human embryonic 
fibroblasts 
Phloridzin  35% (mean RLS) [272] 
41% (max RLS) [272] 
S. cerevisiae 
Propyl gallate  41% (median OLS) [415] C. elegans 
Quercetin  60% (mean CLS) [273] S. cerevisiae 
15% (mean OLS) [418] 
18% (mean OLS) [426] 
14% (median OLS) [443] 
C. elegans 
5% (max RLS) [432]   Human embryonic 
fibroblasts 
Rapamycin  16% (mean RLS) [63] 
36% (mean CLS) [62] 
S. cerevisiae 
17% (mean OLS) [430] D. melanogaster 
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23% (max OLS) [430] 
13% (females; mean OLS); 9% (males; mean OLS) [428] 
14% (females; max OLS); 9% (males; max OLS) [428] 
Mice 
Reserpine 64% (mean OLS); 50% (max OLS) [421] C. elegans 
52% (mean OLS) [424] C. elegans model of 
Alzheimer’s disease 
Resveratrol 61% (mean RLS) [271] S. cerevisiae 
10% (mean OLS) [408] C. elegans 
20% (females; mean OLS); 16% (males; mean OLS) [408] D. melanogaster 
56% (median OLS) [410] 
59% (max OLS) [410] 
The short-lived fish 
Nothobranchius furzeri 
38% (mean OLS) [447] The honey bee Apis 
mellifera 
4% (max OLS) [420] Mice on a high-calorie 
diet  
Rosmarinic acid 10% (mean OLS) [440] C. elegans 
SkQ1 38% (mean CLS) [429] 
16% (max CLS) [429] 
The fungus Podospora 
anserina  
69% (mean CLS) [429] 
64% (max CLS) [429] 
The crustacean 
Ceriodaphnia affinis 
13% (females; mean OLS) [429] 
7% (females; max OLS) [429] 
D. melanogaster 
43% (mean OLS) [429] 
58% (max OLS) [429] 
p53-Deficient mice 
52% (mean OLS) [429] 
34% (max OLS) [429] 
Tumor-bearing 
immunodeficient mice 
Sodium nitroprusside 60% (max RLS) [416] Human peripheral 
blood mononuclear 
cells  
Spermidine 200% (mean CLS) [83] 




17% (max RLS) [83] 
15% (mean OLS) [83] 
14% (max) OLS) [83]  
C. elegans 
30% (mean OLS) [83] 
8% (max OLS) [83] 
D. melanogaster 
178% (max RLS) [83] Human peripheral 
blood mononuclear 
cells  
Tannic acid 18% - 25% (mean OLS) [435, 438, 442]; 18% (median OLS) 
[435, 442] 
59% (max OLS) [438] 
C. elegans 
Taxifolin 26% (median OLS) [415] C. elegans 
Trolox 15% (median OLS) [415] C. elegans 
Tyrosol 21% (mean OLS); 21% (median OLS) [445] 
11% (maximum OLS) [445] 
C. elegans 
Valproic acid 35% (mean OLS) [417] 
42% (max OLS) [417] 
C. elegans 
2.4.2 Future perspectives 
            In the future, it would be necessary to explore the following critical aspects of the 
mechanisms through which each of the six longevity-extending PEs slows biological aging. 
            First, it is intriguing to identify the individual chemical compounds responsible for the 
ability of each of these PEs to postpone the onset and decrease the rate of yeast chronological 
aging. Such identification is already underway in our laboratory; of note, it is conceivable that only 
some combinations of certain chemicals composing these PEs (but not individual chemical 
compounds per se) can be responsible for their extremely high efficiencies as aging-delaying 
interventions. 
            Second, it is interesting to elucidate how genetic interventions that impair any of the few 
nutrient-responding and energy-sensing signaling pathways known to define the longevity of 
chronologically aging yeast [14, 15, 17, 110] influence the extent to which each of the six 
longevity-extending PEs can slow aging. These studies may allow us to identify protein 
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components of the longevity-defining signaling pathways that are targeted by each of the PEs. 
These studies may also reveal that certain combinations of these PEs and genetically impaired 
components of pro-aging signaling pathways have additive or synergistic effects on the 
efficiencies of lifespan and healthspan extensions. 
            Third, it is important to investigate how various combinations of the six longevity-
extending PEs with each other and with presently known aging-delaying chemical compounds 
alter the extent of CLS extension in yeast. These studies may identify combinations of various 
pharmacological interventions that impose substantial additive or synergistic effects on the 
efficiencies with which organismal lifespan and healthspan can be prolonged. 
            Fourth, our ongoing studies indicate that the six longevity-extending PEs also extend 
longevities of other eukaryotic model organisms, delay the onset of age-related diseases and/or 
exhibit anti-tumor effects. In this regard, it needs to be mentioned that genetic, dietary and 
pharmacological interventions known to delay aging in yeast and other eukaryotes have been 
shown to selectively kill cultured human cancer cells and/or decrease the incidence of cancer [56, 
113, 209, 334, 335, 452-460]. The challenge for the future is to uncover mechanisms through 










3 Six plant extracts slow the chronological aging of S. cerevisiae through different 
signaling pathways 
3.1 Introduction 
            As described in Chapter 2 of my Thesis, we discovered six plant extracts that delay yeast 
chronological aging more efficiently than any chemical compound presently known. The rate of 
aging in yeast is controlled by an evolutionarily conserved network of integrated signaling 
pathways and protein kinases. Here, we investigated how single-gene-deletion mutations that 
eliminate each of these pathways and kinases influence the aging-delaying efficiencies of the six 
geroprotective plant extracts. Our findings indicate that these extracts slow aging in the following 
ways: 1) plant extract 4 lowers the efficiency with which the pro-aging TORC1 pathway 
suppresses the anti-aging SNF1 pathway, 2) plant extract 5 alleviates two different branches of the 
pro-aging PKA pathway, 3) plant extract 6 organizes processes that are not integrated into the 
network of presently known signaling pathways and protein kinases, 4) plant extract 8 weakens 
the inhibitory action of PKA on SNF1, 5) plant extract 12 stimulates the anti-aging protein kinase 
Rim15, and 6) plant extract 21 suppresses a form of the pro-aging protein kinase Sch9 that is 
activated by the pro-aging PKH1/2 pathway. Chapter 3 describes these findings.   
3.2 Materials and methods 
3.2.1 Yeast strains, media and culture conditions 
            The wild-type strain Saccharomyces cerevisiae BY4742 (MATα his3∆ leu2∆ lys2∆ ura3∆) 
and single-gene-deletion mutant strains in the BY4742 genetic background (all from Thermo 
Scientific/Open Biosystems) were cultured in a synthetic minimal YNB medium (0.67% (w/v) 
Yeast Nitrogen Base without amino acids) initially containing 2% (w/v) glucose and supplemented 
with 20 mg/l histidine, 30 mg/l leucine, 30 mg/l lysine and 20 mg/l uracil. Cells were cultured at 
30oC with rotational shaking at 200 rpm in Erlenmeyer flasks at a “flask volume/medium volume” 
ratio of 5:1. 
3.2.2 Aging-delaying plant extracts (PEs) 
            0.5% (w/v) PE4 from Cimicifuga racemosa, 0.5% (w/v) PE5 from Valeriana officinalis L., 
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1.0% (w/v) PE6 from Passiflora incarnata L., 0.3% (w/v) PE8 from Ginkgo biloba, 0.1% (w/v) 
PE12 from Apium graveolens L. and 0.1% (w/v) PE21 from Salix alba were used [461]. A 20% 
(w/v) stock solution of each PE in ethanol was made on the day of adding this PE to cell cultures. 
For each PE, the stock solution was added to growth medium with 2% (w/v) glucose immediately 
following cell inoculation into the medium. 
3.2.3 CLS assay 
            A sample of cells was taken from a culture at a certain day following cell inoculation and 
PE addition into the medium. A fraction of the sample was diluted to determine the total number 
of cells using a hemacytometer. Another fraction of the cell sample was diluted, and serial dilutions 
of cells were plated in duplicate onto YEP (1% (w/v) yeast extract, 2% (w/v) peptone) plates 
containing 2% (w/v) glucose as carbon source. After 2 d of incubation at 30oC, the number of 
colony-forming units (CFU) per plate was counted. The number of CFU was defined as the number 
of viable cells in a sample. For each culture, the percentage of viable cells was calculated as 
follows: (number of viable cells per ml/total number of cells per ml) × 100. The percentage of 
viable cells in the mid-logarithmic growth phase was set at 100%. 
3.2.4 Miscellaneous procedures 
            The age-specific mortality rate (qx) [359, 360], Gompertz slope or mortality rate coefficient 
(α) [360, 361], and mortality rate doubling time (MRDT) [360, 361] were calculated as previously 
described. The value of qx was calculated as the number of cells that lost viability (i.e., are unable 
to form a colony on the surface of a solid nutrient-rich medium) during each time interval divided 
by the number of viable (i.e., clonogenic) cells at the end of the interval. The natural logarithms of 
the values of qx for each time interval were plotted against time. The value of α was calculated as 
the slope of the Gompertz mortality line, whereas the value of MRDT was calculated as ln2/α. 
3.2.5 Statistical analysis 
            Statistical analysis was performed using Microsoft Excel’s (2010) Analysis ToolPack-
VBA. All data on cell survival are presented as mean ± SEM. The p values for comparing the 
means of two groups (using an unpaired two-tailed t test) and survival curves (using a two-tailed t 




3.3.1 The rationale of our experimental approach 
            PE4, PE5, PE6, PE8, PE12 and PE21 may have different effects on signaling pathways 
and/or protein kinases integrated into the signaling network of longevity regulation. To identify 
the signaling pathways and protein kinases through which each of these PEs slows yeast 
chronological aging, we examined such effects. Specifically, we elucidated how mutations that 
eliminate these signaling pathways and protein kinases affect the efficiency with which each of 
the six geroprotective PEs extends yeast CLS. Table 3.1 shows the single-gene-deletion mutations 
used in this study. This table also demonstrates how each of the mutations affects different 
longevity-defining signaling pathways and protein kinases, and how it alters yeast CLS. We 
investigated the effects of the following single-gene-deletion mutations shown in Table 3.1: 1) 
tor1Δ, which impairs the pro-aging TORC1 pathway and increases CLS [61, 62], 2) ras2Δ, which 
weakens the pro-aging PKA pathway and extends CLS [64], 3) rim15Δ, which eliminates the anti-
aging protein kinase Rim15 and shortens CLS [66], 4) sch9Δ, which removes the pro-aging protein 
kinase Sch9 and prolongs CLS [66], 5) pkh2Δ, which weakens the pro-aging PKH1/2 pathway and 
extends CLS [43, 70], 6) snf1Δ, which impairs the anti-aging SNF1 pathway and shortens CLS 
[74, 95], and 7) atg1Δ, which weakens the anti-aging ATG pathway and decreases CLS [81, 82]. 
 
Table 3.1. Single-gene-deletion mutations used in this study and their known effects on 








Effect on longevity 
tor1Δ Tor1 TORC1 Extended [61, 62] 
ras2Δ Ras2 PKA Extended [64] 
rim15Δ Rim15 TORC1, PKA, PKH1/2 Shortened [66] 
sch9Δ Sch9 TORC1, PKA Extended [66] 
pkh2Δ Pkh2 PKH1/2 Extended [43, 70] 
snf1Δ Snf1 SNF1 Shortened [74, 95] 




            A logical framework for identifying signaling pathways and/or protein kinases controlled 
by each of the six geroprotective PEs is schematically shown in Figure 3.1. Pro-aging signaling 
pathways or protein kinases A and B in this Figure are displayed in black color, whereas their anti-
aging counterparts C and D are shown in grey color. One could envision that if a PE(x) extends 
yeast CLS by inhibiting a pro-aging pathway/protein kinase A, this PE: 1) is unable to prolong the 
longevity of the ΔA mutant strain lacking this signaling pathway/protein kinase (Figure 3.1B), 2) 
exhibits an additive or synergistic longevity-extending effect with the ΔB mutation, which 
eliminates the pro-aging signaling pathway/protein kinase B (Figure 3.1B), and 3) can extend the 
longevity of the ΔC or ΔD mutant strain, which lacks the anti-aging signaling pathway/protein 
kinase C or D (respectively), but to a lesser extent than that of wild-type (WT) strain (Figure 3.1B). 
It is also conceivable that if a PE(y) prolongs yeast CLS by activating an anti-aging 
pathway/protein kinase C, this PE: 1) displays an additive or synergistic longevity-extending effect 
with the ΔA or ΔB mutation, which eliminates the pro-aging signaling pathway/protein kinase A 
or B (respectively) (Figure 3.1C), 2) is incapable of extending the longevity of the ΔC mutant strain 
deficient in the anti-aging signaling pathway/protein kinase C (Figure 3.1C), and 3) can prolong 
the longevity of the ΔD mutant strain, which lacks the anti-aging signaling pathway/protein kinase 
D, although not as considerably as that of WT strain (Figure 3.1C). 
3.3.2  PE4 slows yeast chronological aging by attenuating the inhibitory effect of TORC1 
on SNF1 
            PE4 exhibited additive longevity-extending effects with the ras2Δ, sch9Δ and pkh2Δ 
mutations, which eliminate different signaling pathways/protein kinases comprising the longevity-
defining network (Figure 3.2A, Tables 3.2 and 3.3, Figure 3.3; note that data for the mock-treated 
WT strain and the WT strain cultured with PE4 are replicated in all graphs of Figure 3.2A and 
Figure 3.3). PE4 elicited a decline in the slope of the Gompertz mortality rate (also known as 
mortality rate coefficient α) and a rise in the mortality rate doubling time (MRDT) for ras2Δ, sch9Δ 
and pkh2Δ (Figure 3.4; note that data for the mock-treated WT strain and the WT strain cultured 
with PE4 are replicated in all graphs of this figure). Such changes in the values of α and MRDT 
are characteristic of interventions that lower the rate of biological aging [355, 360, 361, 367, 368]. 
Thus, PE4 slows yeast chronological aging independently of the pro-aging PKA pathway, the pro-
aging PKH1/2 pathway or the pro-aging protein kinase Sch9. 
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            PE4 extended longevities of the rim15Δ and atg1Δ mutant strains, although to a lesser 
extent than that of WT strain (Figure 3.2A, Tables 3.2 and 3.3, Figure 3.3). PE4 decreased the 
value of α and increased the value of MRDT for rim15Δ and atg1Δ, though not as significantly as 
for WT (Figure 3.4). Hence, PE4 slows yeast chronological aging not through the anti-aging 
protein kinase Rim15 or the anti-aging ATG pathway. 
            PE4 was unable to increase the CLS of tor1Δ and snf1Δ (Figure 3.2A, Tables 3.2 and 3.3, 
Figure 3.3) and did not alter the values of α or MRDT for these mutant strains (Figure 3.4). We 
concluded that PE4 slows yeast chronological aging via the pro-aging TORC1 pathway and the 
anti-aging SNF1 pathway, by deteriorating the known [96, 99] inhibitory effect of TORC1 on 
SNF1 (Figure 3.2B). 
 
Figure 3.1. A logical framework for identifying signaling pathways and/or protein kinases 
controlled by the longevity-extending PE(x) and PE(y). (A) A schematic depiction of a network 
that integrates several signaling pathways and protein kinases to define the rate of yeast 
chronological aging. Pro-aging signaling pathways or protein kinases A and B are shown in black 
color. Anti-aging signaling pathways or protein kinases C and D are displayed in grey color. 
Abbreviations are as in Figure 1.2. (B) Predicted effect of PE(x), which extends yeast CLS by 
inhibiting a pro-aging pathway/protein kinase A, on the longevity of the ΔA, ΔB, ΔC or ΔD mutant 
strain lacking a signaling pathway/protein kinase A, B, C or D. (C) Predicted effect of PE(y), which 
extends yeast CLS by activating an anti-aging pathway/protein kinase C, on the longevity of the 
ΔA, ΔB, ΔC or ΔD mutant strain lacking the corresponding signaling pathway/protein kinase. 
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Abbreviation: WT, wild-type strain. 
 
Figure 3.2. PE4 extends yeast CLS by weakening the restraining action of TORC1 on SNF1. 
(A) Cells of the wild-type (WT) and indicated mutant strains were grown in the synthetic minimal 
YNB medium (0.67% Yeast Nitrogen Base without amino acids) initially containing 2% glucose, 
in the presence of 0.5% PE4 (ethanol was used as a vehicle at the final concentration of 2.5%) or 
in its absence (cells were subjected to ethanol-mock treatment). Survival curves of chronologically 
aging WT and mutant strains cultured with or without 0.5% PE4 are shown. Data are presented as 
means ± SEM (n = 7). The dotted line indicates the predicted survival curve of a particular mutant 
strain cultured with PE4 if this PE exhibits an additive longevity-extending effect with the 
mutation. Data for the mock-treated WT strain are replicated in all graphs of this Figure and all 
graphs of Figure 3.5. Data for each of the mock-treated mutant strains presented in this Figure are 
reproduced in the corresponding graphs of Figure 3.5. Data for the WT strain cultured with PE4 
are replicated in all graphs of this Figure. (B) The effect of PE4 on the signaling pathways and 
protein kinases comprising the longevity-defining signaling network. This effect is inferred from 
the data presented in (A), Tables 3.2 and 3.3, and Figures 3.3 and 3.4. Abbreviations: as in the 
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legend to Figure 1.2. 
 
Table 3.2. p Values for pairs of survival curves of a yeast strain cultured with or without the 
indicated plant extract (PE). Survival curves shown in Figs. 3.2A, 3.5, 3.8, 3.11, 3.14 and 3.17 
were compared. The survival curve of a strain cultured with the indicated PE was considered 
statistically different from the survival curve of the same strain cultured without it if the p value 
was lower than 0.05; such p values are shown in red color. For each pair of survival curves with 
the p value less than 0.05, the survival rate of the strain cultured with the indicated PE was higher 
than the survival rate of the same strain cultured without it. The p values for comparing pairs of 




Same strain with the indicated PE 
PE4 PE5 PE6 PE8 PE12 PE21 
WT < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
tor1Δ 0.8899 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
ras2Δ < 0.0001 0.3664 < 0.0001 0.41888 < 0.0001 < 0.0001 
rim15Δ 0.0042 0.0168 < 0.0001 0.0184 0.6453 < 0.0001 
sch9Δ < 0.0001 < 0.0001 < 0.0001 0.0006 < 0.0001 0.0306 
pkh2Δ < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
snf1Δ 0.5873 0.0075 < 0.0001 0.7124 0.0132 < 0.0001 
atg1Δ 0.0027 0.0061 < 0.0001 0.0086 0.0208 < 0.0001 
 
Table 3.3. p Values for pairs of survival curves of the wild-type (WT) and mutant strain, both 
cultured in the presence of the indicated PE. Survival curves shown in Figures 3.2A, 3.5, 3.8, 
3.11, 3.14 and 3.17 were compared. The survival curve for the WT strain cultured with the 
indicated PE was considered statistically different from the survival curve for the mutant strain 
cultured with this PE if the p value was lower than 0.05. The p values less than 0.05 are shown in 
red color if the survival rate of the mutant strain cultured with the indicated PE was higher than 
the survival rate of the WT strain cultured with this PE. The p values less than 0.05 are displayed 
in blue color if the survival rate of the mutant strain cultured with the indicated PE was lower than 
the survival rate of the WT strain cultured with this PE. The p values for comparing pairs of 
survival curves were calculated as described in Materials and methods.     
















0.0827 0.0002 < 0.0001 0.0004 0.0007 < 0.0001 < 0.0001 
 
















< 0.0001 0.0724 < 0.0001 0.0008 < 0.0001 < 0.0001 0.0004 
 




































< 0.0001 0.0124 < 0.0001 0.0032 < 0.0001 < 0.0001 0.0008 
 
















0.0003 0.0011 < 0.0001 0.0018 < 0.0001 0.0004 0.0012 
 
















0.0036 0.0062 0.0109 < 0.0001 0.0044 0.0009 0.0086 
 
 
Figure 3.3. PE4 is unable to prolong the chronological lifespans (CLS) of the tor1Δ and snf1Δ 
mutant strains and has additive CLS-extending effects with the ras2Δ, sch9Δ and pkh2Δ 
mutations. Cells of the wild-type (WT) and indicated mutant strains were grown in the synthetic 
minimal YNB medium (0.67% Yeast Nitrogen Base without amino acids) initially containing 2% 
glucose, in the presence of 0.5% PE4 (ethanol was used as a vehicle at the final concentration of 
2.5%) or in its absence (cells were subjected to ethanol-mock treatment). Survival curves shown 
in Figure 3.2A were used to calculate the mean and maximum CLS for WT and mutant strains 
cultured with or without 0.5% PE4. Data are presented as means ± SEM (n = 7; ns, not significant; 
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). The ability of PE4 to cause a significant 
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(*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001) increase in the CLS of a particular mutant 
strain is displayed in red color. The ability of a combination between PE4 and a particular mutation 
to cause a significant (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001) increase in CLS-
extending efficiencies of each other (i.e. the ability of such combination to exhibit an additive 
extending effect on yeast CLS) is displayed in green color. Data for the mock-treated WT strain 
are replicated in all graphs of this Figure. Data for the WT strain cultured with PE4 are replicated 
in all graphs of this Figure. 
 
 
Figure 3.4. Analysis of the Gompertz mortality function indicates that PE4 slows yeast 
chronological aging by weakening the inhibitory effect of TORC1 on SNF1. Cells of the wild-
type (WT) and indicated mutant strains were grown in the synthetic minimal YNB medium (0.67% 
Yeast Nitrogen Base without amino acids) initially containing 2% glucose, in the presence of 0.5% 
PE4 (ethanol was used as a vehicle at the final concentration of 2.5%) or in its absence (cells were 
subjected to ethanol-mock treatment). Survival curves shown in Fig. 3.2A were used to calculate 
the age-specific mortality rates (qx), the Gompertz mortality rates (also known as mortality rate 
coefficient α) and the mortality rate doubling times (MRDT) for WT and mutant yeast populations 
cultured with or without 0.5% PE4. The values of qx, α and MRDT were calculated as described 
in Materials and methods. Data for the mock-treated WT strain are replicated in all graphs of this 




3.3.3 PE5 slows chronological aging by weakening two branches of the PKA pathway 
            PE5 displayed an additive longevity-extending effect with the sch9Δ mutation, and 
increased yeast CLS in synergy with the tor1Δ and pkh2Δ mutations (Figure 3.5A, Tables 3.2 and 
3.3, Figure 3.6; note that data for the mock-treated WT strain and for the WT strain cultured with 
PE5 are replicated in all graphs of Figure 3.5A and Figure 3.6). PE5 decreased the values of α and 
increased the values of MRDT for chronologically aging cultures of strains carrying each of these 
three mutations (Figure 3.7; note that data for the mock-treated WT strain and the WT strain 
cultured with PE5 are replicated in all graphs of this figure). Therefore, PE5 slows aging not 
through TORC1, PKH1/2 or Sch9. 
            PE5 increased CLS of the rim15Δ, snf1Δ and atg1Δ mutant strains, however, to a lesser 
extent than that of WT strain (Figure 3.5A, Tables 3.2 and 3.3, Figure 3.6). PE5 decreased the 
value of α and increased the value of MRDT strains carrying each of these mutations, although not 
as considerably as for WT (Figure 3.7). Thus, PE5 slows aging independently of Rim15, SNF1 
and ATG. 
            PE5 was unable to extend the CLS of ras2Δ (Figure 3.5A, Tables 3.2 and 3.3, Figure 3.6) 
and did not alter the values of α or MRDT for this mutant strain (Figure 3.7). Hence, PE5 slows 
aging by weakening two branches of the PKA signaling pathway (Figure 3.5B). One of these 
branches involves the Rim15-independent processes of autophagy inhibition and protein 
translation activation in the cytosol, whereas the other branch attenuates the Rim15-driven 
establishment of an anti-aging transcriptional program of many nuclear genes [15, 63, 68, 95-97, 




Figure 3.5. PE5 extends yeast CLS by weakening two branches of the PKA signaling 
pathway. (A) Cells of the wild-type (WT) and indicated mutant strains were grown in the synthetic 
minimal YNB medium (0.67% Yeast Nitrogen Base without amino acids) initially containing 2% 
glucose, in the presence of 0.5% PE5 (ethanol was used as a vehicle at the final concentration of 
2.5%) or in its absence (cells were subjected to ethanol-mock treatment). Survival curves of 
chronologically aging WT and mutant strains cultured with or without 0.5% PE5 are shown. Data 
are presented as means ± SEM (n = 7). The dotted line indicates the predicted survival curve of a 
particular mutant strain cultured with PE5 if this PE exhibits an additive longevity-extending effect 
with the mutation. Data for the mock-treated WT strain are replicated in all graphs of this Figure 
and in all graphs of Figure 3.2. Data for each of the mock-treated mutant strains presented in this 
Figure are replicated in the corresponding graphs of Figure 3.2. Data for the WT strain cultured 
with PE5 are replicated in all graphs of this Figure. (B) The effect of PE5 on the signaling pathways 
and protein kinases comprising the longevity-defining network. This effect is inferred from the 
data presented in (A), Tables 3.2 and 3.3, and Figures 3.6 and 3.7. Abbreviations: as in the legend 




Figure 3.6. PE5 is unable to prolong the chronological lifespan (CLS) of the ras2Δ mutant 
strain, has an additive CLS-extending effect with the sch9Δ mutation, and increases yeast 
CLS in synergy with the tor1Δ and pkh2Δ mutations. Cells of the wild-type (WT) and indicated 
mutant strains were grown in the synthetic minimal YNB medium (0.67% Yeast Nitrogen Base 
without amino acids) initially containing 2% glucose, in the presence of 0.5% PE5 (ethanol was 
used as a vehicle at the final concentration of 2.5%) or in its absence (cells were subjected to 
ethanol-mock treatment). Survival curves shown in Fig. 3.5A were used to calculate the mean and 
maximum CLS for WT and mutant strains cultured with or without 0.5% PE5. Data are presented 
as means ± SEM (n = 7; ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). 
The ability of PE5 to cause a significant (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001) 
increase in the CLS of a particular mutant strain is shown in red color. The ability of a combination 
between PE5 and a particular mutation to cause a significant (*p < 0.05; **p < 0.01; ***p < 0.001; 
****p < 0.0001) increase in CLS-extending efficiencies of each other (i.e. the ability of such 
combination to exhibit an additive or synergistic CLS-extending effect) is displayed in green color. 
Data for the mock-treated WT strain are replicated in all graphs of this Figure and in all graphs of 
Figure 3.3. Data for each of the mock-treated mutant strains presented in this Figure are replicated 
in the corresponding graphs of Figure 3.3. Data for the WT strain cultured with PE5 are replicated 





Figure 3.7. Analysis of the Gompertz mortality function indicates that PE5 slows yeast 
chronological aging by weakening two branches of the PKA signaling pathway. Cells of the 
wild-type (WT) and indicated mutant strains were grown in the synthetic minimal YNB medium 
(0.67% Yeast Nitrogen Base without amino acids) initially containing 2% glucose, in the presence 
of 0.5% PE5 (ethanol was used as a vehicle at the final concentration of 2.5%) or in its absence 
(cells were subjected to ethanol-mock treatment). Survival curves shown in Fig. 3.5A were used 
to calculate the age-specific mortality rates (qx), the Gompertz mortality rates (also known as 
mortality rate coefficient α) and the mortality rate doubling times (MRDT) for WT and mutant 
yeast populations cultured with or without 0.5% PE5. The values of qx, α and MRDT were 
calculated as described in Materials and methods. Data for the mock-treated WT strain are 
replicated in all graphs of this Figure and in all graphs of Figure 3.4. Data for each of the mock-
treated mutant strains presented in this Figure are reproduced in the corresponding graphs of Figure 
3.4. Data for the WT strain cultured with PE5 are replicated in all graphs of this Figure. 
3.3.4 PE6 slows chronological aging by coordinating processes that are not integrated into 
the signaling network of longevity regulation  
            PE6 had additive longevity-extending effects with the rim15Δ, sch9Δ and atg1Δ mutations, 
and extended longevity synergistically with the tor1Δ, ras2Δ, pkh2Δ and snf1Δ mutations (Figure 
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3.8A, Tables 3.2 and 3.3, Figure 3.9; note that data for the mock-treated WT strain and for the WT 
strain cultured with PE6 are replicated in all graphs of Figure 3.8A and Figure 3.9). PE6 lowered 
the values of α and raised the values of MRDT for chronologically aging cultures of strains 
carrying each of these seven mutations (Figure 3.10; note that data for the mock-treated WT strain 
and the WT strain cultured with PE6 are replicated in all graphs of this Figure). Thus, PE6 delays 
aging by activating anti-aging processes and/or inhibiting pro-aging processes that are not 
integrated into the network of presently known signaling pathways/protein kinases (Figure 3.8B). 
            Although rim15Δ, snf1Δ and atg1Δ exhibited decreased CLS in the absence of PE6, this 
PE extended the CLS of each of these mutant strains to a greater extent than that of WT strain 
(Figure 3.8A, Tables 3.2 and 3.3, Figures 3.9 and 3.10). It is possible that the efficiency with which 
PE6 activates anti-aging processes and/or inhibits pro-aging processes outside of the network in 
the absence of Rim15, Snf1 or Atg1 may exceed such efficiency in the presence of any of these 
anti-aging proteins. 
 
Figure 3.8. PE6 extends yeast CLS independently of presently known longevity-defining 
signaling pathways/protein kinases. (A) Cells of the wild-type (WT) and indicated mutant strains 
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were grown in the synthetic minimal YNB medium (0.67% Yeast Nitrogen Base without amino 
acids) initially containing 2% glucose, in the presence of 1.0% PE6 (ethanol was used as a vehicle 
at the final concentration of 5.0%) or in its absence (cells were subjected to ethanol-mock 
treatment). Survival curves of chronologically aging WT and mutant strains cultured with or 
without 1.0% PE6 are shown. Data are presented as means ± SEM (n = 8). The dotted line indicates 
the predicted survival curve of a particular mutant strain cultured with PE6 if this PE exhibits an 
additive longevity-extending effect with the mutation. Data for the mock-treated WT strain and 
the WT strain cultured with PE6 are replicated in all graphs of this Figure. (B) The effects of PE6 
on anti-aging and/or pro-aging processes that are not controlled by the network of presently known 
signaling pathways/protein kinases. These effects are inferred from the data presented in (A), 





Figure 3.9. PE6 has additive CLS-extending effects with the rim15Δ, sch9Δ and atg1Δ 
mutations; PE6 also increases yeast CLS in synergy with the tor1Δ, ras2Δ, pkh2Δ and snf1Δ 
mutations. Cells of the wild-type (WT) and indicated mutant strains were grown in the synthetic 
minimal YNB medium (0.67% Yeast Nitrogen Base without amino acids) initially containing 2% 
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glucose, in the presence of 1.0% PE6 (ethanol was used as a vehicle at the final concentration of 
5.0%) or in its absence (cells were subjected to ethanol-mock treatment). Survival curves shown 
in Fig. 3.8A were used to calculate the mean and maximum CLS for WT and mutant strains 
cultured with or without 1.0% PE6. Data are presented as means ± SEM (n = 8; ns, not significant; 
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). The ability of PE6 to cause a significant 
(*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001) increase in the CLS of a particular mutant 
strain is shown in red color. The ability of a combination between PE6 and a particular mutation 
to cause a significant (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001) increase in CLS-
extending efficiencies of each other (i.e. the ability of such combination to exhibit an additive or 
synergistic CLS-extending effect) is displayed in green color. Data for the mock-treated WT strain 






Figure 3.10. Analysis of the Gompertz mortality function indicates that PE6 slows yeast 
chronological aging independently of presently known longevity-defining signaling 
pathways/protein kinases. Cells of the wild-type (WT) and indicated mutant strains were grown 
in the synthetic minimal YNB medium (0.67% Yeast Nitrogen Base without amino acids) initially 
containing 2% glucose, in the presence of 1.0% PE6 (ethanol was used as a vehicle at the final 
100 
 
concentration of 5.0%) or in its absence (cells were subjected to ethanol-mock treatment). Survival 
curves shown in Fig. 3.8A were used to calculate the age-specific mortality rates (qx), the 
Gompertz mortality rates (also known as mortality rate coefficient α) and the mortality rate 
doubling times (MRDT) for WT and mutant yeast populations cultured with or without 1.0% PE6. 
The values of qx, α and MRDT were calculated as described in Materials and methods. Data for 
the mock-treated WT strain and the WT strain cultured with PE6 are replicated in all graphs of this 
Figure. 
3.3.5 PE8 slows chronological aging by weakening the inhibitory effect of PKA on SNF1 
            PE8 displayed an additive longevity-extending effect with the sch9Δ mutation, and 
extended yeast CLS in synergy with the tor1Δ and pkh2Δ mutations (Figure 3.11A, Tables 3.2 and 
3.3, Figure 3.12; note that data for the mock-treated WT strain and for the WT strain cultured with 
PE8 are replicated in all graphs of Figure 3.11A and Figure 3.12). PE8 decreased the values of α 
and increased the values of MRDT for chronologically aging cultures of strains carrying each of 
these three mutations (Figure 3.13; note that data for the mock-treated WT strain and the WT strain 
cultured with PE8 are replicated in all graphs of this Figure). Therefore, PE8 slows aging 
independently of Sch9, TORC1 and PKH1/2. 
            PE8 increased CLS of the rim15Δ and atg1Δ mutant strains, though not as considerably as 
for WT (Figure 3.11A, Tables 3.2 and 3.3, Figure 3.12). PE8 lowered the values of α and raised 
the values of MRDT for chronologically aging cultures of strains carrying each of these mutations 
(Figure 3.13). Hence, PE8 delays aging not through Rim15 or ATG. 
            PE8 was unable to extend the CLS of ras2Δ and snf1Δ (Figure 3.11A, Tables 3.2 and 3.3, 
Figure 3.12) and did not alter the values of α or MRDT for these mutant strains (Figure 3.13). 
Thus, PE8 slows aging via PKA and SNF1 by weakening the known inhibitory action of PKA on 












Figure 3.11. PE8 extends yeast CLS by weakening the inhibitory effect of PKA on SNF1. (A) 
Cells of the wild-type (WT) and indicated mutant strains were grown in the synthetic minimal 
YNB medium (0.67% Yeast Nitrogen Base without amino acids) initially containing 2% glucose, 
in the presence of 0.3% PE8 (ethanol was used as a vehicle at the final concentration of 1.5%) or 
in its absence (cells were subjected to ethanol-mock treatment). Survival curves of chronologically 
aging WT and mutant strains cultured with or without 0.3% PE8 are shown. Data are presented as 
means ± SEM (n = 6). The dotted line indicates the predicted survival curve of a particular mutant 
strain cultured with PE8 if this PE exhibits an additive longevity-extending effect with the 
mutation. Data for the mock-treated WT strain and the WT strain cultured with PE8 are replicated 
in all graphs of this Figure. (B) The effect of PE8 on the signaling pathways and protein kinases 
integrated into the longevity-defining network. This effect is inferred from the data presented in 





Figure 3.12. PE8 is unable to extend the chronological lifespans (CLS) of the ras2Δ and snf1Δ 
mutant strains, shows an additive CLS-extending effect with the sch9Δ mutation, and 
increases yeast CLS in synergy with the tor1Δ and pkh2Δ mutations. Cells of the wild-type 
(WT) and indicated mutant strains were grown in the synthetic minimal YNB medium (0.67% 
Yeast Nitrogen Base without amino acids) initially containing 2% glucose, in the presence of 0.3% 
PE8 (ethanol was used as a vehicle at the final concentration of 1.5%) or in its absence (cells were 
subjected to ethanol-mock treatment). Survival curves shown in Fig. 3.11A were used to calculate 
the mean and maximum CLS for WT and mutant strains cultured with or without 0.3% PE8. Data 
are presented as means ± SEM (n = 6; ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001; 
****p < 0.0001). The ability of PE8 to cause a significant (*p < 0.05; **p < 0.01; ***p < 0.001; 
****p < 0.0001) increase in the CLS of a particular mutant strain is shown in red color. The ability 
of a combination between PE8 and a particular mutation to elicit a significant (*p < 0.05; **p < 
0.01; ***p < 0.001; ****p < 0.0001) increase in CLS-extending efficiencies of each other (i.e. the 
ability of such combination to exhibit an additive or synergistic CLS-extending effect) is displayed 
in green color. Data for the mock-treated WT strain and the WT strain cultured with PE8 are 








Figure 3.13. Analysis of the Gompertz mortality function indicates that PE8 slows yeast 
chronological aging by weakening the inhibitory effect of PKA on SNF1. Cells of the wild-
type (WT) and indicated mutant strains were grown in the synthetic minimal YNB medium (0.67% 
Yeast Nitrogen Base without amino acids) initially containing 2% glucose, in the presence of 0.3% 
PE8 (ethanol was used as a vehicle at the final concentration of 1.5%) or in its absence (cells were 
subjected to ethanol-mock treatment). Survival curves shown in Fig. 3.11A were used to calculate 
the age-specific mortality rates (qx), the Gompertz mortality rates (also known as mortality rate 
coefficient α) and the mortality rate doubling times (MRDT) for WT and mutant yeast populations 
cultured with or without 0.3% PE8. The values of qx, α and MRDT were calculated as described 
in Materials and methods. Data for the mock-treated WT strain and the WT strain cultured with 
PE8 are replicated in all graphs of this Figure. 
3.3.6 PE12 slows chronological aging by stimulating Rim15 
            PE12 increased yeast CLS synergistically with the pkh2Δ mutation and displayed additive 
longevity-extending effects with the tor1Δ, ras2Δ and sch9Δ mutations (Figure 3.14A, Tables 3.2 
and 3.3, Figure 3.15; note that data for the mock-treated WT strain and for the WT strain cultured 
with PE12 are replicated in all graphs of Figure 3.14A and Figure 3.15). PE12 reduced the values 
104 
 
of α and augmented the values of MRDT for chronologically aging cultures of strains carrying 
each of these four mutations (Figure 3.16; note that data for the mock-treated WT strain and the 
WT strain cultured with PE12 are replicated in all graphs of this Figure). Hence, PE12 slows aging 
not through PKH1/2, TORC1, PKA or Sch9. 
            PE12 extended longevities of the snf1Δ and atg1Δ mutant strains, although to a lesser extent 
than that of WT strain (Figure 3.14A, Tables 3.2 and 3.3, Figure 3.15). PE12 decreased the value 
of α and increased the value of MRDT strains carrying each of these mutations, however not as 
considerably as for WT (Figure 3.16). Therefore, PE12 slows aging independently of SNF1 and 
ATG. 
            PE12 was unable to extend the CLS of rim15Δ (Figure 3.14A, Tables 3.2 and 3.3, Figure 
3.15) and did not alter the values of α or MRDT for this mutant strain (Figure 3.16). Hence, PE12 
slows aging by activating Rim15 (Figure 3.14B). 
 
 
Figure 3.14. PE12 prolongs yeast CLS by stimulating Rim15. (A) Cells of the wild-type (WT) 
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and indicated mutant strains were grown in the synthetic minimal YNB medium (0.67% Yeast 
Nitrogen Base without amino acids) initially containing 2% glucose, in the presence of 0.1% PE12 
(ethanol was used as a vehicle at the final concentration of 0.5%) or in its absence (cells were 
subjected to ethanol-mock treatment). Survival curves of chronologically aging WT and mutant 
strains cultured with or without 0.1% PE12 are shown. Data are presented as means ± SEM (n = 
8). The dotted line indicates the predicted survival curve of a particular mutant strain cultured with 
PE12 if this PE exhibits an additive longevity-extending effect with the mutation. Data for the 
mock-treated WT strain are replicated in all graphs of this Figure. Data for the WT strain cultured 
with PE12 are reproduced in all graphs of this Figure. (B) The effect of PE12 on the signaling 
pathways and protein kinases integrated into the longevity-defining network. This effect is inferred 
from the data presented in (A), Tables 3.2 and 3.3, and Figures 3.15 and 3.16. Abbreviations: as 





Figure 3.15. PE12 is unable to extend the chronological lifespan (CLS) of the rim15Δ mutant 
strain, has additive CLS-extending effects with the tor1Δ, ras2Δ and sch9Δ mutations, and 
increases yeast CLS in synergy with the pkh2Δ mutation. Cells of the wild-type (WT) and 
indicated mutant strains were grown in the synthetic minimal YNB medium (0.67% Yeast 
Nitrogen Base without amino acids) initially containing 2% glucose, in the presence of 0.1% PE12 
(ethanol was used as a vehicle at the final concentration of 0.5%) or in its absence (cells were 
subjected to ethanol-mock treatment). Survival curves shown in Fig. 3.14A were used to calculate 
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the mean and maximum CLS for WT and mutant strains cultured with or without 0.1% PE12. Data 
are presented as means ± SEM (n = 8; ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001; 
****p < 0.0001). The ability of PE12 to cause a significant (*p < 0.05; **p < 0.01; ***p < 0.001; 
****p < 0.0001) increase in the CLS of a particular mutant strain is shown in red color. The ability 
of a combination between PE12 and a particular mutation to cause a significant (*p < 0.05; **p < 
0.01; ***p < 0.001; ****p < 0.0001) increase in CLS-extending efficiencies of each other (i.e. the 
ability of such combination to exhibit an additive or synergistic CLS-extending effect) is displayed 
in green color. Data for the mock-treated WT strain are replicated in all graphs of this Figure. Data 





Figure 3.16. Analysis of the Gompertz mortality function indicates that PE12 slows yeast 
chronological aging by stimulating Rim15. Cells of the wild-type (WT) and indicated mutant 
strains were grown in the synthetic minimal YNB medium (0.67% Yeast Nitrogen Base without 
amino acids) initially containing 2% glucose, in the presence of 0.1% PE12 (ethanol was used as 
a vehicle at the final concentration of 0.5%) or in its absence (cells were subjected to ethanol-mock 
treatment). Survival curves shown in Fig. 3.14A were used to calculate the age-specific mortality 
rates (qx), the Gompertz mortality rates (also known as mortality rate coefficient α) and the 
mortality rate doubling times (MRDT) for WT and mutant yeast populations cultured with or 
without 0.1% PE12. The values of qx, α and MRDT were calculated as described in Materials and 
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methods. Data for the mock-treated WT strain are replicated in all graphs of this Figure. Data for 
the WT strain cultured with PE12 are replicated in all graphs of this Figure. 
3.3.7  PE21 slows chronological aging by inhibiting a PKH1/2-sensitive form of Sch9 
            PE21 increased yeast CLS in synergy with the pkh2Δ mutation and displayed additive 
longevity-extending effects with the tor1Δ and ras2Δ mutations (Figure 3.17A, Tables 3.2 and 3.3, 
Figure 3.18; note that data for the mock-treated WT strain and for the WT strain cultured with 
PE21 are replicated in all graphs of Figure 3.17A and Figure 3.18). PE21 decreased the values of 
α and increased the values of MRDT for chronologically aging cultures of strains carrying each of 
these three mutations (Figure 3.19; note that data for the mock-treated WT strain and the WT strain 
cultured with PE21 are replicated in all graphs of this Figure). Thus, PE21 slows aging 
independently of PKH1/2, TORC1 and PKA. 
            PE21 increased CLS of the rim15Δ, snf1Δ and atg1Δ mutant strains, although to a slightly 
lesser extent than that of WT (Figure 3.17A, Tables 3.2 and 3.3, Figure 3.18). PE12 lowered the 
values of α and raised the values of MRDT for chronologically aging cultures of strains carrying 
each of these mutations, however somewhat less considerably than those for WT (Figure 3.19). 
Hence, PE12 delays aging not through Rim15, SNF1 or ATG. 
            PE21 extended the CLS (Figure 3.17A, Tables 3.2 and 3.3, Figure 3.18), decreased the 
value of α (Figure 3.19) and increased the value of MRDT (Figure 3.19) significantly less 
efficiently for sch9Δ than it did for WT. We therefore concluded that PE21 slows aging by 
















Figure 3.17. PE21 extends yeast CLS by weakening a PKH1/2-sensitive form of Sch9. (A) 
Cells of the wild-type (WT) and indicated mutant strains were grown in the synthetic minimal 
YNB medium (0.67% Yeast Nitrogen Base without amino acids) initially containing 2% glucose, 
in the presence of 0.1% PE21 (ethanol was used as a vehicle at the final concentration of 0.5%) or 
in its absence (cells were subjected to ethanol-mock treatment). Survival curves of chronologically 
aging WT and mutant strains cultured with or without 0.1% PE21 are shown. Data are presented 
as means ± SEM (n = 8). The dotted line indicates the predicted survival curve of a particular 
mutant strain cultured with PE21 if this PE shows an additive longevity-extending effect with the 
mutation. Data for the mock-treated WT strain are replicated in all graphs of this Figure and in all 
graphs of Figure 3.14. Data for each of the mock-treated mutant strains presented in this Figure 
are reproduced in the corresponding graphs of Figure 3.14. Data for the WT strain cultured with 
PE21 are replicated in all graphs of this Figure. (B) The effect of PE21 on the signaling pathways 
and protein kinases integrated into the longevity-defining network. This effect is inferred from the 
data presented in (A), Tables 3.2 and 3.3, and Figures 3.18 and 3.19. Abbreviations: as in the 
109 
 




Figure 3.18. PE21 extends the chronological lifespan (CLS) of the sch9Δ mutant strain 
significantly less efficient than that of the wild-type (WT) strain, has additive CLS-extending 
effects with the tor1Δ and ras2Δ mutations, and increases yeast CLS in synergy with the 
pkh2Δ mutation. Cells of the WT and indicated mutant strains were grown in the synthetic 
minimal YNB medium (0.67% Yeast Nitrogen Base without amino acids) initially containing 2% 
glucose, in the presence of 0.1% PE21 (ethanol was used as a vehicle at the final concentration of 
0.5%) or in its absence (cells were subjected to ethanol-mock treatment). Survival curves shown 
in Fig. 3.17A were used to calculate the mean and maximum CLS for WT and mutant strains 
cultured with or without 0.1% PE21. Data are presented as means ± SEM (n = 42 for WT; n = 5-
7 for WT with PE21 and mutants strains with or without PE; ns, not significant; *p < 0.05; **p < 
0.01; ***p < 0.001; ****p < 0.0001). The ability of PE21 to cause a significant (*p < 0.05; **p < 
0.01; ***p < 0.001; ****p < 0.0001) increase in the CLS of a particular mutant strain is shown in 
red color. The ability of a combination between PE21 and a particular mutation to cause a 
significant (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001) increase in CLS-extending 
efficiencies of each other (i.e. the ability of such combination to exhibit an additive or synergistic 
CLS-extending effect) is displayed in green color. Data for the mock-treated WT strain are 
replicated in all graphs of this Figure and in all graphs of Figure 3.15. Data for each of the mock-
treated mutant strains presented in this Figure are duplicated in the corresponding graphs of Figure 







Figure 3.19. Analysis of the Gompertz mortality function indicates that PE21 slows yeast 
chronological aging by inhibiting a PKH1/2-sensitive form of Sch9. Cells of the wild-type 
(WT) and indicated mutant strains were grown in the synthetic minimal YNB medium (0.67% 
Yeast Nitrogen Base without amino acids) initially containing 2% glucose, in the presence of 0.1% 
PE21 (ethanol was used as a vehicle at the final concentration of 0.5%) or in its absence (cells 
were subjected to ethanol-mock treatment). Survival curves shown in Fig. 3.17A were used to 
calculate the age-specific mortality rates (qx), the Gompertz mortality rates (also known as 
mortality rate coefficient α) and the mortality rate doubling times (MRDT) for WT and mutant 
yeast populations cultured with or without 0.1% PE21. The values of qx, α and MRDT were 
calculated as described in Materials and methods. Data for the mock-treated WT strain are 
replicated in all graphs of this Figure and in all graphs of Figure 3.16. Data for each of the mock-
treated mutant strains presented in this Figure are duplicated in the corresponding graphs of Figure 
3.16. Data for the WT strain cultured with PE21 are replicated in all graphs of this Figure. 
3.4 Discussion 
            A hypothetical model for how the six geroprotective PEs slow yeast chronological aging 
via the longevity-defining network of signaling pathways/protein kinases emerges from our 
analysis. This model is shown schematically in Figure 3.20. The model suggests that these PEs 
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slow aging as follows: 1) PE4 attenuates the inhibitory effect of TORC1 on SNF1, 2) PE5 weakens 
both the Rim15-dependent and Rim15-independent branches of the PKA signaling pathway, 3) 
PE6 activates anti-aging processes and/or inhibits pro-aging processes that are not integrated into 
the network of signaling pathways/protein kinases, 4) PE8 attenuates the inhibitory effect of PKA 
on SNF1, 5) PE12 activates Rim15, and 6) PE21 inhibits a PKH1/2-sensitive form of Sch9.
 
Figure 3.20. A model for how PE4, PE5, PE6, PE8, PE12 and PE21 slow yeast chronological 
aging via the longevity-defining network of signaling pathways/protein kinases. Activation arrows 
and inhibition bars denote pro-aging processes (displayed in blue color) or anti-aging processes 
(shown in red color). Pro-aging or anti-aging signaling pathways and protein kinases are displayed 
in blue or red color, respectively. Please see text for additional details. Abbreviations: as in the 
legend to Figure 1.2. 
 
Thus, geroprotective chemical compounds from some plants can slow yeast chronological aging 
by targeting different hubs, nodes and/or links of the longevity-defining network that integrates 
specific evolutionarily conserved signaling pathways and protein kinases. In the future, it would 
be important to test the above hypothesis by investigating how each of the six aging-delaying PEs 
influences the physical links that connect individual hubs and nodes of the chronological aging 
network shown in Figure 3.20. These links are known to be mainly activating or inhibiting 
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phosphorylations and dephosphorylations of specific target proteins that are transiently or 
permanently reside in various cellular locations, including the plasma membrane, vacuole, nucleus, 
mitochondria or cytosol [14, 15, 17, 43, 48, 61-64, 66, 68, 70, 74, 81-83, 95-97, 99, 104, 105, 111, 
116, 199, 202, 203, 340]. 
            Of note, we found that each of the six geroprotective PEs slows aging through different 
signaling pathways and/or protein kinases (Figure 3.20). It is possible, therefore, that if these PEs 
are mixed in various combinations, some of the combinations may display additive or synergistic 
effects on the aging-delaying efficiencies of each other. Our ongoing studies explore this 
possibility. 
            This study also revealed that certain combinations of PE4, PE5, PE8, PE12 or PE21 and 
the tor1Δ, ras2Δ, pkh2Δ or sch9Δ mutation (each of which impairs a pro-aging signaling pathway 
or protein kinase) markedly increase aging-delaying proficiencies of each other. Furthermore, all 
combinations of PE6 and mutations impairing either anti-aging or pro-aging signaling 
pathways/protein kinases display additive or synergistic effects on the extent of the aging delay. It 
is known that the network of longevity-defining signaling pathways/protein kinases is controlled 
by such aging-delaying chemical compounds like resveratrol, rapamycin, caffeine, spermidine, 
myriocin, methionine sulfoxide, lithocholic acid and cryptotanshinone [14, 32, 72, 83, 84, 109-
116, 340, 461]. One could envision, therefore, that certain combinations of these chemical 
compounds and the six PEs may have additive or synergistic effects on the aging-delaying 
proficiencies of each other. Our ongoing studies address the validity of this assumption. 
            The evolutionarily conserved nutrient-sensing signaling pathways that accelerate 
chronological aging in yeast (Figure 3.20) are known to stimulate chronological senescence and 
geroconversion of post-mitotic human cells; these pathways are likely to expedite organismal 
aging and cancer development in humans [462-468]. Moreover, genetic and pharmacological 
manipulations that weaken these signaling pathways and slow chronological aging in yeast are 
known to decelerate chronological senescence and geroconversion of post-mitotic human cells; it 
is believed that these manipulations may also slow organismal aging and tumorigenesis in humans 
[462-468]. Thus, some of the six geroprotective PEs that slow down yeast chronological aging 
through these signaling pathways (Figure 3.20) may prolong healthy lifespan and decelerate 
tumorigenesis. 
            The challenge for the future is to examine whether any of the six geroprotective PEs can 
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postpone the onset and/or slow the advancement of chronic diseases associated with human aging. 
Such diseases include arthritis, diabetes, heart disease, kidney disease, liver dysfunction, 
sarcopenia, stroke, neurodegenerative diseases (including Parkinson’s, Alzheimer’s and 
Huntington’s diseases), and many forms of cancer [23, 26, 50, 56, 114-116, 334, 335, 338-340, 
342, 359, 460, 469-475]. Because the major aspects of aging and age-related pathology are 
conserved across species [14, 17, 18, 26, 56, 83, 116, 340, 364, 475], it is noteworthy that this 
study, recent findings [461] and our ongoing research have revealed several features of the six PEs 
as potential interventions for decelerating chronic diseases of old age. These features are the 
following: 1) the six PEs are caloric restriction (CR) mimetics that imitate the aging-delaying 
effects of the CR diet in yeast under non-CR conditions, 2) they are geroprotectors that slow yeast 
aging by eliciting a hormetic stress response, 3) they extend yeast longevity more efficiently than 
any lifespan-prolonging chemical compound yet discovered, 4) they slow aging through signaling 
pathways and protein kinases implicated in such age-related pathologies as type 2 diabetes, 
neurodegenerative diseases, cardiac hypertrophy, cardiovascular disease, sarcopenia and cancers, 
and 5) they extend longevity and postpone the onset of age-related diseases in other eukaryotic 
model organisms. The potential of using the six geroprotective PEs for delaying the onset of age-
related diseases in humans is further underscored by the fact that the Health Canada government 
agency classifies these PEs as safe for human consumption and recommends to use five of them 










4 Pairwise combinations of plant extracts that slow yeast chronological aging through 
different signaling pathways display synergistic effects on the extent of the aging delay 
4.1 Introduction 
            We have discovered, as described in Chapter 2 of my Thesis, six plant extracts that slow 
yeast chronological aging. Chapter 3 of my Thesis provided evidence that most of these plant 
extracts affect different nodes, edges and modules of an evolutionarily conserved network of 
longevity regulation that integrates specific signaling pathways and protein kinases. This network 
is also controlled by some other aging-delaying (geroprotective) chemical compounds, including 
spermidine and resveratrol. Studies presented in Chapter 3 of my Thesis also revealed that, if a 
strain carrying an aging-delaying single-gene mutation affecting a specific node, edge or module 
of the network is exposed to some of the six plant extracts, the mutation and the plant extract 
enhance geroprotective efficiencies of each other so that their combination has a synergistic effect 
on the extent of the aging delay. We, therefore, hypothesized that a pairwise combination of two 
geroprotective plant extracts or a combination of one of these plant extracts and spermidine or 
resveratrol might have a synergistic effect on the extent of aging delay only if each component of 
this combination targets a different element of the network. To test our hypothesis, we assessed 
longevity-extending efficiencies of all possible pairwise combinations of the six plant extracts or 
of one of them and spermidine or resveratrol in chronologically aging yeast. In support of our 
hypothesis, we show that only pairwise combinations of naturally occurring chemical compounds 
that slow aging through different nodes, edges and modules of the network delay aging 
synergistically. Chapter 4 describes these findings.   
4.2 Materials and methods 
4.2.1 Yeast strains, media and culture conditions 
            The wild-type strain Saccharomyces cerevisiae BY4742 (MATα his3∆ leu2∆ lys2∆ ura3∆) 
and single-gene-deletion mutant strains in the BY4742 genetic background (all from Thermo 
Scientific/Open Biosystems) were cultured in a synthetic minimal YNB medium (0.67% (w/v) 
Yeast Nitrogen Base without amino acids) initially containing 2% (w/v) glucose and supplemented 
with 20 mg/l histidine, 30 mg/l leucine, 30 mg/l lysine and 20 mg/l uracil. Cells were cultured at 
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30oC with rotational shaking at 200 rpm in Erlenmeyer flasks at a “flask volume/medium volume” 
ratio of 5:1. 
4.2.2 Aging-delaying plant extracts (PEs) 
            PE4 (an extract from the root and rhizome of Cimicifuga racemosa), PE5 (an extract from 
the root of Valeriana officinalis L.), PE6 (an extract from the whole plant of Passiflora incarnate 
L.), PE8 (an extract from the leaf of Ginkgo biloba), PE12 (an extract from the seed of Apium 
graveolens L.) and PE21 (an extract from the bark of Salix alba) were used at the final 
concentration of 0.1% (w/v), 0.3% (w/v), 0.5% (w/v) or 1.0% (w/v) [461]. A stock solution of 
each PE in ethanol was made on the day of adding this PE to cell cultures. For each PE, the stock 
solution was added to growth medium with 2% (w/v) glucose immediately following cell 
inoculation into the medium. In a culture supplemented with a PE, ethanol was used as a vehicle 
at the final concentration of 2.5% (v/v). In the same experiment, yeast cells were also subjected to 
ethanol-mock treatment by being cultured in the growth medium, initially containing 2% glucose 
and 2.5% (v/v) ethanol. 
4.2.3 Chronological lifespan (CLS) assay 
            A sample of cells was taken from a culture at a certain day following cell inoculation and 
PE addition into the medium. A fraction of the sample was diluted to determine the total number 
of cells using a hemacytometer. Another fraction of the cell sample was diluted, and serial dilutions 
of cells were plated in duplicate onto YEP (1% (w/v) yeast extract, 2% (w/v) peptone) plates 
containing 2% (w/v) glucose as carbon source. After 2 d of incubation at 30°C, the number of 
colony-forming units (CFU) per plate was counted. The number of CFU was defined as the number 
of viable cells in a sample. For each culture, the percentage of viable cells was calculated as 
follows: (number of viable cells per ml/total number of cells per ml) × 100. The percentage of 
viable cells in the mid-logarithmic growth phase was set at 100%. 
4.2.4 Statistical analysis 
            Statistical analysis was performed using Microsoft Excel’s (2010) Analysis ToolPack-
VBA. All data on cell survival are presented as mean ± SEM. The p values for comparing the 
means of two groups using an unpaired two-tailed t test were calculated with the help of the 
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GraphPad Prism 7 statistics software. The logrank test for comparing each pair of survival curves 
was performed with GraphPad Prism 7. Two survival curves were considered statistically different 
if the p value was less than 0.05. 
4.3 Results 
4.3.1 Our hypothesis on possible synergistic longevity-extending effects of certain 
pairwise combinations of the six aging-delaying PEs and/or spermidine and resveratrol 
            A signaling network that controls the rate of yeast chronological aging is schematically 
depicted in Figure 4.1. This network integrates the following signaling pathways and protein 
kinases: 1) the pro-aging TORC1 (target of rapamycin complex 1) pathway, 2) the pro-aging PKA 
(protein kinase A) pathway, 3) the pro-aging PKH1/2 (Pkb-activating kinase homolog) pathway, 
4) the anti-aging SNF1 (sucrose non-fermenting) pathway, 5) the anti-aging ATG (autophagy) 
pathway, 6) the pro-aging protein kinase Sch9, which is activated by the TORC1 and PKH1/2 
pathways, and 7) the anti-aging protein kinase Rim15, which is suppressed by the TORC1, PKA 
and PKH1/2 pathways (Figure 4.1) [15, 17, 66, 68, 95, 96, 198, 340, 477]. The network modulates 
such longevity-defining cellular processes as gluconeogenesis, glyoxylate cycle, glycogen 
synthesis and degradation, amino acids synthesis, fatty acids synthesis, mitochondrial respiration, 
protein synthesis in the cytosol and mitochondria, maintenance of nuclear and mitochondrial 
genomes, peroxisome biogenesis, autophagy, and stress responses (Figure 4.1) [15, 17, 51, 55, 59, 
73, 95-97, 99, 101, 104, 105, 198, 340, 478]. PE4, PE5, PE6, PE8, PE12 and PE21 delay yeast 
chronological aging because they elicit the following effects on different nodes, edges and modules 
of the network: 1) PE4 lessens the inhibitory action of the pro-aging TORC1 pathway on the anti-
aging SNF1 pathway, 2) PE5 suppresses two different branches of the pro-aging PKA pathway, 
3) PE6 regulates cellular processes that are not integrated into the network, 4) PE8 inhibits the 
suppressive effect of PKA on SNF1, 5) PE12 stimulates the anti-aging protein kinase Rim15, and 
6) PE21 downregulates a form of the pro-aging protein kinase Sch9 that is stimulated by the pro-
aging PKH1/2 pathway (Figure 4.1) [477]. 
            It has previously demonstrated that spermidine, a polyamine of plant origin, delays the 
chronological mode of aging in yeast and other organisms by activating the anti-aging ATG1 
(autophagy) pathway (Figure 4.1) [17, 83, 84, 111, 479]. Moreover, although resveratrol has been 
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shown to extend mammalian healthspan by suppressing cAMP-dependent phosphodiesterases to 
elicit AMPK activation [480] and by stimulating the tyrosyl transfer-RNA synthetase to promote 
poly(ADP-ribose) polymerase 1 auto-poly-ADP-ribosylation [481], the molecular targets of this 
plant phenolic compound in chronologically aging yeast remain unknown (Figure 4.1). 
 
Figure 4.1. PE4, PE5, PE8, PE12, PE21 and spermidine (S) delay yeast chronological aging 
because they regulate various pro-aging or anti-aging nodes, edges and modules of an 
evolutionarily conserved signaling network known to control the rate of aging. PE6 and 
resveratrol (R) delay yeast chronological aging by regulating a presently unknown pro-aging or 
anti-aging node that may be integrated into this signaling network. The signaling network that 
controls the rate of yeast chronological aging coordinates various longevity-defining cellular 
processes; these processes are named in the boxes. Activation arrows and inhibition bars denote 
pro-aging processes (displayed in blue color) or anti-aging processes (shown in red color). Pro-
aging or anti-aging nodes (i.e., the key protein components of pro-aging or anti-aging signaling 
pathways) integrated into this signaling network are displayed in blue or red color, respectively. 
Please see text for additional details. Abbreviations: ATG, autophagy; PKA, protein kinase A; 
PKH1/2, Pkb-activating kinase homologs 1 and 2; Rim15, an anti-aging protein kinase; Sch9, a 
pro-aging protein kinase; SNF1, sucrose non-fermenting protein 1; TORC1, target of rapamycin 
complex 1; A and X, presently unknown anti-aging nodes of this signaling network; B and Y, 
currently unknown pro-aging nodes of this signaling network. 
 
            As we have already mentioned, the following two observations provide the basis for our 
hypothesis: 1) most of the six aging-delaying PEs, as well as spermidine and resveratrol, modulate 
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different nodes, edges and modules of the signaling network that controls the rate of yeast 
chronological aging (Figure 4.1) [477]; the only possible exception is the demonstrated abilities of 
PE4 and PE8 to weaken the restraining action of two different network’s edges (i.e., the pro-aging 
TORC1 pathway and PKA pathway, respectively) on the same node (i.e., the anti-aging SNF1 
pathway) of the network (Figure 4.1) [477], and 2) certain combinations of one of the six PEs and 
aging-delaying single-gene mutations that affect these nodes, edges and modules display 
synergistic effects on the extent of yeast chronological aging delay [477]. We therefore put forward 
the hypothesis that most of 27 possible pairwise combinations of two aging-delaying PEs or one 
of these PEs and spermidine or resveratrol (Table 4.1) may slow down yeast chronological aging 
in a synergistic manner. We also hypothesized that a combination of PE4 and PE8 might not 
display a synergistic effect on the extent of yeast chronological aging delay. To test these 
hypotheses, we assessed longevity-extending efficiencies of all possible pairwise combinations of 
PE4, PE5, PE6, PE8, PE12 and PE21 or of one of these PEs and spermidine or resveratrol in 
chronologically aging yeast. 
 
Table 4.1. This study assessed how each possible pairwise combination of PE4, PE5, PE6, 
PE8, PE12 and PE21 or of one of these PEs and spermidine (S) or resveratrol (R) influences 
yeast chronological aging. These pairwise combinations are displayed on a yellow color 
background. 
 PE5 PE6 PE8 PE12 PE21 S R 
PE4 PE4 + PE5 PE4 + PE6 PE4 + PE8 PE4 + 
PE12 
PE4 + PE21 PE4 + S PE4 + R 
PE5  PE5 + PE6 PE5 + PE8 PE5 + 
PE12 
PE5 + PE21 PE5 + S PE5 + R 
PE6   PE6 + PE8 PE6 + 
PE12 
PE6 + PE21 PE6 + S PE6 + R 
PE8    PE8 + 
PE12 
PE8 + PE21 PE8 + S PE8 + R 
PE12     PE12 + 
PE21 
PE12 + S PE12 + R 
PE21      PE21 + S PE21 + R 
 
4.3.2 An effect-based model that we used to assess if a pairwise combination of aging-
delaying chemical compounds has a synergistic effect on the extent of the aging delay 
            Several effect-based models have been developed to assess if a pairwise combination of 
chemical compounds exhibits a synergistic effect on the monitored process, i.e., if the positive 
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effect of this combination on the process exceeds the positive effects of individual compounds 
comprising the combination [296, 301, 302, 323, 329, 482-485]. In this study, we have used the 
highest single agent (HSA) model for evaluating if two PEs or a PE and spermidine or resveratrol 
extend yeast longevity synergistically if used in a pairwise combination; this model has been 
recently used to demonstrate that certain drug combinations have synergistic effects on aging delay 
and healthspan extension in the nematode C. elegans [356]. According to the HSA model, two 
chemical compounds are considered to act in synergy if the effect of their combination exceeds 
the effect of a component of this combination that exhibits the highest effect if it is used alone 
[323, 329, 482, 485]. Using the HSA model, we have calculated the Combination Index (CI) value 
(which is considered as the standard measure of combination effect [323, 329, 482, 485]) as 
follows: CI = CLSX/CLSX+Y (if chemical compound X is the HSA) or CI = CLSY/CLSX+Y (if 
chemical compound Y is the HSA) for both the mean and maximum CLS of yeast exposed to 
compound X alone, to compound Y alone or a mixture of compounds X and Y. We have calculated 
the significance of a synergistic effect (i.e., CI < 1) as the p value of the two-tailed t test for 
comparing the effect of a combination of chemical compounds (i.e., CLSX+Y) to that of the HSA 
(i.e., CLSX or CLSY for the mean and maximum CLS). 
4.3.3 Mixtures of PE4 and PE5, PE4 and PE6, PE4 and PE12, and PE4 and PE21 have 
synergistic effects on the extent of the aging delay 
            PE4, PE5, PE6, PE12 or PE21 have been shown to modulate different nodes, edges and 
modules of the signaling network that controls the rate of yeast chronological aging [477]. 
Specifically, these PEs delay aging as follows: 1) PE4 weakens the restraining action of the pro-
aging TORC1 pathway on the anti-aging SNF1 pathway, 2) PE5 mitigates two different branches 
of the pro-aging PKA pathway, 3) PE6 modulates a presently unknown pro-aging or anti-aging 
node that may be integrated into this network, 4) PE12 stimulates the anti-aging protein kinase 
Rim15, and 5) PE21 inhibits a form of the pro-aging protein kinase Sch9 that is activated by the 
pro-aging PKH1/2 pathway (Figure 4.1) [477]. We, therefore, hypothesized that mixtures of PE4 
with PE5, PE6, PE12 or PE21 might exhibit synergistic effects on the extent of yeast chronological 
aging delay. To test this hypothesis, we cultured wild-type (WT) cells in the synthetic minimal 
medium initially containing 2% glucose, either without a PE (i.e. cells were subjected to ethanol-
mock treatment) or with the following additions: 1) PE4, PE5, PE6, PE12 or PE21 alone (each 
121 
 
being used at the final concentration of 0.1%, 0.5% or 1.0%, see below), or 2) a mixture of 0.1%, 
0.3%, 0.5% or 1.0% PE4 with PE5, PE6, PE12 or PE21 (each being used at the final concentration 
of 0.1%, 0.3%, 0.5% or 1.0%). 
            We found that the longevity-extending efficiencies of the following pairwise combinations 
of aging-delaying PEs statistically significantly exceed that of a PE within the pair which was 
considered as the HSA if this PE was used alone at the optimal aging-delaying concentration: 1) a 
mixture of 0.3% PE4 and 0.3% PE5 (if PE4 and PE5 were used at these final concentrations, their 
mixture exhibited the highest longevity-extending effect) as compared to 0.5% PE4 (which was 
used as the HSA for both the mean and maximum CLS), with CI = 0.63 for the mean CLS and CI 
= 0.56 for the maximum CLS (Figure 4.2), 2) a mixture of 0.5% PE4 and 1.0% PE6 as compared 
to 0.5% PE4 (which was used as the HSA for both the mean and maximum CLS) (Figure 4.3), 3) 
a mixture of 0.5% PE4 and 0.1% PE12 as compared to 0.5% PE4 (which was used as the HSA for 
the mean CLS) or 0.1% PE12 (which was used as the HSA for the maximum CLS) (Figure 4.4), 
and 4) a mixture of 0.5% PE4 and 0.1% PE21 as compared to 0.1% PE21 (which was used as the 
HSA for both the mean and maximum CLS), with CI = 0.61 for the mean CLS and CI = 0.73 for 




Figure 4.2. The longevity-extending efficiency of a mixture of 0.3% PE4 and 0.3% PE5 
statistically significantly exceeds those of PE4 and PE5, each being used at the optimal 
concentration of 0.5%. Thus, PE4 and PE5 enhance the longevity-extending efficiency of 
each other. Hence, according to the highest single agent (HSA) model, PE4 and PE5 act in 
synergy to extend the longevity of chronologically aging yeast. (A) PE4 and PE5 are known to 
inhibit different pro-aging nodes of the signaling network that controls the rate of yeast 
chronological aging. PE4 weakens the restraining action of the pro-aging TORC1 pathway on the 
anti-aging SNF1 pathway, whereas PE5 mitigates two different branches of the pro-aging PKA 
pathway. (B, C) Wild-type (WT) cells were grown in the synthetic minimal YNB medium initially 
containing 2% glucose, with PE4 and/or PE5 (at the final concentration of 0.1%, 0.3%, 0.5% or 
1.0%) or without a PE. Effects of different concentrations of PE4 and PE5 (added alone or in 
pairwise combinations) on the mean (B) or maximum (C) chronological lifespan (CLS) of WT 
cells are shown. The table cell at the intersection of the column for 0.3% PE4 and the row for 0.3% 
PE5 is marked “max” because the mixture of 0.3% PE4 and 0.3% PE5 exhibits the highest 
extending effect on the mean and maximum lifespans of chronologically aging WT cells. (D, E) 
WT cells were cultured in the synthetic minimal YNB medium initially containing 2% glucose 
and one of the following supplements: 0.5% PE4, 0.5% PE5, or a mixture of 0.3% PE4 and 0.3% 
PE5. In the cultures supplemented with PE4 and/or PE5, ethanol was used as a vehicle at the final 
concentration of 2.5%. In the same experiment, WT cells were also subjected to ethanol-mock 
treatment by being cultured in the synthetic minimal YNB medium, initially containing 2% 
glucose and 2.5% ethanol. Survival curves (D) and the mean and maximum lifespans (E) of 
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chronologically aging WT cells cultured without a PE (cells were subjected to ethanol-mock 
treatment), with 0.5% PE4, with 0.5% PE5, or with the mixture of 0.3% PE4 and 0.3% PE5 are 
shown. Data in D and E are presented as means ± SEM (n = 3; *p < 0.05; **p < 0.01). The 
Combination Index (CI) values in E were calculated as follows: CI = CLSPE4/CLSPE4+PE5 for both 
the mean and maximum CLS; the significance of a synergistic effect (i.e., CI < 1) is provided as 
the p value of the two-tailed t test for comparing the effect of a PE combination (i.e., CLSPE4+PE5) 
to that of the HSA (i.e., CLSPE4 for both the mean and maximum CLS). (F) p Values for different 
pairs of survival curves of WT cells cultured in the presence of 0.5% PE4, 0.5% PE5, a mixture of 
0.3% PE4 and 0.3% PE5, or in the absence of a PE (cells were subjected to ethanol-mock 
treatment) are shown. Survival curves shown in (D) were compared. Two survival curves were 
considered statistically different if the p value was less than 0.05. The p values for comparing pairs 
of survival curves using the logrank test were calculated as described in Materials and Methods. 
The p values displayed on a yellow color background indicate that 0.5% PE4, 0.5% PE5, and the 
mixture of 0.3% PE4 and 0.3% PE5 significantly extend the CLS of WT cells. The p values 
displayed on a blue color background indicate that the CLS-extending efficiency of the mixture of 
0.3% PE4 and 0.3% PE5 significantly exceeds that of 0.5% PE4 or 0.5% PE5. Abbreviations: 
ATG, autophagy; PKA, protein kinase A; PKH1/2, Pkb-activating kinase homologs 1 and 2; 
Rim15, an anti-aging protein kinase; Sch9, a pro-aging protein kinase; SNF1, sucrose non-
fermenting protein 1; TORC1, a target of rapamycin complex 1; X, a presently unknown anti-












Figure 4.3. The longevity-extending efficiency of a mixture of 0.5% PE4 and 0.5% PE6 
statistically significantly exceeds those of PE4 and PE6, which were used at the optimal 
concentration of 0.5% or 1.0% (respectively). Thus, PE4 and PE6 enhance the longevity-
extending efficiency of each other. Hence, according to the highest single agent (HSA) model, 
PE4 and PE6 act in synergy to extend the longevity of chronologically aging yeast. (A) PE4 
and PE6 are known to regulate different nodes of the signaling network that controls the rate of 
yeast chronological aging. PE4 weakens the restraining action of the pro-aging TORC1 pathway 
on the anti-aging SNF1 pathway, whereas PE6 modulates a presently unknown pro-aging or anti-
aging node that may be integrated into this signaling network. (B, C) WT cells were grown in the 
synthetic minimal YNB medium initially containing 2% glucose, with PE4 and/or PE6 (at the final 
concentration of 0.1%, 0.3%, 0.5% or 1.0%) or without a PE.  Effects of different concentrations 
of PE4 and PE6 (added alone or in pairwise combinations) on the mean (B) or maximum (C) CLS 
of WT cells are shown. The table cell at the intersection of the column for 0.5% PE4 and the row 
for 0.5% PE6 is marked “max” because the mixture of 0.5% PE4 and 0.5% PE6 exhibits the highest 
extending effect on the mean and maximum lifespans of chronologically aging WT cells. (D, E) 
WT cells were cultured in the synthetic minimal YNB medium initially containing 2% glucose 
and one of the following supplements: 0.5% PE4, 1.0% PE6, or a mixture of 0.5% PE4 and 0.5% 
PE6. In the cultures supplemented with PE4 and/or PE6, ethanol was used as a vehicle at the final 
concentration of 2.5%. In the same experiment, WT cells were also subjected to ethanol-mock 
treatment by being cultured in the synthetic minimal YNB medium, initially containing 2% 
glucose and 2.5% ethanol. Survival curves (D) and the mean and maximum lifespans (E) of 
chronologically aging WT cells cultured without a PE (cells were subjected to ethanol-mock 
treatment), with 0.5% PE4, with 1.0% PE6, or with the mixture of 0.5% PE4 and 0.5% PE6 are 
shown. Data in D and E are presented as means ± SEM (n = 3; *p < 0.05; **p < 0.01). The CI 
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values in E were calculated as follows: CI = CLSPE4/CLSPE4+PE6 for both the mean and maximum 
CLS; the significance of a synergistic effect (i.e., CI < 1) is provided as the p value of the two-
tailed t test for comparing the effect of a PE combination (i.e., CLSPE4+PE6) to that of the HSA (i.e., 
CLSPE4 for both the mean and maximum CLS). (F) p Values for different pairs of survival curves 
of WT cells cultured in the presence of 0.5% PE4, 1.0% PE6, a mixture of 0.5% PE4 and 0.5% 
PE6, or in the absence of a PE (cells were subjected to ethanol-mock treatment) are shown. 
Survival curves shown in (D) were compared. Two survival curves were considered statistically 
different if the p value was less than 0.05. The p values for comparing pairs of survival curves 
using the logrank test were calculated as described in Materials and Methods. The p values 
displayed on a yellow color background indicate that 0.5% PE4, 1.0% PE6, and the mixture of 
0.5% PE4 and 0.5% PE6 significantly extend the CLS of WT cells. The p values displayed on a 
blue color background indicate that the CLS-extending efficiency of the mixture of 0.5% PE4 and 





Figure 4.4. The longevity-extending efficiency of a mixture of 0.3% PE4 and 0.1% PE12 
statistically significantly exceeds those of PE4 and PE12, which were used at the optimal 
concentration of 0.5% or 0.1% (respectively). Thus, PE4 and PE12 enhance the longevity-
extending efficiency of each other. Hence, according to the HSA model, PE4 and PE12 act in 
synergy to extend the longevity of chronologically aging yeast. (A) PE4 and PE12 are known 
to inhibit different pro-aging nodes of the signaling network that controls the rate of yeast 
chronological aging. PE4 weakens the restraining action of the pro-aging TORC1 pathway on the 
anti-aging SNF1 pathway, whereas PE12 stimulates the anti-aging protein kinase Rim15. (B, C) 
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WT cells were grown as described in the legend to Figure 4.2, with PE4 and/or PE12 (at the final 
concentration of 0.1%, 0.3%, 0.5% or 1.0%) or without a PE.  Effects of different concentrations 
of PE4 and PE12 (added alone or in pairwise combinations) on the mean (B) or maximum (C) 
CLS of WT cells are shown. The table cell at the intersection of the column for 0.3% PE4 and the 
row for 0.1% PE12 is marked “max” for a reason described in the legend to Figure 4.2. (D, E) WT 
cells were cultured as described in the legend to Figure 4.2, with one of the following supplements: 
0.5% PE4, 0.1% PE12, or a mixture of 0.3% PE4 and 0.1% PE12. Ethanol was used as a vehicle 
or for mock treatment, as described in the legend to Figure 4.2. Survival curves (D) and the mean 
and maximum lifespans (E) of chronologically aging WT cells cultured without a PE (cells were 
subjected to ethanol-mock treatment), with 0.5% PE4, with 0.1% PE12, or with the mixture of 
0.3% PE4 and 0.1% PE12 are shown. Data in D and E are presented as means ± SEM (n = 3; *p < 
0.05; **p < 0.01). The CI and p values in E were calculated as described in the legend to Figure 
4.2. (F) p Values for different pairs of survival curves of WT cells cultured in the presence of 0.5% 
PE4, 0.1% PE12, a mixture of 0.3% PE4 and 0.1% PE12, or in the absence of a PE (cells were 
subjected to ethanol-mock treatment) are shown. Survival curves shown in (D) were compared. 
The p values are displayed on a yellow or blue color background for the reasons described in the 






Figure 4.5. The longevity-extending efficiency of a mixture of 0.5% PE4 and 0.1% PE21 
statistically significantly exceeds those of PE4 and PE21, which were used at the optimal 
concentration of 0.5% or 0.1% (respectively). Thus, PE4 and PE21 enhance the longevity-
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extending efficiency of each other. Hence, according to the HSA model, PE4 and PE21 act in 
synergy to extend the longevity of chronologically aging yeast. (A) PE4 and PE21 are known 
to inhibit different pro-aging nodes of the signaling network that controls the rate of yeast 
chronological aging. PE4 weakens the restraining action of the pro-aging TORC1 pathway on the 
anti-aging SNF1 pathway, whereas PE21 mitigates a form of the pro-aging protein kinase Sch9 
that is activated by the pro-aging PKH1/2 pathway. (B, C) WT cells were grown as described in 
the legend to Figure 4.2, with PE4 and/or PE21 (at the final concentration of 0.1%, 0.3%, 0.5% or 
1.0%) or without a PE.  Effects of different concentrations of PE4 and PE21 (added alone or in 
pairwise combinations) on the mean (B) or maximum (C) CLS of WT cells are shown. The table 
cell at the intersection of the column for 0.5% PE4 and the row for 0.1% PE21 is marked “max” 
for a reason described in the legend to Figure 4.2. (D, E) WT cells were cultured as described in 
the legend to Figure 4.2, with one of the following supplements: 0.5% PE4, 0.1% PE21, or a 
mixture of 0.5% PE4 and 0.1% PE21. Ethanol was used as a vehicle or for mock treatment, as 
described in the legend to Figure 4.2. Survival curves (D) and the mean and maximum lifespans 
(E) of chronologically aging WT cells cultured without a PE (cells were subjected to ethanol-mock 
treatment), with 0.5% PE4, with 0.1% PE21, or with the mixture of 0.5% PE4 and 0.1% PE21 are 
shown. Data in D and E are presented as means ± SEM (n = 3; *p < 0.05; **p < 0.01; ***p < 
0.001). The CI and p values in E were calculated as described in the legend to Figure 4.2. (F) p 
Values for different pairs of survival curves of WT cells cultured in the presence of 0.5% PE4, 
0.1% PE21, a mixture of 0.5% PE4 and 0.1% PE21, or in the absence of a PE (cells were subjected 
to ethanol-mock treatment) are shown. Survival curves shown in (D) were compared. The p values 
are displayed on a yellow or blue color background for the reasons described in the legend to 
Figure 4.2. Abbreviations: as in the legend to Figure 4.2. 
 
            In sum, these findings confirm our hypothesis that mixtures of PE4 with PE5, PE6, PE12 
or PE21 slow down yeast chronological aging in a synergistic manner. 
4.3.4 A mixture of PE4 and PE8 does not slow down yeast chronological aging in a 
synergistic manner 
            PE4 and PE8 have been shown to weaken the restraining action of the pro-aging TORC1 
or PKA pathway on the same node (i.e., the anti-aging SNF1 pathway) of the signaling network 
that controls the rate of yeast chronological aging (Figure 4.1) [477]. We therefore hypothesized 
that PE4 and PE8 might not act in synergy to delay yeast chronological aging. To test this 
hypothesis, we cultured WT cells in the synthetic minimal medium initially containing 2% glucose, 
either without a PE (i.e. cells were subjected to ethanol-mock treatment) or with the following 
additions: 1) 0.5% PE4 or 0.3% PE8 alone (if PE4 or PE8 was used at this final concentration, it 
exhibited the highest longevity-extending effect), or 2) a mixture of 0.1%, 0.3%, 0.5% or 1.0% 
PE4 with 0.1%, 0.3%, 0.5% or 1.0% PE8. 
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            In support of our hypothesis, we found that the longevity-extending efficiency of a mixture 
of 0.5% PE4 and 0.5% PE8 is not statistically different from those of PE4 and PE8, which were 
used at the optimal concentration of 0.5% or 0.3% (respectively) (Figure 4.6). The CI values were 
1.16 and 1.07 for the mean CLS and the maximum CLS (respectively) when 0.5% PE4 was used 
as the HSA for the mean CLS and 0.3% PE8 was used as the HSA for the maximum CLS (Figure 
4.6). 
 
Figure 4.6. The longevity-extending efficiency of a mixture of 0.5% PE4 and 0.5% PE8 is not 
statistically different from those of PE4 and PE8, which were used at the optimal 
concentration of 0.5% or 0.3% (respectively). Thus, PE4 and PE8 do not enhance the 
longevity-extending efficiency of each other. Hence, according to the HSA model, PE4 and 
PE8 do not act in synergy to extend the longevity of chronologically aging yeast. (A) PE4 and 
PE8 are known to weaken the restraining action of the pro-aging TORC1 or PKA pathway on the 
same node (i.e., the anti-aging SNF1 pathway) of the signaling network that controls the rate of 
yeast chronological aging. (B, C) WT cells were grown as described in the legend to Figure 4.2, 
with PE4 and/or PE8 (at the final concentration of 0.1%, 0.3%, 0.5% or 1.0%) or without a PE.  
Effects of different concentrations of PE4 and PE8 (added alone or in pairwise combinations) on 
the mean (B) or maximum (C) CLS of WT cells are shown. The table cell at the intersection of the 
column for 0.5% PE4 and the row for 0.5% PE8 is marked “max” for a reason described in the 
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legend to Figure 4.2. (D, E) WT cells were cultured as described in the legend to Figure 4.2, with 
one of the following supplements: 0.5% PE4, 0.3% PE8, or a mixture of 0.5% PE4 and 0.5% PE8. 
Ethanol was used as a vehicle or for mock treatment, as described in the legend to Figure 4.2. 
Survival curves (D) and the mean and maximum lifespans (E) of chronologically aging WT cells 
cultured without a PE (cells were subjected to ethanol-mock treatment), with 0.5% PE4, with 0.3% 
PE8, or with the mixture of 0.5% PE4 and 0.5% PE8 are shown. Data in D and E are presented as 
means ± SEM (n = 3; *p < 0.05; **p < 0.01). The CI and p values in E were calculated as described 
in the legend to Figure 4.2. (F) p Values for different pairs of survival curves of WT cells cultured 
in the presence of 0.5% PE4, 0.3% PE8, a mixture of 0.5% PE4 and 0.5% PE8, or in the absence 
of a PE (cells were subjected to ethanol-mock treatment) are shown. Survival curves shown in (D) 
were compared. Abbreviations: as in the legend to Figure 4.2. 
4.3.5 Pairwise combinations of PE5 and PE6, PE5 and PE8, PE5 and PE12, and PE5 and 
PE21 delay yeast chronological aging in a synergistic fashion 
            As we have already mentioned, PE5, PE6, PE8, PE12 and PE21 are known to affect 
different nodes, edges and modules of the signaling network that controls the rate of yeast 
chronological aging (Figure 4.1) [477]. We, therefore, put forward the hypothesis that pairwise 
combinations of PE5 and PE6, PE5 and PE8, PE5 and PE12, and PE5 and PE21 may 
synergistically extend the longevity of chronologically aging yeast. To test this hypothesis, WT 
cells were cultured in the synthetic minimal medium initially containing 2% glucose, either 
without a PE (i.e. cells were subjected to ethanol-mock treatment) or with the following additions: 
1) PE5, PE6, PE8, PE12 or PE21 alone (each being used at the final concentration of 0.1%, 0.3%, 
0.5% or 1.0%, see below), or 2) a pairwise combination of 0.1%, 0.3%, 0.5% or 1.0% PE5 and 
PE6, PE8, PE12 or PE21 (each being used at the final concentration of 0.1%, 0.3%, 0.5% or 1.0%). 
            We found that the longevity-extending efficiencies of the following pairwise combinations 
of aging-delaying PEs are statistically significantly higher than that of a PE component of the pair 
which was used as the HSA if added alone at the concentration exhibiting the highest aging-
delaying effect: 1) a pairwise combination of 0.3% PE5 and 0.3% PE6 as compared to 0.5% PE5 
(which was used as the HSA for both the mean and maximum CLS) (Figure 4.7), 2) a pairwise 
combination of 0.1% PE5 and 0.1% PE8 as compared to 0.5% PE5 (which was considered as the 
HSA for the mean CLS) or 0.3% PE8 (which was considered as the HSA for the maximum CLS) 
(Figure 4.8), 3) a pairwise combination of 0.1% PE5 and 0.1% PE12 as compared to 0.5% PE5 
(which was used as the HSA for the mean CLS) or 0.1% PE12 (which was used as the HSA for 
the maximum CLS) (Figure 4.9), and 4) a pairwise combination of 0.1% PE5 and 0.1% PE21 as 
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compared to 0.1% PE21 (which was used as the HSA for both the mean and maximum CLS) 
(Figure 4.10). 
            These findings confirm our hypothesis that pairwise combinations of PE5 and PE6, PE5 
and PE8, PE5 and PE12, and PE5 and PE21 synergistically extend the longevity of chronologically 
aging yeast. 
 
Figure 4.7. The longevity-extending efficiency of a mixture of 0.3% PE5 and 0.3% PE6 
statistically significantly exceeds those of PE5 and PE6, which were used at the optimal 
concentration of 0.5% or 1.0% (respectively). Thus, PE5 and PE6 enhance the longevity-
extending efficiency of each other. Hence, according to the highest single agent (HSA) model, 
PE5 and PE6 act in synergy to extend the longevity of chronologically aging yeast. (A) PE5 
and PE6 are known to regulate different nodes of the signaling network that controls the rate of 
yeast chronological aging. PE5 mitigates two different branches of the pro-aging PKA pathway, 
whereas PE6 modulates a presently unknown pro-aging or anti-aging node that may be integrated 
into this signaling network. (B, C) WT cells were grown in the synthetic minimal YNB medium 
initially containing 2% glucose, with PE5 and/or PE6 (at the final concentration of 0.1%, 0.3%, 
0.5% or 1.0%) or without a PE.  Effects of different concentrations of PE5 and PE6 (added alone 
or in pairwise combinations) on the mean (B) or maximum (C) CLS of WT cells are shown. The 
table cell at the intersection of the column for 0.3% PE5 and the row for 0.3% PE6 is marked 
“max” because the mixture of 0.3% PE5 and 0.3% PE6 exhibits the highest extending effect on 
the mean and maximum lifespans of chronologically aging WT cells. (D, E) WT cells were 
cultured in the synthetic minimal YNB medium initially containing 2% glucose and one of the 
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following supplements: 0.5% PE5, 1.0% PE6, or a mixture of 0.3% PE5 and 0.3% PE6. In the 
cultures supplemented with PE5 and/or PE6, ethanol was used as a vehicle at the final 
concentration of 2.5%. In the same experiment, WT cells were also subjected to ethanol-mock 
treatment by being cultured in the synthetic minimal YNB medium, initially containing 2% 
glucose and 2.5% ethanol. Survival curves (D) and the mean and maximum lifespans (E) of 
chronologically aging WT cells cultured without a PE (cells were subjected to ethanol-mock 
treatment), with 0.5% PE5, with 1.0% PE6, or with the mixture of 0.3% PE5 and 0.3% PE6 are 
shown. Data in D and E are presented as means ± SEM (n = 3; *p < 0.05; **p < 0.01). The CI 
values in E were calculated as follows: CI = CLSPE5/CLSPE5+PE6 for both the mean and maximum 
CLS; the significance of a synergistic effect (i.e., CI < 1) is provided as the p value of the two-
tailed t test for comparing the effect of a PE combination (i.e., CLSPE5+PE6) to that of the HSA (i.e., 
CLSPE5 for both the mean and maximum CLS). (F) p Values for different pairs of survival curves 
of WT cells cultured in the presence of 0.5% PE5, 1.0% PE6, a mixture of 0.3% PE5 and 0.3% 
PE6, or in the absence of a PE (cells were subjected to ethanol-mock treatment) are shown. 
Survival curves shown in (D) were compared. Two survival curves were considered statistically 
different if the p value was less than 0.05. The p values for comparing pairs of survival curves 
using the logrank test were calculated as described in Materials and Methods. The p values 
displayed on a yellow color background indicate that 0.5% PE5, 1.0% PE6, and the mixture of 
0.3% PE5 and 0.3% PE6 significantly extend the CLS of WT cells. The p values displayed on a 
blue color background indicate that the CLS-extending efficiency of the mixture of 0.3% PE5 and 







Figure 4.8. The longevity-extending efficiency of a mixture of 0.1% PE5 and 0.1% PE8 
statistically significantly exceeds those of PE5 and PE8, which were used at the optimal 
concentration of 0.5% or 0.3% (respectively). Thus, PE5 and PE8 enhance the longevity-
extending efficiency of each other. Hence, according to the HSA model, PE5 and PE8 act in 
synergy to extend the longevity of chronologically aging yeast. (A) PE5 and PE8 are known to 
inhibit different pro-aging nodes of the signaling network that controls the rate of yeast 
chronological aging. PE5 mitigates two different branches of the pro-aging PKA pathway, whereas 
PE8 weakens the restraining action of this pathway on the anti-aging SNF1 pathway. (B, C) WT 
cells were grown as described in the legend to Figure 4.2, with PE5 and/or PE8 (at the final 
concentration of 0.1%, 0.3%, 0.5% or 1.0%) or without a PE.  Effects of different concentrations 
of PE5 and PE8 (added alone or in pairwise combinations) on the mean (B) or maximum (C) CLS 
of WT cells are shown. The table cell at the intersection of the column for 0.1% PE5 and the row 
for 0.1% PE8 is marked “max” for a reason described in the legend to Figure 4.2. (D, E) WT cells 
were cultured as described in the legend to Figure 4.2, with one of the following supplements: 
0.5% PE5, 0.3% PE8, or a mixture of 0.1% PE5 and 0.1% PE8. Ethanol was used as a vehicle or 
for mock treatment, as described in the legend to Figure 4.2. Survival curves (D) and the mean and 
maximum lifespans (E) of chronologically aging WT cells cultured without a PE (cells were 
subjected to ethanol-mock treatment), with 0.5% PE5, with 0.3% PE8, or with the mixture of 0.1% 
PE5 and 0.1% PE8 are shown. Data in D and E are presented as means ± SEM (n = 3; *p < 0.05; 
**p < 0.01). The CI and p values in E were calculated as described in the legend to Figure 4.2. (F) 
p Values for different pairs of survival curves of WT cells cultured in the presence of 0.5% PE5, 
0.3% PE8, a mixture of 0.1% PE5 and 0.1% PE8, or in the absence of a PE (cells were subjected 
to ethanol-mock treatment) are shown. Survival curves shown in (D) were compared. The p values 
are displayed on a yellow or blue color background for the reasons described in the legend to 





Figure 4.9. The longevity-extending efficiency of a mixture of 0.1% PE5 and 0.1% PE12 
statistically significantly exceeds those of PE5 and PE12, which were used at the optimal 
concentration of 0.5% or 0.1% (respectively). Thus, PE5 and PE12 enhance the longevity-
extending efficiency of each other. Hence, according to the highest single agent (HSA) model, 
PE5 and PE12 act in synergy to extend the longevity of chronologically aging yeast. (A) PE5 
and PE12 are known to regulate different nodes of the signaling network that controls the rate of 
yeast chronological aging. PE5 mitigates two different branches of the pro-aging PKA pathway, 
whereas PE12 stimulates the anti-aging protein kinase Rim15. (B, C) WT cells were grown in the 
synthetic minimal YNB medium initially containing 2% glucose, with PE5 and/or PE12 (at the 
final concentration of 0.1%, 0.3%, 0.5% or 1.0%) or without a PE.  Effects of different 
concentrations of PE5 and PE12 (added alone or in pairwise combinations) on the mean (B) or 
maximum (C) CLS of WT cells are shown. The table cell at the intersection of the column for 
0.1% PE5 and the row for 0.1% PE12 is marked “max” because the mixture of 0.1% PE5 and 0.1% 
PE12 exhibits the highest extending effect on the mean and maximum lifespans of chronologically 
aging WT cells. (D, E) WT cells were cultured in the synthetic minimal YNB medium initially 
containing 2% glucose and one of the following supplements: 0.5% PE5, 0.1% PE12, or a mixture 
of 0.1% PE5 and 0.1% PE12. In the cultures supplemented with PE5 and/or PE12, ethanol was 
used as a vehicle at the final concentration of 2.5%. In the same experiment, WT cells were also 
subjected to ethanol-mock treatment by being cultured in the synthetic minimal YNB medium, 
initially containing 2% glucose and 2.5% ethanol. Survival curves (D) and the mean and maximum 
lifespans (E) of chronologically aging WT cells cultured without a PE (cells were subjected to 
ethanol-mock treatment), with 0.5% PE5, with 0.1% PE12, or with the mixture of 0.1% PE5 and 
0.1% PE12 are shown. Data in D and E are presented as means ± SEM (n = 3; *p < 0.05; **p < 
0.01; ***p < 0.001). The CI values in E were calculated as follows: CI = CLSPE5/CLSPE5+PE12 for 
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the mean CLS and CI = CLSPE12/CLSPE5+PE12 for the maximum CLS; the significance of a 
synergistic effect (i.e., CI < 1) is provided as the p value of the two-tailed t test for comparing the 
effect of a PE combination (i.e., CLSPE5+PE12) to that of the HSA (i.e., CLSPE5 for the mean CLS 
and CLSPE12 for the maximum CLS). (F) p Values for different pairs of survival curves of WT 
cells cultured in the presence of 0.5% PE5, 0.1% PE12, a mixture of 0.1% PE5 and 0.1% PE12, or 
in the absence of a PE (cells were subjected to ethanol-mock treatment) are shown. Survival curves 
shown in (D) were compared. Two survival curves were considered statistically different if the p 
value was less than 0.05. The p values for comparing pairs of survival curves using the logrank 
test were calculated as described in Materials and Methods. The p values displayed on a yellow 
color background indicate that 0.5% PE5, 0.1% PE12, and the mixture of 0.1% PE5 and 0.1% 
PE12 significantly extend the CLS of WT cells. The p values displayed on a blue color background 
indicate that the CLS-extending efficiency of the mixture of 0.1% PE5 and 0.1% PE12 






Figure 4.10. The longevity-extending efficiency of a mixture of 0.1% PE5 and 0.1% PE21 
statistically significantly exceeds those of PE5 and PE21, which were used at the optimal 
concentration of 0.5% or 0.1% (respectively). Thus, PE5 and PE21 enhance the longevity-
extending efficiency of each other. Hence, according to the HSA model, PE5 and PE21 act in 
synergy to extend the longevity of chronologically aging yeast. (A) PE5 and PE21 are known 
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to inhibit different pro-aging nodes of the signaling network that controls the rate of yeast 
chronological aging. PE5 mitigates two different branches of the pro-aging PKA pathway, whereas 
PE21 mitigates a form of the pro-aging protein kinase Sch9 that is activated by the pro-aging 
PKH1/2 pathway. (B, C) WT cells were grown as described in the legend to Figure 4.2, with PE5 
and/or PE21 (at the final concentration of 0.1%, 0.3%, 0.5% or 1.0%) or without a PE. Effects of 
different concentrations of PE5 and PE21 (added alone or in pairwise combinations) on the mean 
(B) or maximum (C) CLS of WT cells are shown. The table cell at the intersection of the column 
for 0.1% PE5 and the row for 0.1% PE21 is marked “max” for a reason described in the legend to 
Figure 4.2. (D, E) WT cells were cultured as described in the legend to Figure 4.2, with one of the 
following supplements: 0.5% PE5, 0.1% PE21, or a mixture of 0.1% PE5 and 0.1% PE21. Ethanol 
was used as a vehicle or for mock treatment, as described in the legend to Figure 4.2. Survival 
curves (D) and the mean and maximum lifespans (E) of chronologically aging WT cells cultured 
without a PE (cells were subjected to ethanol-mock treatment), with 0.5% PE5, with 0.1% PE21, 
or with the mixture of 0.1% PE5 and 0.1% PE21 are shown. Data in D and E are presented as 
means ± SEM (n = 3; *p < 0.05; **p < 0.01; ***p < 0.001). The CI and p values in E were 
calculated as described in the legend to Figure 4.2. (F) p Values for different pairs of survival 
curves of WT cells cultured in the presence of 0.5% PE5, 0.1% PE21, a mixture of 0.1% PE5 and 
0.1% PE21, or in the absence of a PE (cells were subjected to ethanol-mock treatment) are shown. 
Survival curves shown in (D) were compared. The p values are displayed on a yellow or blue color 
background for the reasons described in the legend to Figure 1. Abbreviations: as in the legend to 
Figure 4.2. 
4.3.6 Mixtures of PE6 and PE8, PE6 and PE12, and PE6 and PE21 synergistically extend 
the longevity of chronologically aging yeast 
            Because PE6, PE8, PE12 and PE21 are known to affect different nodes, edges and modules 
of the signaling network that controls the rate of yeast chronological aging (Figure 4.1) [477], we 
hypothesized that mixtures of PE6 with PE8, PE12 or PE21 may have synergistic effects on the 
efficiency of aging delay. To test this hypothesis, we cultured WT cells in the synthetic minimal 
medium initially containing 2% glucose, either without a PE (i.e. cells were subjected to ethanol-
mock treatment) or with the following additions: 1) PE6, PE8, PE12 or PE21 alone (each being 
used at the final concentration of 0.1%, 0.3% or 1.0%, see below), or 2) a mixture of 0.1%, 0.3%, 
0.5% or 1.0% PE6 with PE8, PE12 or PE21 (each being used at the final concentration of 0.1%, 
0.3%, 0.5% or 1.0%). 
            We found that the longevity-extending efficiencies of the following mixtures of aging-
delaying PEs are statistically significantly greater than that of a PE component of the mixture 
which was considered as the HSA if used alone at the concentration having the maximum aging-
delaying effect: 1) a mixture of 0.3% PE6 and 0.3% PE8 as compared to 1.0% PE6 (which was 
considered as the HSA for the mean CLS) or 0.3% PE8 (which was considered as the HSA for the 
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maximum CLS) (Figure 4.11), 2) a mixture of 0.3% PE6 and 0.1% PE12 as compared to 1.0% 
PE6 (which was used as the HSA for the mean CLS) or 0.1% PE12 (which was used as the HSA 
for the maximum CLS) (Figure 4.12), and 3) a mixture of 0.1% PE6 and 0.1% PE21 as compared 
to 0.1% PE21 (which was considered as the HSA for both the mean and maximum CLS) (Figure 
4.13). 
            Thus, in support of our hypothesis, mixtures of PE6 with PE8, PE12 or PE21 delay yeast 






Figure 4.11. The longevity-extending efficiency of a mixture of 0.3% PE6 and 0.3% PE8 
statistically significantly exceeds those of PE6 and PE8, which were used at the optimal 
concentration of 1.0% or 0.3% (respectively). Thus, PE6 and PE8 enhance the longevity-
extending efficiency of each other. Hence, according to the highest single agent (HSA) model, 
PE6 and PE8 act in synergy to extend the longevity of chronologically aging yeast. (A) PE6 
and PE8 are known to regulate different nodes of the signaling network that controls the rate of 
yeast chronological aging. PE8 weakens the restraining action of the pro-aging PKA pathway on 
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the anti-aging SNF1 pathway, whereas PE6 modulates a presently unknown pro-aging or anti-
aging node that may be integrated into this signaling network. (B, C) WT cells were grown in the 
synthetic minimal YNB medium initially containing 2% glucose, with PE6 and/or PE8 (at the final 
concentration of 0.1%, 0.3%, 0.5% or 1.0%) or without a PE.  Effects of different concentrations 
of PE6 and PE8 (added alone or in pairwise combinations) on the mean (B) or maximum (C) CLS 
of WT cells are shown. The table cell at the intersection of the column for 0.3% PE6 and the row 
for 0.3% PE8 is marked “max” because the mixture of 0.3% PE6 and 0.3% PE8 exhibits the highest 
extending effect on the mean and maximum lifespans of chronologically aging WT cells. (D, E) 
WT cells were cultured in the synthetic minimal YNB medium initially containing 2% glucose 
and one of the following supplements: 1.0% PE6, 0.3% PE8, or a mixture of 0.3% PE6 and 0.3% 
PE8. In the cultures supplemented with PE6 and/or PE8, ethanol was used as a vehicle at the final 
concentration of 2.5%. In the same experiment, WT cells were also subjected to ethanol-mock 
treatment by being cultured in the synthetic minimal YNB medium, initially containing 2% 
glucose and 2.5% ethanol. Survival curves (D) and the mean and maximum lifespans (E) of 
chronologically aging WT cells cultured without a PE (cells were subjected to ethanol-mock 
treatment), with 1.0% PE6, with 0.3% PE8, or with the mixture of 0.3% PE6 and 0.3% PE8 are 
shown. Data in D and E are presented as means ± SEM (n = 3; *p < 0.05; **p < 0.01). The CI 
values in E were calculated as follows: CI = CLSPE6/CLSPE6+PE8 for the mean CLS and CI = 
CLSPE8/CLSPE6+PE8 for the maximum CLS; the significance of a synergistic effect (i.e., CI < 1) is 
provided as the p value of the two-tailed t test for comparing the effect of a PE combination (i.e., 
CLSPE6+PE8) to that of the HSA (i.e., CLSPE6 for the mean CLS and CLSPE8 for the maximum CLS). 
(F) p Values for different pairs of survival curves of WT cells cultured in the presence of 1.0% 
PE6, 0.3% PE8, a mixture of 0.3% PE6 and 0.3% PE8, or in the absence of a PE (cells were 
subjected to ethanol-mock treatment) are shown. Survival curves shown in (D) were compared. 
Two survival curves were considered statistically different if the p value was less than 0.05. The 
p values for comparing pairs of survival curves using the logrank test were calculated as described 
in Materials and Methods. The p values displayed on a yellow color background indicate that 1.0% 
PE6, 0.3% PE8, and the mixture of 0.3% PE6 and 0.3% PE8 significantly extend the CLS of WT 
cells. The p values displayed on a blue color background indicate that the CLS-extending 
efficiency of the mixture of 0.3% PE6 and 0.3% PE8 significantly exceeds that of 1.0% PE6 or 





Figure 4.12. The longevity-extending efficiency of a mixture of 0.3% PE6 and 0.1% PE12 
statistically significantly exceeds those of PE6 and PE12, which were used at the optimal 
concentration of 1.0% or 0.1% (respectively). Thus, PE6 and PE12 enhance the longevity-
extending efficiency of each other. Hence, according to the HSA model, PE6 and PE12 act in 
synergy to extend the longevity of chronologically aging yeast. (A) PE6 and PE12 are known 
to regulate different nodes of the signaling network that controls the rate of yeast chronological 
aging. PE12 stimulates the anti-aging protein kinase Rim15 assimilated into this signaling 
network, whereas PE6 modulates a presently unknown pro-aging or anti-aging node that may be 
integrated into this network. (B, C) WT cells were grown as described in the legend to Figure 4.2, 
with PE6 and/or PE12 (at the final concentration of 0.1%, 0.3%, 0.5% or 1.0%) or without a PE. 
Effects of different concentrations of PE6 and PE12 (added alone or in pairwise combinations) on 
the mean (B) or maximum (C) CLS of WT cells are shown. The table cell at the intersection of the 
column for 0.3% PE6 and the row for 0.1% PE12 is marked “max” for a reason described in the 
legend to Figure 4.2. (D, E) WT cells were cultured as described in the legend to Figure 4.2, with 
one of the following supplements: 1.0% PE6, 0.1% PE12, or a mixture of 0.3% PE6 and 0.1% 
PE12. Ethanol was used as a vehicle or for mock treatment, as described in the legend to Figure 
4.2. Survival curves (D) and the mean and maximum lifespans (E) of chronologically aging WT 
cells cultured without a PE (cells were subjected to ethanol-mock treatment), with 1.0% PE6, with 
0.1% PE12, or with the mixture of 0.3% PE6 and 0.1% PE12 are shown. Data in D and E are 
presented as means ± SEM (n = 3; *p < 0.05; **p < 0.01). The CI and p values in E were calculated 
as described in the legend to Figure 4.2. (F) p Values for different pairs of survival curves of WT 
cells cultured in the presence of 1.0% PE6, 0.1% PE12, a mixture of 0.3% PE6 and 0.1% PE12, or 
in the absence of a PE (cells were subjected to ethanol-mock treatment) are shown. Survival curves 
shown in (D) were compared. The p values displayed on a yellow color background indicate that 
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1.0% PE6, 0.1% PE12, and the mixture of 0.3% PE6 and 0.1% PE12 significantly extend the CLS 
of WT cells. The p values are displayed on a yellow or blue color background for the reasons 
described in the legend to Figure 1. Abbreviations: as in the legend to Figure 4.2. 
 
 
Figure 4.13. The longevity-extending efficiency of a mixture of 0.1% PE6 and 0.1% PE21 
statistically significantly exceeds those of PE6 and PE21, which were used at the optimal 
concentration of 1.0% or 0.1% (respectively). Thus, PE6 and PE21 enhance the longevity-
extending efficiency of each other. Hence, according to the highest single agent (HSA) model, 
PE6 and PE21 act in synergy to extend the longevity of chronologically aging yeast. (A) PE6 
and PE21 are known to regulate different nodes of the signaling network that controls the rate of 
yeast chronological aging. PE21 mitigates a form of the pro-aging protein kinase Sch9 that is 
activated by the pro-aging PKH1/2 pathway, whereas PE6 modulates a presently unknown pro-
aging or anti-aging node that may be integrated into this signaling network. (B, C) WT cells were 
grown in the synthetic minimal YNB medium initially containing 2% glucose, with PE6 and/or 
PE21 (at the final concentration of 0.1%, 0.3%, 0.5% or 1.0%) or without a PE.  Effects of different 
concentrations of PE6 and PE21 (added alone or in pairwise combinations) on the mean (B) or 
maximum (C) CLS of WT cells are shown. The table cell at the intersection of the column for 
0.1% PE6 and the row for 0.1% PE21 is marked “max” because the mixture of 0.1% PE6 and 0.1% 
PE21 exhibits the highest extending effect on the mean and maximum lifespans of chronologically 
aging WT cells. (D, E) WT cells were cultured in the synthetic minimal YNB medium initially 
containing 2% glucose and one of the following supplements: 1.0% PE6, 0.1% PE21, or a mixture 
of 0.1% PE6 and 0.1% PE21. In the cultures supplemented with PE6 and/or PE21, ethanol was 
used as a vehicle at the final concentration of 2.5%. In the same experiment, WT cells were also 
subjected to ethanol-mock treatment by being cultured in the synthetic minimal YNB medium, 
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initially containing 2% glucose and 2.5% ethanol. Survival curves (D) and the mean and maximum 
lifespans (E) of chronologically aging WT cells cultured without a PE (cells were subjected to 
ethanol-mock treatment), with 1.0% PE6, with 0.1% PE21, or with the mixture of 0.1% PE6 and 
0.1% PE21 are shown. Data in D and E are presented as means ± SEM (n = 3; *p < 0.05; **p < 
0.01; ***p < 0.001). The CI values in E were calculated as follows: CI = CLSPE21/CLSPE6+PE21 for 
both the mean and maximum CLS; the significance of a synergistic effect (i.e., CI < 1) is provided 
as the p value of the two-tailed t test for comparing the effect of a PE combination (i.e., 
CLSPE6+PE21) to that of the HSA (i.e., CLSPE21 for both the mean and maximum CLS). (F) p Values 
for different pairs of survival curves of WT cells cultured in the presence of 1.0% PE6, 0.1% PE21, 
a mixture of 0.1% PE6 and 0.1% PE21, or in the absence of a PE (cells were subjected to ethanol-
mock treatment) are shown. Survival curves shown in (D) were compared. Two survival curves 
were considered statistically different if the p value was less than 0.05. The p values for comparing 
pairs of survival curves using the logrank test were calculated as described in Materials and 
Methods. The p values displayed on a yellow color background indicate that 1.0% PE6, 0.1% 
PE21, and the mixture of 0.1% PE6 and 0.1% PE21 significantly extend the CLS of WT cells. The 
p values displayed on a blue color background indicate that the CLS-extending efficiency of the 
mixture of 0.1% PE6 and 0.1% PE21 significantly exceeds that of 1.0% PE6 or 0.1% PE21. 
Abbreviations: as in the legend to Figure 4.2. 
4.3.7 Pairwise combinations of PE8 with PE12 or PE21 synergistically slow down yeast 
chronological aging 
            As has been noted above, PE8, PE12 and PE21 modulate different nodes, edges and 
modules of the signaling network that defines the rate of yeast chronological aging (Figure 4.1) 
[477]. We therefore put forward the hypothesis that pairwise combinations of PE8 and PE12, and 
PE8 and PE21 may synergistically prolong the longevity of chronologically aging yeast. To test 
this hypothesis, WT cells were cultured in the synthetic minimal medium initially containing 2% 
glucose, either without a PE (i.e. cells were subjected to ethanol-mock treatment) or with the 
following additions: 1) PE8, PE12 or PE21 alone (each being used at the final concentration of 
0.1% or 0.3%, see below), or 2) a pairwise combination of 0.1%, 0.3%, 0.5% or 1.0% PE8 and 
PE12 or PE21 (each being used at the final concentration of 0.1%, 0.3%, 0.5% or 1.0%). 
            We found that the longevity-extending efficiencies of the following pairwise combinations 
of aging-delaying PEs statistically significantly exceed that of a PE component of the pair which 
was considered as the HSA if added alone at the concentration displaying the highest aging-
delaying effect: 1) a pairwise combination of 0.1% PE8 and 0.1% PE12 as compared to 0.1% PE12 
(which was considered as the HSA for both the mean and maximum CLS) (Figure 4.14), and 2) a 
pairwise combination of 0.1% PE8 and 0.1% PE21 as compared to 0.1% PE21 (which was used 
as the HSA for both the mean and maximum CLS) (Figure 4.15). 
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            In sum, these findings confirm our hypothesis that pairwise combinations of PE8 with 
PE12 or PE21 synergistically prolong the longevity of chronologically aging yeast. 
 
 
Figure 4.14. The longevity-extending efficiency of a mixture of 0.1% PE8 and 0.1% PE12 
statistically significantly exceeds those of PE8 and PE12, which were used at the optimal 
concentration of 0.3% or 0.1% (respectively). Thus, PE8 and PE12 enhance the longevity-
extending efficiency of each other. Hence, according to the HSA model, PE8 and PE12 act in 
synergy to extend the longevity of chronologically aging yeast. (A) PE8 and PE12 are known 
to regulate different nodes of the signaling network that controls the rate of yeast chronological 
aging. PE8 weakens the restraining action of the pro-aging PKA pathway on the anti-aging SNF1 
pathway, whereas PE12 stimulates the anti-aging protein kinase Rim15 integrated into this 
signaling network. (B, C) WT cells were grown as described in the legend to Figure 4.2, with PE8 
and/or PE12 (at the final concentration of 0.1%, 0.3%, 0.5% or 1.0%) or without a PE. Effects of 
different concentrations of PE8 and PE12 (added alone or in pairwise combinations) on the mean 
(B) or maximum (C) CLS of WT cells are shown. The table cell at the intersection of the column 
for 0.1% PE8 and the row for 0.1% PE12 is marked “max” for a reason described in the legend to 
Figure 4.2. (D, E) WT cells were cultured as described in the legend to Figure 4.2, with one of the 
following supplements: 0.3% PE8, 0.1% PE12, or a mixture of 0.1% PE8 and 0.1% PE12. Ethanol 
was used as a vehicle or for mock treatment, as described in the legend to Figure 4.2. Survival 
curves (D) and the mean and maximum lifespans (E) of chronologically aging WT cells cultured 
without a PE (cells were subjected to ethanol-mock treatment), with 0.3% PE8, with 0.1% PE12, 
or with the mixture of 0.1% PE8 and 0.1% PE12 are shown. Data in D and E are presented as 
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means ± SEM (n = 3; **p < 0.01). The CI and p values in E were calculated as described in the 
legend to Figure 4.2. (F) p Values for different pairs of survival curves of WT cells cultured in the 
presence of 0.3% PE8, 0.1% PE12, a mixture of 0.1% PE8 and 0.1% PE12, or in the absence of a 
PE (cells were subjected to ethanol-mock treatment) are shown. Survival curves shown in (D) were 
compared. The p values are displayed on a yellow or blue color background for the reasons 
described in the legend to Figure 4.2. Abbreviations: as in the legend to Figure 4.2. 
 
 
Figure 4.15. The longevity-extending efficiency of a mixture of 0.1% PE8 and 0.1% PE21 
statistically significantly exceeds those of PE8 and PE21, which were used at the optimal 
concentration of 0.3% or 0.1% (respectively). Thus, PE8 and PE21 enhance the longevity-
extending efficiency of each other. Hence, according to the highest single agent (HSA) model, 
PE8 and PE21 act in synergy to extend the longevity of chronologically aging yeast. (A) PE8 
and PE21 are known to regulate different nodes of the signaling network that controls the rate of 
yeast chronological aging. PE8 weakens the restraining action of the pro-aging PKA pathway on 
the anti-aging SNF1 pathway, whereas PE21 mitigates a form of the pro-aging protein kinase Sch9 
that is activated by the pro-aging PKH1/2 pathway. (B, C) WT cells were grown in the synthetic 
minimal YNB medium initially containing 2% glucose, with PE8 and/or PE21 (at the final 
concentration of 0.1%, 0.3%, 0.5% or 1.0%) or without a PE. Effects of different concentrations 
of PE6 and PE21 (added alone or in pairwise combinations) on the mean (B) or maximum (C) 
CLS of WT cells are shown. The table cell at the intersection of the column for 0.1% PE8 and the 
row for 0.1% PE21 is marked “max” because the mixture of 0.1% PE8 and 0.1% PE21 exhibits 
the highest extending effect on the mean and maximum lifespans of chronologically aging WT 
cells. (D, E) WT cells were cultured in the synthetic minimal YNB medium initially containing 
2% glucose and one of the following supplements: 0.3% PE8, 0.1% PE21, or a mixture of 0.1% 
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PE8 and 0.1% PE21. In the cultures supplemented with PE8 and/or PE21, ethanol was used as a 
vehicle at the final concentration of 2.5%. In the same experiment, WT cells were also subjected 
to ethanol-mock treatment by being cultured in the synthetic minimal YNB medium, initially 
containing 2% glucose and 2.5% ethanol. Survival curves (D) and the mean and maximum 
lifespans (E) of chronologically aging WT cells cultured without a PE (cells were subjected to 
ethanol-mock treatment), with 0.3% PE8, with 0.1% PE21, or with the mixture of 0.1% PE8 and 
0.1% PE21 are shown. Data in D and E are presented as means ± SEM (n = 3; *p < 0.05; **p < 
0.01; ***p < 0.001). The CI values in E were calculated as follows: CI = CLSPE21/CLSPE8+PE21 for 
both the mean and maximum CLS; the significance of a synergistic effect (i.e., CI < 1) is provided 
as the p value of the two-tailed t test for comparing the effect of a PE combination (i.e., 
CLSPE8+PE21) to that of the HSA (i.e., CLSPE21 for both the mean and maximum CLS). (F) p Values 
for different pairs of survival curves of WT cells cultured in the presence of 0.3% PE8, 0.1% PE21, 
a mixture of 0.1% PE8 and 0.1% PE21, or in the absence of a PE (cells were subjected to ethanol-
mock treatment) are shown. Survival curves shown in (D) were compared. Two survival curves 
were considered statistically different if the p value was less than 0.05. The p values for comparing 
pairs of survival curves using the logrank test were calculated as described in Materials and 
Methods. The p values displayed on a yellow color background indicate that 0.3% PE8, 0.1% 
PE21, and the mixture of 0.1% PE8 and 0.1% PE21 significantly extend the CLS of WT cells. The 
p values displayed on a blue color background indicate that the CLS-extending efficiency of the 
mixture of 0.1% PE8 and 0.1% PE21 significantly exceeds that of 0.3% PE8 or 0.1% PE21. 
Abbreviations: as in the legend to Figure 4.2. 
4.3.8 A mixture of PE12 and PE21 slows yeast chronological aging in a synergistic 
manner 
            Because PE12 and PE21 are known to affect two different nodes of the signaling network 
that controls the rate of yeast chronological aging (Figure 4.1) [477], we hypothesized that PE12 
and PE21 might not act in synergy to delay yeast chronological aging. To test this hypothesis, we 
cultured WT cells in the synthetic minimal medium initially containing 2% glucose, either without 
a PE (i.e. cells were subjected to ethanol-mock treatment) or with the following additions: 1) 0.1% 
PE12 or 0.1% PE21 alone (if PE12 or PE21 was used at this final concentration, it had the greatest 
longevity-extending effect), or 2) a mixture of 0.1%, 0.3%, 0.5% or 1.0% PE12 with 0.1%, 0.3%, 
0.5% or 1.0% PE21. 
            In support of our hypothesis, we found that the longevity-extending efficiency of a mixture 
of 0.1% PE12 and 0.1% PE21 is statistically significantly greater than that of 0.1% PE21 (which 
was considered as the HSA if used alone at this concentration to attain the maximum aging-




Figure 4.16. The longevity-extending efficiency of a mixture of 0.1% PE12 and 0.1% PE21 
statistically significantly exceeds those of PE12 and PE21, each being used at the optimal 
concentration of 0.1%. Thus, PE12 and PE21 enhance the longevity-extending efficiency of 
each other. Hence, according to the highest single agent (HSA) model, PE12 and PE21 act in 
synergy to extend the longevity of chronologically aging yeast. (A) PE12 and PE21 are known 
to regulate different nodes of the signaling network that controls the rate of yeast chronological 
aging. PE12 stimulates the anti-aging protein kinase Rim15, whereas PE21 mitigates a form of the 
pro-aging protein kinase Sch9 that is activated by the pro-aging PKH1/2 pathway. (B, C) WT cells 
were grown in the synthetic minimal YNB medium initially containing 2% glucose, with PE12 
and/or PE21 (at the final concentration of 0.1%, 0.3%, 0.5% or 1.0%) or without a PE.  Effects of 
different concentrations of PE12 and PE21 (added alone or in pairwise combinations) on the mean 
(B) or maximum (C) CLS of WT cells are shown. The table cell at the intersection of the column 
for 0.1% PE12 and the row for 0.1% PE21 is marked “max” because the mixture of 0.1% PE12 
and 0.1% PE21 exhibits the highest extending effect on the mean and maximum lifespans of 
chronologically aging WT cells. (D, E) WT cells were cultured in the synthetic minimal YNB 
medium initially containing 2% glucose and one of the following supplements: 0.1% PE12, 0.1% 
PE21, or a mixture of 0.1% PE12 and 0.1% PE21. In the cultures supplemented with PE12 and/or 
PE21, ethanol was used as a vehicle at the final concentration of 2.5%. In the same experiment, 
WT cells were also subjected to ethanol-mock treatment by being cultured in the synthetic minimal 
YNB medium, initially containing 2% glucose and 2.5% ethanol. Survival curves (D) and the mean 
and maximum lifespans (E) of chronologically aging WT cells cultured without a PE (cells were 
subjected to ethanol-mock treatment), with 0.1% PE12, with 0.1% PE21, or with the mixture of 
0.1% PE12 and 0.1% PE21 are shown. Data in D and E are presented as means ± SEM (n = 3; *p 
< 0.05; **p < 0.01; ***p < 0.001). The CI values in E were calculated as follows: CI = 
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CLSPE21/CLSPE12+PE21 for both the mean and maximum CLS; the significance of a synergistic effect 
(i.e. CI < 1) is provided as the p value of the two-tailed t test for comparing the effect of a PE 
combination (i.e., CLSPE12+PE21) to that of the HSA (i.e., CLSPE21 for both the mean and maximum 
CLS). (F) p Values for different pairs of survival curves of WT cells cultured in the presence of 
0.1% PE12, 0.1% PE21, a mixture of 0.1% PE12 and 0.1% PE21, or in the absence of a PE (cells 
were subjected to ethanol-mock treatment) are shown. Survival curves shown in (D) were 
compared. Two survival curves were considered statistically different if the p value was less than 
0.05. The p values for comparing pairs of survival curves using the logrank test were calculated as 
described in Materials and Methods. The p values displayed on a yellow color background indicate 
that 0.1% PE12, 0.1% PE21, and the mixture of 0.1% PE12 and 0.1% PE21 significantly extend 
the CLS of WT cells. The p values displayed on a blue color background indicate that the CLS-
extending efficiency of the mixture of 0.1% PE12 and 0.1% PE21 significantly exceeds that of 
0.1% PE12 or 0.1% PE21. Abbreviations: as in the legend to Figure 4.2. 
4.3.9 Pairwise combinations of spermidine with PE4, PE5, PE6, PE8, PE12 or PE21 have 
synergistic effects on the extent of the aging delay 
            Spermidine has been shown to delay yeast chronological aging by activating the anti-aging 
ATG1 pathway (Figure 4.1) [17, 83, 84, 111, 479]. Neither PE4, PE5, PE6, PE8, PE12 nor PE21 
affects the ATG1 node of the signaling network that defines the rate of yeast chronological aging 
(Figure 4.1) [477]. We, therefore, hypothesized that pairwise combinations of spermidine with 
PE4, PE5, PE6, PE8, PE12 or PE21 might exhibit synergistic effects on the extent of yeast 
chronological aging delay. To test this hypothesis, WT cells were cultured in the synthetic minimal 
medium initially containing 2% glucose, either without a PE (i.e. cells were subjected to ethanol-
mock treatment) or with the following additions: 1) PE4, PE5, PE6, PE8, PE12 or PE21 alone 
(each being used at the final concentration of 0.1%, 0.3%, 0.5% or 1.0%, see below), or 2) a 
mixture of 50 μM, 100 μM, 200 μM or 500 μM spermidine with PE4, PE5, PE6, PE8, PE12 or 
PE21 (each being used at the final concentration of 0.1%, 0.3%, 0.5% or 1.0%). 
            We found that the longevity-extending efficiencies of the following pairwise combinations 
of spermidine and an aging-delaying PE statistically significantly exceed that of a PE within the 
pair which was considered as the HSA (i.e. if this PE was used alone at the optimal aging-delaying 
concentration): 1) a mixture of 0.1% PE4 and 100 μM spermidine as compared to 0.5% PE4 (which 
was considered as the HSA for both the mean and maximum CLS) (Figure 4.17), 2) a mixture of 
0.3% PE5 and 100 μM spermidine as compared to 0.5% PE5 (which was used as the HSA for both 
the mean and maximum CLS) (Figure 4.18), 3) a mixture of 0.5% PE6 and 100 μM spermidine as 
compared to 1.0% PE6 (which was considered as the HSA for both the mean and maximum CLS) 
146 
 
(Figure 4.19), 4) a mixture of 0.1% PE8 and 100 μM spermidine as compared to 0.3% PE8 (which 
was used as the HSA for both the mean and maximum CLS) (Figure 4.20), 5) a mixture of 0.1% 
PE12 and 100 μM spermidine as compared to 0.1% PE12 (which was considered as the HSA for 
both the mean and maximum CLS) (Figure 4.21), and 6) a mixture of 0.1% PE21 and 100 μM 
spermidine as compared to 0.1% PE21 (which was used as the HSA for both the mean and 
maximum CLS) (Figure 4.22). These findings confirm our hypothesis that pairwise combinations 
of spermidine with PE4, PE5, PE6, PE8, PE12 or PE21 have synergistic effects on the extent of 
yeast chronological aging delay. 
 
 
Figure 4.17. The longevity-extending efficiency of a mixture of 0.1% PE4 and 100 µM 
spermidine (S) statistically significantly exceeds those of PE4 and S, which were used at the 
optimal concentration of 0.5% or 100 µM (respectively). Thus, PE4 and S enhance the 
longevity-extending efficiency of each other. Hence, according to the highest single agent 
(HSA) model, PE4 and S act in synergy to extend the longevity of chronologically aging yeast. 
(A) PE4 and S are known to regulate different nodes of the signaling network that controls the rate 
of yeast chronological aging. PE4 weakens the restraining action of the pro-aging TORC1 pathway 
on the anti-aging SNF1 pathway, whereas S stimulates the anti-aging ATG pathway. (B, C) WT 
cells were grown in the synthetic minimal YNB medium initially containing 2% glucose, with PE4 
(at the final concentration of 0.1%, 0.3%, 0.5% or 1.0%) and/or S (at the final concentration of 50 
147 
 
µM, 100 µM, 200 µM or 500 µM), or without a PE and S. Effects of different concentrations of 
PE4 and S (added alone or in pairwise combinations) on the mean (B) or maximum (C) CLS of 
WT cells are shown. The table cell at the intersection of the column for 0.1% PE4 and the row for 
100 µM S is marked “max” because the mixture of 0.1% PE4 and 100 µM S exhibits the highest 
extending effect on the mean and maximum lifespans of chronologically aging WT cells. (D, E) 
WT cells were cultured in the synthetic minimal YNB medium initially containing 2% glucose 
and one of the following supplements: 0.5% PE4, 100 µM S, or a mixture of 0.1% PE4 and 100 
µM S. In the cultures supplemented with PE4 and/or S, ethanol was used as a vehicle at the final 
concentration of 2.5%. In the same experiment, WT cells were also subjected to ethanol-mock 
treatment by being cultured in the synthetic minimal YNB medium, initially containing 2% 
glucose and 2.5% ethanol. Survival curves (D) and the mean and maximum lifespans (E) of 
chronologically aging WT cells cultured without a PE and S (cells were subjected to ethanol-mock 
treatment), with 0.5% PE4, with 100 µM S, or with the mixture of 0.1% PE4 and 100 µM S are 
shown. Data in D and E are presented as means ± SEM (n = 3; *p < 0.05; **p < 0.01; ***p < 
0.001). The CI values in E were calculated as follows: CI = CLSPE4/CLSPE4+S for both the mean 
and maximum CLS; the significance of a synergistic effect (i.e. CI < 1) is provided as the p value 
of the two-tailed t test for comparing the effect of a PE combination (i.e., CLSPE3+S) to that of the 
HSA (i.e., CLSPE4 for both the mean and maximum CLS). (F) p Values for different pairs of 
survival curves of WT cells cultured in the presence of 0.5% PE4, 100 µM S, a mixture of 0.1% 
PE4 and 100 µM S, or in the absence of a PE and S (cells were subjected to ethanol-mock 
treatment) are shown. Survival curves shown in (D) were compared. Two survival curves were 
considered statistically different if the p value was less than 0.05. The p values for comparing pairs 
of survival curves using the logrank test were calculated as described in Materials and Methods. 
The p values displayed on a yellow color background indicate that 0.5% PE4, 100 µM S, and the 
mixture of 0.1% PE4 and 100 µM S significantly extend the CLS of WT cells. The p values 
displayed on a blue color background indicate that the CLS-extending efficiency of the mixture of 
0.1% PE4 and 100 µM S significantly exceeds that of 0.5% PE4 or 100 µM S. Abbreviations: as 















Figure 4.18. The longevity-extending efficiency of a mixture of 0.3% PE5 and 100 µM 
spermidine (S) statistically significantly exceeds those of PE5 and S, which were used at the 
optimal concentration of 0.5% or 100 µM (respectively). Thus, PE5 and S enhance the 
longevity-extending efficiency of each other. Hence, according to the HSA model, PE5 and S 
act in synergy to extend the longevity of chronologically aging yeast. (A) PE5 and S are known 
to regulate different nodes of the signaling network that controls the rate of yeast chronological 
aging. PE5 mitigates two different branches of the pro-aging PKA pathway, whereas S stimulates 
the anti-aging ATG pathway. (B, C) WT cells were grown as described in the legend to Figure 4.2, 
with PE5 (at the final concentration of 0.1%, 0.3%, 0.5% or 1.0%) and/or S (at the final 
concentration of 50 µM, 100 µM, 200 µM or 500 µM), or without a PE and S. Effects of different 
concentrations of PE5 and S (added alone or in pairwise combinations) on the mean (B) or 
maximum (C) CLS of WT cells are shown. The table cell at the intersection of the column for 
0.3% PE5 and the row for 100 µM S is marked “max” for a reason described in the legend to 
Figure 4.2. (D, E) WT cells were cultured as described in the legend to Figure 4.2, with one of the 
following supplements: 0.5% PE5, 100 µM S, or a mixture of 0.3% PE5 and 100 µM S. Ethanol 
was used as a vehicle or for mock treatment as described in the legend to Figure 4.2. Survival 
curves (D) and the mean and maximum lifespans (E) of chronologically aging WT cells cultured 
without a PE and S (cells were subjected to ethanol-mock treatment), with 0.5% PE5, with 100 
µM S, or with the mixture of 0.3% PE5 and 100 µM S are shown. Data in D and E are presented 
as means ± SEM (n = 3; *p < 0.05; **p < 0.01; ***p < 0.001). The CI and p values in E were 
calculated as described in the legend to Figure 4.2. (F) p Values for different pairs of survival 
curves of WT cells cultured in the presence of 0.5% PE5, 100 µM S, a mixture of 0.3% PE5 and 
100 µM S, or in the absence of a PE and S (cells were subjected to ethanol-mock treatment) are 
shown. Survival curves shown in (D) were compared. The p values are displayed on a yellow or 
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blue color background for the reasons described in the legend to Figure 4.2. Abbreviations: as in 





Figure 4.19. The longevity-extending efficiency of a mixture of 0.5% PE6 and 100 µM 
spermidine (S) statistically significantly exceeds those of PE6 and S, which were used at the 
optimal concentration of 1.0% or 100 µM (respectively). Thus, PE6 and S enhance the 
longevity-extending efficiency of each other. Hence, according to the highest single agent 
(HSA) model, PE6 and S act in synergy to extend the longevity of chronologically aging yeast. 
(A) PE6 and S are known to regulate different nodes of the signaling network that controls the rate 
of yeast chronological aging. S stimulates the anti-aging ATG pathway, whereas PE6 modulates a 
presently unknown pro-aging or anti-aging node that may be integrated into this network. (B, C) 
WT cells were grown in the synthetic minimal YNB medium initially containing 2% glucose, with 
PE6 (at the final concentration of 0.1%, 0.3%, 0.5% or 1.0%) and/or S (at the final concentration 
of 50 µM, 100 µM, 200 µM or 500 µM), or without a PE and S. Effects of different concentrations 
of PE6 and S (added alone or in pairwise combinations) on the mean (B) or maximum (C) CLS of 
WT cells are shown. The table cell at the intersection of the column for 0.5% PE6 and the row for 
100 µM S is marked “max” because the mixture of 0.5% PE6 and 100 µM S exhibits the highest 
extending effect on the mean and maximum lifespans of chronologically aging WT cells. (D, E) 
WT cells were cultured in the synthetic minimal YNB medium initially containing 2% glucose 
and one of the following supplements: 1.0% PE6, 100 µM S, or a mixture of 0.5% PE6 and 100 
µM S. In the cultures supplemented with PE6 and/or S, ethanol was used as a vehicle at the final 
concentration of 2.5%. In the same experiment, WT cells were also subjected to ethanol-mock 
150 
 
treatment by being cultured in the synthetic minimal YNB medium, initially containing 2% 
glucose and 2.5% ethanol. Survival curves (D) and the mean and maximum lifespans (E) of 
chronologically aging WT cells cultured without a PE and S (cells were subjected to ethanol-mock 
treatment), with 1.0% PE6, with 100 µM S, or with the mixture of 0.5% PE6 and 100 µM S are 
shown. Data in D and E are presented as means ± SEM (n = 3; *p < 0.05; **p < 0.01; ***p < 
0.001). The CI values in E were calculated as follows: CI = CLSPE6/CLSPE6+S for both the mean 
and maximum CLS; the significance of a synergistic effect (i.e. CI < 1) is provided as the p value 
of the two-tailed t test for comparing the effect of a PE combination (i.e., CLSPE6+S) to that of the 
HSA (i.e., CLSPE6 for both the mean and maximum CLS). (F) p Values for different pairs of 
survival curves of WT cells cultured in the presence of 1.0% PE6, 100 µM S, a mixture of 0.5% 
PE6 and 100 µM S, or in the absence of a PE and S (cells were subjected to ethanol-mock 
treatment) are shown. Survival curves shown in (D) were compared. Two survival curves were 
considered statistically different if the p value was less than 0.05. The p values for comparing pairs 
of survival curves using the logrank test were calculated as described in Materials and Methods. 
The p values displayed on a yellow color background indicate that 1.0% PE6, 100 µM S, and the 
mixture of 0.5% PE6 and 100 µM S significantly extend the CLS of WT cells. The p values 
displayed on a blue color background indicate that the CLS-extending efficiency of the mixture of 
0.5% PE6 and 100 µM S significantly exceeds that of 1.0% PE6 or 100 µM S. Abbreviations: as 





Figure 4.20. The longevity-extending efficiency of a mixture of 0.1% PE8 and 100 µM 
spermidine (S) statistically significantly exceeds those of PE8 and S, which were used at the 
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optimal concentration of 0.3% or 100 µM (respectively). Thus, PE8 and S enhance the 
longevity-extending efficiency of each other. Hence, according to the HSA model, PE8 and S 
act in synergy to extend the longevity of chronologically aging yeast. (A) PE8 and S are known 
to regulate different nodes of the signaling network that controls the rate of yeast chronological 
aging. PE8 weakens the restraining action of the pro-aging PKA pathway on the anti-aging SNF1 
pathway, whereas S stimulates the anti-aging ATG pathway. (B, C) WT cells were grown as 
described in the legend to Figure 4.2, with PE8 (at the final concentration of 0.1%, 0.3%, 0.5% or 
1.0%) and/or S (at the final concentration of 50 µM, 100 µM, 200 µM or 500 µM), or without a 
PE and S. Effects of different concentrations of PE8 and S (added alone or in pairwise 
combinations) on the mean (B) or maximum (C) CLS of WT cells are shown. The table cell at the 
intersection of the column for 0.1% PE8 and the row for 100 µM S is marked “max” for a reason 
described in the legend to Figure 4.2. (D, E) WT cells were cultured as described in the legend to 
Figure 4.2, with one of the following supplements: 0.3% PE8, 100 µM S, or a mixture of 0.1% 
PE8 and 100 µM S. Ethanol was used as a vehicle or for mock treatment as described in the legend 
to Figure 4.2. Survival curves (D) and the mean and maximum lifespans (E) of chronologically 
aging WT cells cultured without a PE and S (cells were subjected to ethanol-mock treatment), with 
0.3% PE8, with 100 µM S, or with the mixture of 0.1% PE8 and 100 µM S are shown. Data in D 
and E are presented as means ± SEM (n = 3; *p < 0.05; **p < 0.01). The CI and p values in E were 
calculated as described in the legend to Figure 4.2. (F) p Values for different pairs of survival 
curves of WT cells cultured in the presence of 0.3% PE8, 100 µM S, a mixture of 0.1% PE8 and 
100 µM S, or in the absence of a PE and S (cells were subjected to ethanol-mock treatment) are 
shown. Survival curves shown in (D) were compared. The p values are displayed on a yellow or 
blue color background for the reasons described in the legend to Figure 4.2. Abbreviations: as in 





Figure 4.21. The longevity-extending efficiency of a mixture of 0.1% PE12 and 100 µM 
spermidine (S) statistically significantly exceeds those of PE12 and S, which were used at the 
optimal concentration of 0.1% or 100 µM (respectively). Thus, PE12 and S enhance the 
longevity-extending efficiency of each other. Hence, according to the highest single agent 
(HSA) model, PE12 and S act in synergy to extend the longevity of chronologically aging 
yeast. (A) PE12 and S are known to regulate different nodes of the signaling network that controls 
the rate of yeast chronological aging. PE12 activates the anti-aging protein kinase Rim15, whereas 
S stimulates the anti-aging ATG pathway. (B, C) WT cells were grown in the synthetic minimal 
YNB medium initially containing 2% glucose, with PE12 (at the final concentration of 0.1%, 0.3%, 
0.5% or 1.0%) and/or S (at the final concentration of 50 µM, 100 µM, 200 µM or 500 µM), or 
without a PE and S. Effects of different concentrations of PE12 and S (added alone or in pairwise 
combinations) on the mean (B) or maximum (C) CLS of WT cells are shown. The table cell at the 
intersection of the column for 0.1% PE12 and the row for 100 µM S is marked “max” because the 
mixture of 0.1% PE12 and 100 µM S exhibits the highest extending effect on the mean and 
maximum lifespans of chronologically aging WT cells. (D, E) WT cells were cultured in the 
synthetic minimal YNB medium initially containing 2% glucose and one of the following 
supplements: 0.1% PE12, 100 µM S, or a mixture of 0.1% PE12 and 100 µM S. In the cultures 
supplemented with PE12 and/or S, ethanol was used as a vehicle at the final concentration of 2.5%. 
In the same experiment, WT cells were also subjected to ethanol-mock treatment by being cultured 
in the synthetic minimal YNB medium, initially containing 2% glucose and 2.5% ethanol. Survival 
curves (D) and the mean and maximum lifespans (E) of chronologically aging WT cells cultured 
without a PE and S (cells were subjected to ethanol-mock treatment), with 0.1% PE12, with 100 
µM S, or with the mixture of 0.1% PE12 and 100 µM S are shown. Data in D and E are presented 
as means ± SEM (n = 3; *p < 0.05; **p < 0.01). The CI values in E were calculated as follows: CI 
153 
 
= CLSPE12/CLSPE12+S for both the mean and maximum CLS; the significance of a synergistic effect 
(i.e. CI < 1) is provided as the p value of the two-tailed t test for comparing the effect of a PE 
combination (i.e., CLSPE12+S) to that of the HSA (i.e., CLSPE12 for both the mean and maximum 
CLS). (F) p Values for different pairs of survival curves of WT cells cultured in the presence of 
0.1% PE12, 100 µM S, a mixture of 0.1% PE12 and 100 µM S, or in the absence of a PE and S 
(cells were subjected to ethanol-mock treatment) are shown. Survival curves shown in (D) were 
compared. Two survival curves were considered statistically different if the p value was less than 
0.05. The p values for comparing pairs of survival curves using the logrank test were calculated as 
described in Materials and Methods. The p values displayed on a yellow color background indicate 
that 0.1% PE12, 100 µM S, and the mixture of 0.1% PE12 and 100 µM S significantly extend the 
CLS of WT cells. The p values displayed on a blue color background indicate that the CLS-
extending efficiency of the mixture of 0.1% PE12 and 100 µM S significantly exceeds that of 0.1% 
















Figure 4.22. The longevity-extending efficiency of a mixture of 0.1% PE21 and 100 µM 
spermidine (S) statistically significantly exceeds those of PE21 and S, which were used at the 
optimal concentration of 0.1% or 100 µM (respectively). Thus, PE21 and S enhance the 
longevity-extending efficiency of each other. Hence, according to the highest single agent 
(HSA) model, PE21 and S act in synergy to extend the longevity of chronologically aging 
yeast. (A) PE21 and S are known to regulate different nodes of the signaling network that controls 
the rate of yeast chronological aging. PE21 mitigates a form of the pro-aging protein kinase Sch9 
that is activated by the pro-aging PKH1/2 pathway, whereas S stimulates the anti-aging ATG 
pathway. (B, C) WT cells were grown in the synthetic minimal YNB medium initially containing 
2% glucose, with PE21 (at the final concentration of 0.1%, 0.3%, 0.5% or 1.0%) and/or S (at the 
final concentration of 50 µM, 100 µM, 200 µM or 500 µM), or without a PE and S. Effects of 
different concentrations of PE21 and S (added alone or in pairwise combinations) on the mean (B) 
or maximum (C) CLS of WT cells are shown. The table cell at the intersection of the column for 
0.1% PE21 and the row for 100 µM S is marked “max” because the mixture of 0.1% PE21 and 
100 µM S exhibits the highest extending effect on the mean and maximum lifespans of 
chronologically aging WT cells. (D, E) WT cells were cultured in the synthetic minimal YNB 
medium initially containing 2% glucose and one of the following supplements: 0.1% PE21, 100 
µM S, or a mixture of 0.1% PE21 and 100 µM S. In the cultures supplemented with PE21 and/or 
S, ethanol was used as a vehicle at the final concentration of 2.5%. In the same experiment, WT 
cells were also subjected to ethanol-mock treatment by being cultured in the synthetic minimal 
YNB medium, initially containing 2% glucose and 2.5% ethanol. Survival curves (D) and the mean 
and maximum lifespans (E) of chronologically aging WT cells cultured without a PE and S (cells 
were subjected to ethanol-mock treatment), with 0.1% PE21, with 100 µM S, or with the mixture 
of 0.1% PE21 and 100 µM S are shown. Data in D and E are presented as means ± SEM (n = 3; 
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*p < 0.05; **p < 0.01; ***p < 0.001). The CI values in E were calculated as follows: CI = 
CLSPE21/CLSPE21+S for both the mean and maximum CLS; the significance of a synergistic effect 
(i.e. CI < 1) is provided as the p value of the two-tailed t test for comparing the effect of a PE 
combination (i.e., CLSPE21+S) to that of the HSA (i.e., CLSPE21 for both the mean and maximum 
CLS). (F) p Values for different pairs of survival curves of WT cells cultured in the presence of 
0.1% PE21, 100 µM S, a mixture of 0.1% PE21 and 100 µM S, or in the absence of a PE and S 
(cells were subjected to ethanol-mock treatment) are shown. Survival curves shown in (D) were 
compared. Two survival curves were considered statistically different if the p value was less than 
0.05. The p values for comparing pairs of survival curves using the logrank test were calculated as 
described in Materials and Methods. The p values displayed on a yellow color background indicate 
that 0.1% PE21, 100 µM S, and the mixture of 0.1% PE21 and 100 µM S significantly extend the 
CLS of WT cells. The p values displayed on a blue color background indicate that the CLS-
extending efficiency of the mixture of 0.1% PE21 and 100 µM S significantly exceeds that of 0.1% 
PE21 or 100 µM S. Abbreviations: as in the legend to Figure 4.2. 
4.3.10 Mixtures of resveratrol with PE4, PE5, PE6, PE8, PE12 or PE21 synergistically slow 
down yeast chronological aging 
            Resveratrol modulates a presently unknown pro-aging or anti-aging node that may be 
integrated into the signaling network that controls the rate of yeast chronological aging (Figure 
4.1). PE4, PE5, PE8, PE12 and PE21 affect known nodes, edges and modules of this network, 
whereas PE6 (akin to resveratrol) regulates a currently unidentified node of the network (Figure 
4.1) [477]. Based on these observations, we put forward the following hypotheses: 1) mixtures of 
resveratrol with PE4, PE5, PE8, PE12 or PE21 may have synergistic effects on the efficiency of 
yeast chronological aging delay, 2) if resveratrol and PE6 target different nodes of the network, 
their mixture may delay yeast chronological aging in a synergistic manner, and 3) if resveratrol 
and PE6 target the same node of the network, resveratrol and PE6 may not act in synergy to slow 
down yeast chronological aging. To test these hypotheses, we cultured WT cells in the synthetic 
minimal medium initially containing 2% glucose, either without a PE (i.e. cells were subjected to 
ethanol-mock treatment) or with the following additions: 1) PE4, PE5, PE6, PE8, PE12 or PE21 
alone (each being used at the final concentration of 0.1%, 0.3%, 0.5% or 1.0%, see below), or 2) 
a mixture of 10 μM, 20 μM, 50 μM or 100 μM resveratrol with PE4, PE5, PE6, PE8, PE12 or PE21 
(each being used at the final concentration of 0.1%, 0.3%, 0.5% or 1.0%). 
            We found that the longevity-extending efficiencies of the following mixtures of resveratrol 
and an aging-delaying PE are statistically significantly greater than that of a PE within the mixture 
which was used as the HSA (i.e. if this PE was added alone at the optimal aging-delaying 
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concentration): 1) a mixture of 0.5% PE4 and 50 μM resveratrol as compared to 0.5% PE4 (which 
was used as the HSA for both the mean and maximum CLS) (Figure 4.23), 2) a mixture of 0.3% 
PE5 and 50 μM resveratrol as compared to 0.5% PE5 (which was considered as the HSA for both 
the mean and maximum CLS) (Figure 4.24), 3) a mixture of 0.5% PE6 and 50 μM resveratrol as 
compared to 1.0% PE6 (which was used as the HSA for both the mean and maximum CLS) (Figure 
4.25), 4) a mixture of 0.3% PE8 and 50 μM resveratrol as compared to 0.3% PE8 (which was 
considered as the HSA for both the mean and maximum CLS) (Figure 4.26), 5) a mixture of 0.1% 
PE12 and 50 μM resveratrol as compared to 0.1% PE12 (which was used as the HSA for both the 
mean and maximum CLS) (Figure 4.27), and 6) a mixture of 0.1% PE21 and 50 μM resveratrol as 
compared to 0.1% PE21 (which was considered as the HSA for both the mean and maximum CLS) 
(Figure 4.28). 
            In sum, these findings confirm the following hypotheses: 1) mixtures of resveratrol with 
PE4, PE5, PE8, PE12 or PE21 exhibit synergistic effects on the efficiency of yeast chronological 
aging delay, and 2) if resveratrol and PE6 target different nodes of the network, a mixture of 
resveratrol and PE6 delays yeast chronological aging in a synergistic manner. 
 
Figure 4.23. The longevity-extending efficiency of a mixture of 0.5% PE4 and 50 µM 
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resveratrol (R) statistically significantly exceeds those of PE4 and R, which were used at the 
optimal concentration of 0.5% or 50 µM (respectively). Thus, PE4 and R enhance the 
longevity-extending efficiency of each other. Hence, according to the HSA model, PE4 and R 
act in synergy to extend the longevity of chronologically aging yeast. (A) PE4 and R are known 
to regulate different nodes of the signaling network that controls the rate of yeast chronological 
aging. PE4 weakens the restraining action of the pro-aging TORC1 pathway on the anti-aging 
SNF1 pathway, whereas R modulates a presently unknown pro-aging or anti-aging node that may 
be integrated into this signaling network. (B, C) WT cells were grown as described in the legend 
to Figure 4.2, with PE4 (at the final concentration of 0.1%, 0.3%, 0.5% or 1.0%) and/or R (at the 
final concentration of 10 µM, 20 µM, 50 µM or 100 µM), or without a PE and R. Effects of 
different concentrations of PE4 and R (added alone or in pairwise combinations) on the mean (B) 
or maximum (C) CLS of WT cells are shown. The table cell at the intersection of the column for 
0.5% PE4 and the row for 50 µM R is marked “max” for a reason described in the legend to Figure 
4.2. (D, E) WT cells were cultured as described in the legend to Figure 4.2, with one of the 
following supplements: 0.5% PE4, 50 µM R, or a mixture of 0.5% PE4 and 50 µM R. Ethanol was 
used as a vehicle or for mock treatment as described in the legend to Figure 4.2. Survival curves 
(D) and the mean and maximum lifespans (E) of chronologically aging WT cells cultured without 
a PE and R (cells were subjected to ethanol-mock treatment), with 0.5% PE4, with 50 µM R, or 
with the mixture of 0.5% PE4 and 50 µM R are shown. Data in D and E are presented as means ± 
SEM (n = 3; *p < 0.05; **p < 0.01). The CI and p values in E were calculated as described in the 
legend to Figure 4.2. (F) p Values for different pairs of survival curves of WT cells cultured in the 
presence of 0.5% PE4, 50 µM R, a mixture of 0.5% PE4 and 50 µM R, or in the absence of a PE 
and R (cells were subjected to ethanol-mock treatment) are shown. Survival curves shown in (D) 
were compared. The p values are displayed on a yellow or blue color background for the reasons 
described in the legend to Figure 4.2. Abbreviations: A, a presently unknown anti-aging node of 
the signaling network; B, a presently unknown pro-aging node of the signaling network; other 




Figure 4.24. The longevity-extending efficiency of a mixture of 0.3% PE5 and 50 µM 
resveratrol (R) statistically significantly exceeds those of PE5 and R, which were used at the 
optimal concentration of 0.5% or 50 µM (respectively). Thus, PE5 and R enhance the 
longevity-extending efficiency of each other. Hence, according to the highest single agent 
(HSA) model, PE5 and R act in synergy to extend the longevity of chronologically aging yeast. 
(A) PE5 and R are known to regulate different nodes of the signaling network that controls the rate 
of yeast chronological aging. PE5 mitigates two different branches of the pro-aging PKA pathway, 
whereas R modulates a presently unknown pro-aging or anti-aging node that may be integrated 
into this signaling network. (B, C) WT cells were grown in the synthetic minimal YNB medium 
initially containing 2% glucose, with PE5 (at the final concentration of 0.1%, 0.3%, 0.5% or 1.0%) 
and/or R (at the final concentration of 10 µM, 20 µM, 50 µM or 100 µM), or without a PE and R. 
Effects of different concentrations of PE5 and R (added alone or in pairwise combinations) on the 
mean (B) or maximum (C) CLS of WT cells are shown. The table cell at the intersection of the 
column for 0.3% PE5 and the row for 50 µM R is marked “max” because the mixture of 0.3% PE5 
and 50 µM R exhibits the highest extending effect on the mean and maximum lifespans of 
chronologically aging WT cells. (D, E) WT cells were cultured in the synthetic minimal YNB 
medium initially containing 2% glucose and one of the following supplements: 0.5% PE5, 50 µM 
R, or a mixture of 0.3% PE5 and 50 µM R. In the cultures supplemented with PE5 and/or R, ethanol 
was used as a vehicle at the final concentration of 2.5%. In the same experiment, WT cells were 
also subjected to ethanol-mock treatment by being cultured in the synthetic minimal YNB medium, 
initially containing 2% glucose and 2.5% ethanol. Survival curves (D) and the mean and maximum 
lifespans (E) of chronologically aging WT cells cultured without a PE and R (cells were subjected 
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to ethanol-mock treatment), with 0.5% PE5, with 50 µM R, or with the mixture of 0.3% PE5 and 
50 µM R are shown. Data in D and E are presented as means ± SEM (n = 3; *p < 0.05; **p < 0.01). 
The CI values in E were calculated as follows: CI = CLSPE5/CLSPE5+R for both the mean and 
maximum CLS; the significance of a synergistic effect (i.e. CI < 1) is provided as the p value of 
the two-tailed t test for comparing the effect of a PE combination (i.e. CLSPE5+R) to that of the 
HSA (i.e. CLSPE5 for both the mean and maximum CLS). (F) p Values for different pairs of 
survival curves of WT cells cultured in the presence of 0.5% PE5, 50 µM R, a mixture of 0.3% 
PE5 and 50 µM R, or in the absence of a PE and R (cells were subjected to ethanol-mock treatment) 
are shown. Survival curves shown in (D) were compared. Two survival curves were considered 
statistically different if the p value was less than 0.05. The p values for comparing pairs of survival 
curves using the logrank test were calculated as described in Materials and Methods. The p values 
displayed on a yellow color background indicate that 0.5% PE5, 50 µM R, and the mixture of 0.3% 
PE5 and 50 µM R significantly extend the CLS of WT cells. The p values displayed on a blue 
color background indicate that the CLS-extending efficiency of the mixture of 0.3% PE5 and 50 




Figure 4.25. The longevity-extending efficiency of a mixture of 0.5% PE6 and 50 µM 
resveratrol (R) statistically significantly exceeds those of PE6 and R, which were used at the 
optimal concentration of 1.0% or 50 µM (respectively). Thus, PE6 and R enhance the 
longevity-extending efficiency of each other. Hence, according to the HSA model, PE6 and R 
act in synergy to extend the longevity of chronologically aging yeast. (A) PE6 and R regulate 
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different pro-aging or anti-aging nodes that may be integrated into the signaling network 
controlling the rate of yeast chronological aging; the identities of proteins that form these nodes 
are presently unknown. (B, C) WT cells were grown as described in the legend to Figure 4.2, with 
PE6 (at the final concentration of 0.1%, 0.3%, 0.5% or 1.0%) and/or R (at the final concentration 
of 10 µM, 20 µM, 50 µM or 100 µM), or without a PE and R. Effects of different concentrations 
of PE6 and R (added alone or in pairwise combinations) on the mean (B) or maximum (C) CLS of 
WT cells are shown. The table cell at the intersection of the column for 0.5% PE6 and the row for 
50 µM R is marked “max” for a reason described in the legend to Figure 4.2. (D, E) WT cells were 
cultured as described in the legend to Figure 4.2, with one of the following supplements: 0.5% 
PE6, 50 µM R, or a mixture of 0.5% PE6 and 50 µM R. Ethanol was used as a vehicle or for mock 
treatment as described in the legend to Figure 4.2. Survival curves (D) and the mean and maximum 
lifespans (E) of chronologically aging WT cells cultured without a PE and R (cells were subjected 
to ethanol-mock treatment), with 1.0% PE6, with 50 µM R, or with the mixture of 0.5% PE6 and 
50 µM R are shown. Data in D and E are presented as means ± SEM (n = 3; *p < 0.05; **p < 0.01; 
***p < 0.001; ****p < 0.0001). The CI and p values in E were calculated as described in the legend 
to Figure 4.2. (F) p Values for different pairs of survival curves of WT cells cultured in the presence 
of 1.0% PE6, 50 µM R, a mixture of 0.5% PE6 and 50 µM R, or in the absence of a PE and R 
(cells were subjected to ethanol-mock treatment) are shown. Survival curves shown in (D) were 
compared. The p values are displayed on a yellow or blue color background for the reasons 
described in the legend to Figure 4.2. Abbreviations: as in the legend to Figure 4.2. 
 
 
Figure 4.26. The longevity-extending efficiency of a mixture of 0.3% PE8 and 50 µM 
resveratrol (R) statistically significantly exceeds those of PE8 and R, which were used at the 
optimal concentration of 0.3% or 50 µM (respectively). Thus, PE8 and R enhance the 
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longevity-extending efficiency of each other. Hence, according to the highest single agent 
(HSA) model, PE8 and R act in synergy to extend the longevity of chronologically aging yeast. 
(A) PE8 and R are known to regulate different nodes of the signaling network that controls the rate 
of yeast chronological aging. PE8 weakens the restraining action of the pro-aging PKA pathway 
on the anti-aging SNF1 pathway, whereas R modulates a presently unknown pro-aging or anti-
aging node that may be integrated into this signaling network. (B, C) WT cells were grown in the 
synthetic minimal YNB medium initially containing 2% glucose, with PE8 (at the final 
concentration of 0.1%, 0.3%, 0.5% or 1.0%) and/or R (at the final concentration of 10 µM, 20 µM, 
50 µM or 100 µM), or without a PE and R. Effects of different concentrations of PE8 and R (added 
alone or in pairwise combinations) on the mean (B) or maximum (C) CLS of WT cells are shown. 
The table cell at the intersection of the column for 0.3% PE8 and the row for 50 µM R is marked 
“max” because the mixture of 0.3% PE8 and 50 µM R exhibits the highest extending effect on the 
mean and maximum lifespans of chronologically aging WT cells. (D, E) WT cells were cultured 
in the synthetic minimal YNB medium initially containing 2% glucose and one of the following 
supplements: 0.3% PE8, 50 µM R, or a mixture of 0.3% PE8 and 50 µM R. In the cultures 
supplemented with PE8 and/or R, ethanol was used as a vehicle at the final concentration of 2.5%. 
In the same experiment, WT cells were also subjected to ethanol-mock treatment by being cultured 
in the synthetic minimal YNB medium, initially containing 2% glucose and 2.5% ethanol. Survival 
curves (D) and the mean and maximum lifespans (E) of chronologically aging WT cells cultured 
without a PE and R (cells were subjected to ethanol-mock treatment), with 0.3% PE8, with 50 µM 
R, or with the mixture of 0.3% PE8 and 50 µM R are shown. Data in D and E are presented as 
means ± SEM (n = 3; *p < 0.05; **p < 0.01). The CI values in E were calculated as follows: CI = 
CLSPE8/CLSPE8+R for both the mean and maximum CLS; the significance of a synergistic effect 
(i.e. CI < 1) is provided as the p value of the two-tailed t test for comparing the effect of a PE 
combination (i.e. CLSPE8+R) to that of the HSA (i.e. CLSPE8 for both the mean and maximum CLS). 
(F) p Values for different pairs of survival curves of WT cells cultured in the presence of 0.3% 
PE8, 50 µM R, a mixture of 0.3% PE8 and 50 µM R, or in the absence of a PE and R (cells were 
subjected to ethanol-mock treatment) are shown. Survival curves shown in (D) were compared. 
Two survival curves were considered statistically different if the p value was less than 0.05. The 
p values for comparing pairs of survival curves using the logrank test were calculated as described 
in Materials and Methods. The p values displayed on a yellow color background indicate that 0.3% 
PE8, 50 µM R, and the mixture of 0.3% PE8 and 50 µM R significantly extend the CLS of WT 
cells. The p values displayed on a blue color background indicate that the CLS-extending 
efficiency of the mixture of 0.3% PE8 and 50 µM R significantly exceeds that of 0.3% PE8 or 50 





Figure 4.27. The longevity-extending efficiency of a mixture of 0.1% PE12 and 50 µM 
resveratrol (R) statistically significantly exceeds those of PE12 and R, which were used at the 
optimal concentration of 0.1% or 50 µM (respectively). Thus, PE12 and R enhance the 
longevity-extending efficiency of each other. Hence, according to the HSA model, PE12 and 
R act in synergy to extend the longevity of chronologically aging yeast. (A) PE12 and R 
regulate different nodes of the signaling network that controls the rate of yeast chronological aging. 
PE12 stimulates the anti-aging protein kinase Rim15, whereas R modulates a presently unknown 
pro-aging or anti-aging node that may be integrated into this signaling network. (B, C) WT cells 
were grown as described in the legend to Figure 4.2, with PE12 (at the final concentration of 0.1%, 
0.3%, 0.5% or 1.0%) and/or R (at the final concentration of 10 µM, 20 µM, 50 µM or 100 µM), 
or without a PE and R. Effects of different concentrations of PE12 and R (added alone or in 
pairwise combinations) on the mean (B) or maximum (C) CLS of WT cells are shown. The table 
cell at the intersection of the column for 0.1% PE12 and the row for 50 µM R is marked “max” for 
a reason described in the legend to Figure 4.2. (D, E) WT cells were cultured as described in the 
legend to Figure 4.2, with one of the following supplements: 0.1% PE12, 50 µM R, or a mixture 
of 0.1% PE12 and 50 µM R. Ethanol was used as a vehicle or for mock treatment as described in 
the legend to Figure 4.2. Survival curves (D) and the mean and maximum lifespans (E) of 
chronologically aging WT cells cultured without a PE and R (cells were subjected to ethanol-mock 
treatment), with 0.1% PE12, with 50 µM R, or with the mixture of 0.1% PE12 and 50 µM R are 
shown. Data in D and E are presented as means ± SEM (n = 3; *p < 0.05; **p < 0.01; ***p < 
0.001). The CI and p values in E were calculated as described in the legend to Figure 4.2. (F) p 
Values for different pairs of survival curves of WT cells cultured in the presence of 0.1% PE12, 
50 µM R, a mixture of 0.1% PE12 and 50 µM R, or in the absence of a PE and R (cells were 
subjected to ethanol-mock treatment) are shown. Survival curves shown in (D) were compared. 
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The p values are displayed on a yellow or blue color background for the reasons described in the 





Figure 4.28. The longevity-extending efficiency of a mixture of 0.1% PE21 and 50 µM 
resveratrol (R) statistically significantly exceeds those of PE21 and R, which were used at the 
optimal concentration of 0.1% or 50 µM (respectively). Thus, PE21 and R enhance the 
longevity-extending efficiency of each other. Hence, according to the HSA model, PE21 and 
R act in synergy to extend the longevity of chronologically aging yeast. (A) PE21 and R 
regulate different nodes of the signaling network that controls the rate of yeast chronological aging. 
PE21 mitigates a form of the pro-aging protein kinase Sch9 that is activated by the pro-aging 
PKH1/2 pathway, whereas R modulates a presently unknown pro-aging or anti-aging node that 
may be integrated into this signaling network. (B, C) WT cells were grown as described in the 
legend to Figure 4.2, with PE21 (at the final concentration of 0.1%, 0.3%, 0.5% or 1.0%) and/or 
R (at the final concentration of 10 µM, 20 µM, 50 µM or 100 µM), or without a PE and R. Effects 
of different concentrations of PE21 and R (added alone or in pairwise combinations) on the mean 
(B) or maximum (C) CLS of WT cells are shown. The table cell at the intersection of the column 
for 0.1% PE21 and the row for 50 µM R is marked “max” for a reason described in the legend to 
Figure 4.2. (D, E) WT cells were cultured in the synthetic minimal YNB medium initially 
containing 2% glucose and one of the following supplements: 0.1% PE21, 50 µM R or a mixture 
of 0.1% PE21 and 50 µM R. Ethanol was used as a vehicle or for mock treatment as described in 
the legend to Figure 4.2. Survival curves (D) and the mean and maximum lifespans (E) of 
chronologically aging WT cells cultured without a PE and R (cells were subjected to ethanol-mock 
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treatment), with 0.1% PE21, with 50 µM R, or with the mixture of 0.1% PE21 and 50 µM R are 
shown. Data in D and E are presented as means ± SEM (n = 3; *p < 0.05; **p < 0.01; ***p < 
0.001; ****p < 0.0001). The CI and p values in E were calculated as described in the legend to 
Figure 4.2. (F) p Values for different pairs of survival curves of WT cells cultured in the presence 
of 0.1% PE21, 50 µM R, a mixture of 0.1% PE21 and 50 µM R, or in the absence of a PE and R 
(cells were subjected to ethanol-mock treatment) are shown. Survival curves shown in (D) were 
compared. The p values are displayed on a yellow or blue color background for the reasons 
described in the legend to Figure 4.2. Abbreviations: as in the legend to Figure 4.2. 
4.4 Discussion 
            The objective of this proof-of-concept study was to test our hypothesis that a mixture of 
two aging-delaying PEs or a combination of one of these PEs and spermidine or resveratrol may 
delay yeast chronological aging and synergistically extend yeast longevity only if each of the two 
components of this mixture affects a different node, edge or module of the signaling network of 
longevity regulation. To attain this objective, we performed a systematic assessment of longevity-
extending proficiencies of all possible pairwise combinations of PE4, PE5, PE6, PE8, PE12 and 
PE21 or of one of these PEs and spermidine or resveratrol in chronologically aging S. cerevisiae. 
In support of our hypothesis, we provided evidence that pairwise combinations of naturally 
occurring chemical compounds that slow yeast chronological aging through different nodes, edges 
and modules of this evolutionarily conserved network exhibit synergistic effects on the magnitude 
of aging delay. It needs to be emphasized that studies in mice, fruit flies, aquatic invertebrates, 
nematodes, and budding and fission yeast have recently demonstrated that a two- or three-
component combination of the aging-delaying chemical compounds that target different aging-
associated processes or signaling pathways synergistically delay aging and prolong healthy 
lifespan [352-358]. Given that the major aspects and underlying mechanisms of aging and aging-
associated pathology have been conserved throughout evolution [13-15, 17, 19, 83, 114-116, 340, 
479, 486, 487], findings in budding yeast presented here and the above findings in other model 
eukaryotic organisms [352-358] support the proposed idea [347-351] that multi-component 
combinations of chemical compounds that target different aging-associated processes or signaling 
pathways can be used for therapeutic multiplexing of aging delay and healthspan improvement in 
humans. 
            Of note, our recent study has revealed that PE4, PE5, PE6, PE8, PE12 and PE21 are 
geroprotectors that delay the onset and decrease the rate of yeast chronological aging by triggering 
a hormetic stress response and differently altering the following longevity-defining cellular 
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processes: 1) the maintenance of mitochondrial respiration and membrane potential, 2) the 
preservation of reactive oxygen species homeostasis, 3) the protection of cellular proteins, 
membrane lipids, and mitochondrial and nuclear genomes from oxidative damage, 4) cell defense 
from acute oxidative and thermal stresses, and 5) the lipolytic degradation of neutral lipids 
deposited in lipid droplets [461]. In the future, it would be interesting to investigate how the two-
component mixes of the six aging-delaying PEs that synergistically delay yeast chronological 
aging influence each of these cellular processes. This will allow us to gain insight into the 
mechanisms through which each of these pairwise combinations of PEs can delay the onset and 








CHAPTER 5  
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5 Discovery of fifteen new geroprotective plant extracts and identification of cellular 
processes they affect to prolong the chronological lifespan of budding yeast 
5.1 Introduction 
            In a quest for previously unknown geroprotective natural chemicals, we used a robust cell 
viability assay to search for commercially available plant extracts that can substantially prolong 
the chronological lifespan of budding yeast. Many of these plant extracts have been used in 
traditional Chinese and other herbal medicines or the Mediterranean and other customary diets. 
Our search led to a discovery of fifteen plant extracts that significantly extend the longevity of 
chronologically aging yeast not limited in calorie supply. We show that each of these longevity-
extending plant extracts is a geroprotector that decreases the rate of yeast chronological aging and 
promotes a hormetic stress response. We also show that each of the fifteen geroprotective plant 
extracts mimics the longevity-extending, stress-protecting, metabolic and physiological effects of 
a caloric restriction diet in yeast cells that are not limited in calorie supply. We provide evidence 
that the fifteen geroprotective plant extracts exhibit partially overlapping effects on a distinct set 
of longevity-defining cellular processes. These effects include a rise in coupled mitochondrial 
respiration, an altered age-related chronology of changes in reactive oxygen species abundance, 
protection of cellular macromolecules from oxidative damage, and an age-related increase in the 
resistance to long-term oxidative and thermal stresses. Chapter 5 describes all these findings.           
5.2 Materials and methods 
5.2.1 Yeast strains, media and growth conditions 
            The wild-type (WT) strain Saccharomyces cerevisiae BY4742 (MAT his31 leu20 
lys20 ura30) and single-gene-deletion mutant strains in the BY4742 genetic background (all 
from Thermo Scientific/Open Biosystems) were grown in a synthetic minimal YNB medium 
(0.67% (w/v) Yeast Nitrogen Base without amino acids from Fisher Scientific; #DF0919-15-3) 
initially containing 2% (w/v) or 0.5% (w/v) glucose (#D16-10; Fisher Scientific), 20 mg/l L-
histidine (# H8125; Sigma), 30 mg/l L-leucine (#L8912; Sigma), 30 mg/l L-lysine (#L5501; 
Sigma) and 20 mg/l uracil (#U0750; Sigma), with a PE or without it. A stock solution of each PE 
in ethanol was made on the day of adding this PE to cell cultures. For each PE, the stock solution 
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was added to growth medium with 2% (w/v) or 0.5% (w/v) glucose immediately following cell 
inoculation into the medium. In a culture supplemented with a PE, ethanol was used as a vehicle 
at the final concentration of 2.5% (v/v). In the same experiment, yeast cells were also subjected to 
ethanol-mock treatment by being cultured in growth medium initially containing 2% (w/v) or 0.5% 
(w/v) glucose and 2.5% (v/v) ethanol. Cells were cultured at 30oC with rotational shaking at 200 
rpm in Erlenmeyer flasks at a “flask volume/medium volume” ratio of 5:1. 
5.2.2 Chronological lifespan (CLS) assay 
            A sample of cells was taken from a culture at a certain day following cell inoculation and 
PE addition into the medium. A fraction of the sample was diluted to determine the total number 
of cells using a hemacytometer. Another fraction of the cell sample was diluted, and serial dilutions 
of cells were plated in duplicate onto YEP medium (1% (w/v) yeast extract, 2% (w/v) peptone; 
both from Fisher Scientific; #BP1422-2 and #BP1420-2, respectively) containing 2% (w/v)  
glucose (#D16-10; Fisher Scientific) as carbon source. After 2 d of incubation at 30oC, the number 
of colony-forming units (CFU) per plate was counted. The number of CFU was defined as the 
number of viable cells in a sample. For each culture, the percentage of viable cells was calculated 
as follows: (number of viable cells per ml/total number of cells per ml) × 100. The percentage of 
viable cells in the mid-logarithmic growth phase was set at 100%. 
5.2.3 Miscellaneous procedures 
            The age-specific mortality rate [359, 361], Gompertz slope or mortality rate coefficient (G) 
[360, 361], and mortality rate doubling time (MRDT) [360, 361] were calculated as previously 
described. The value of the mortality rate was calculated as the number of cells that lost viability 
(i.e., are unable to form a colony on the surface of a solid nutrient-rich medium) during each time 
interval divided by the number of viable (i.e., clonogenic) cells at the end of the interval. The 
natural logarithms of the mortality rate values for each time point were plotted against days of cell 
culturing. The coefficient G of the age-specific mortality rate was calculated as the slope of the 
Gompertz mortality line, whereas the value of MRDT was calculated as 0.693/G. Oxygen 
consumption assay for monitoring mitochondrial respiration [32], ROS measurement in live yeast 
[101], fluorescence microscopy [32], quantitative assays for oxidatively damaged proteins and 
membrane lipids [87], measurements of the frequencies of spontaneous mutations in mitochondrial 
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and nuclear DNA [100], plating assays for the analysis of resistance to oxidative and thermal 
stresses [100], and glucose concentration measurement assay [101] have been described elsewhere. 
All these procedures and methods are detailed in Chapter 2 of my Thesis. 
 
5.2.4 Statistical analysis 
            Statistical analysis was performed using Microsoft Excel’s Analysis ToolPack-VBA. All 
data on cell survival are presented as mean ± SEM. The p values for comparing the means of two 
groups using an unpaired two-tailed t-test were calculated with the help of the GraphPad Prism 7 
statistics software. The logrank test for comparing each pair of survival curves was performed with 
GraphPad Prism 7. Two survival curves were considered statistically different if the p value was 
less than 0.05. 
5.3 Results 
5.3.1 Identification of new PEs that prolong the longevity of chronologically aging 
budding yeast 
            In search of new geroprotective PEs, we performed a screen of fifty-three commercially 
available PEs. The origin and properties of these PEs are shown in Table 5.1. These PEs are 
believed to have positive effects on human health, and many of them have been used in traditional 
Chinese and other herbal medicines or the Mediterranean and other long-established diets. 
 
Table 5.1. Properties of plant extracts (PEs) used to conduct a new screen for PEs that can 
prolong the longevity of chronologically aging budding yeast. 
 
Abbreviated 
name of a PE 
The botanical 
name of a plant    
Plant part used 
to make a PE  
Properties of a PE A commercial 
source of a PE 
PE26 Serenoa repens Berry Extraction solvent: carbon 
dioxide. Extract ratio: 15:1. 
Composition: natural extract 





Herb Extraction solvent: alcohol (50-
70%), water (30-50%). Extract 
ratio: (8-12):1. Composition: 








Aerial parts Extraction solvent: ethanol (60-
80%), water (20-40%). Extract 






Resin Extraction solvent: methanol 
(80%), water (20%). Extract 






Root Extraction solvent: ethanol (70-
80%), water (20-30%). Extract 






Leaf Extraction solvent: water. 
Extract ratio: (3-10):1. 





Berry Extraction solvent: ethanol 
(30%), water (70%). Extract 





Leaf Extraction solvent: water. 
Extract ratio: 4:1. Composition: 
> 5% cynarin. 
Idunn 
Technologies 
PE45 Allium cepa L. Bulb skin Extraction solvent: ethanol 
(70%), water (30 %). Extract 
ratio: (20-25):1. Composition: > 






Flower Extraction solvent: ethanol 
(80%), water (20%). Extract 






Leaf Extraction solvent: ethanol 
(90%), water (10%). Extract 





sativus L. var. 
niger 
Root Extraction solvent alcohol (60-
80%), water (40-20%). Extract 






Leaf Extraction solvent: acetone. 
Extract ratio: (35-50):1. 






Root Extraction solvent: ethanol 
(50%), water (50%). Extract 








Herb Extraction solvent: ethanol 
(60%), water (40%). Extract 






Leaf Extraction solvent: aqueous 
alcohol. Extract ratio: 10:1. 





Bean Extraction solvent: aqueous 
alcohol. Extract ratio: 10:1. 
Composition: unknown.  
Idunn 
Technologies 
PE54 Allium sativum 
L. 
Bulb Extraction solvent: water. 
Extract ratio: 120:1. 
Composition: 4.5% alliin. 
Idunn 
Technologies 
PE55 Morus alba Leaf Extraction solvent: ethanol 
(70%), water (30%). Extract 






Flower Extraction solvent: ethanol, 
water. Extract ratio: unknown. 




PE57 Morus nigra Fruit Extraction solvent: ethanol, 






Bark  Extraction solvent: unknown. 
Extract ratio: (35-40):1. 





Herb Extraction solvent: ethanol 
(30%), water (70%). Extract 






Root Extraction solvent: ethanol, 







Root Extraction solvent: water, then 
ethanol (96%) and water (4%). 
Extract ratio: (22-27):1. 






Leaf Extraction solvent: ethanol (70-
80%), water (20-30%). Extract 






Root Extraction solvent: ethanol 





ratio: 15:1. Composition: 0.3-
0.4% phenolic acids (chicoric, 
chlorogenic and 
caftaric acids). 
PE64 Citrus sinensis Fruit Extraction solvent: unknown. 
Extract ratio: unknown. 





Root Extraction solvent: ethanol 
(65%), water (35%,). Extract 






Bark Extraction solvent: ethanol 
(70%), water (30%). Extract 






Fruit Extraction solvent: water. 
Extract ratio: 20:1. 






Whole plant Extraction solvent: unknown. 




PE69 Vitis vinifera Grape skin Extraction solvent: ethanol 
(30%), water (70%). Extract 




PE70 Vitis vinifera Grape Extraction solvent: water (4%), 
ethanol (96%). Extract ratio: 







Grape + Fruit Extraction solvent: water (5%), 
ethanol (95%). Extract ratio: 
(500-600):1. Composition: ≥ 





Whole plant Extraction solvent: unknown. 
Extract ratio: unknown. 




PE73 Oryza sativa 
fermented with 
Monascus 
purpureus yeast  
Fermented rice  Extraction solvent: unknown. 
Extract ratio: unknown. 






Leaf Extraction solvent: unknown. 
Extract ratio: 4:1. Composition: 
≥ 1% rosmarinic acid. 
Idunn 
Technologies 
PE75 Hydrastis Root Extraction solvent: ethanol Idunn 
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canadensis (75%), water (25%). Extract 
ratio: (5-7):1. Composition: ≥ 





Root Extraction solvent: unknown. 
Extract ratio: unknown. 







Seed Extraction solvent: ethanol 
(60%), water (40%). Extract 
ratio: (5-8):1. Composition: 





Root bark Extraction solvent: ethanol 
(50%), water (50%). Extract 
ratio: (10-12):1. Composition: 







Extraction solvent: ethanol 
(80%), water (20%). Extract 








Extraction solvent: water. 
Extract ratio: (16-20):1. 





Leaf Extraction solvent: ethanol (70-
80%), water (20-30%). Extract 




PE82 NA NA Na-RALA Powder, Sodium R-
lipoate (> 80 % Total R-lipoic 





Whole plant Extraction solvent: unknown. 




PE84 Vitis vinifera L. Seed Extraction solvent: ethanol, 
water. Extract ratio: unknown. 







Extraction solvent: unknown. 




PE86 Panax ginseng Root Extraction solvent: unknown. 






Whole plant Extraction solvent: unknown. 




PE88 Hemerocallis Flower Extraction solvent: unknown. Idunn 
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fulva Extract ratio: unknown. 
Composition: unknown. 
Technologies 
PE89 Curcuma L. Root Extraction solvent: unknown. 
Extract ratio: unknown. 
Composition: curcumin solid 




      
            To conduct the screen, we exploited a robust clonogenic cell viability assay for measuring 
yeast CLS [461]. In this assay, the wild-type (WT) strain BY4742 was cultured in the synthetic 
minimal YNB medium initially containing 2% (w/v) glucose, as described in Materials and 
Methods. Cells of budding yeast cultured under such non-caloric restriction (non-CR) conditions 
are known to age chronologically faster than the ones cultured under CR conditions on 0.2% (w/v) 
or 0.5% (w/v) glucose [14, 15, 17, 461]. 
            At the time of cell inoculation into the culturing medium, we added each of the assessed 
PEs at a final concentration ranging from 0.02% (w/v) to 1.0% (w/v). We found that PE40, PE41, 
PE44, PE50, PE53, PE66, PE73, PE84, PE86 and PE87 do not affect the mean and maximum CLS 
of WT yeast if exogenously supplemented within this wide range of initial concentrations (Figures 
5.1-5.7). In contrast, PE38, PE43, PE45, PE46, PE48, PE49, PE51, PE52, PE54-PE58, PE60-
PE63, PE65, PE67, PE70, PE71, PE74, PE76, PE80, PE82, PE85, PE88 and PE89 were cytotoxic 
at certain concentrations; they decreased the mean and/or maximum CLS of WT yeast if used at 
the final concentrations in the 0.1 (w/v) to 1.0% (w/v) range (Figures 5.1-5.7). 
            Our screen revealed that fifteen of fifty-three tested PEs statistically significantly increase 
the mean and maximum CLS of WT yeast cultured under non-CR conditions on 2% (w/v) glucose 
(Figures 5.1-5.6; Figures 5.8-5.9). Each of these fifteen PEs extended the longevity of 
chronologically aging WT yeast if used within a specific concentration range and exhibited the 
highest longevity-extending effect at a certain concentration within this range (Figures 5.1-5.6). 
The following PEs exhibited the highest longevity-extending effect under non-CR conditions of 
cell culturing: 0.5% (w/v) PE26 from berries of Serenoa repens (Figures 5.1 and 5.8A), 0.5% (w/v) 
PE39 from aerial parts of Hypericum perforatum (Figures 5.1 and 5.8B), 0.5% (w/v) PE42 from 
leaves of Ilex paraguariensis (Figures 5.1 and 5.8C), 0.3% (w/v) PE47 from leaves of Ocimum 
tenuiflorum (Figures 5.1 and 5.8D), 0.3% (w/v) PE59 from the whole plant of Solidago virgaurea 
(Figures 5.1 and 5.8E), 0.1% (w/v) PE64 from fruits of Citrus sinensis (Figures 5.4 and 5.8F), 
0.5% (w/v) PE68 from the whole plant of Humulus lupulus (Figures 5.4 and 5.8G), 1.0% (w/v) 
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PE69 from grape skins of Vitis vinifera (Figures 5.5 and 5.8H), 0.1% (w/v) PE72 from the whole 
plant of Andrographis paniculata (Figures 5.5 and 5.9A), 0.3% (w/v) PE75 from roots of Hydrastis 
canadensis (Figures 5.5 and 5.9B), 0.5% (w/v) PE77 from seeds of Trigonella foenum-graecum 
(Figures 5.6 and 5.9C), 0.3% (w/v) PE78 from root barks of Berberis vulgaris (Figures 5.6 and 
5.9D), 0.5% (w/v) PE79 from leaves, flowers and stems of Crataegus monogyna (Figures 5.6 and 
5.9E), 0.3% (w/v) PE81 from leaves of Taraxacum erythrospermum (Figures 5.6 and 5.9F), and 
0.5% (w/v) PE83 from the whole plant of Ilex paraguariensis (Figures 5.6 and 5.9G). 
            We found that none of the fifteen longevity-extending PEs displays a statistically 
significant effect on glucose consumption during culturing of WT cells under non-CR conditions 
on 2% (w/v) glucose (Figure 5.10). This finding shows that each of these PEs prolongs the 
longevity of chronologically aging yeast not because it alters the concentration of exogenous 
glucose and, thus, not because it affects the metabolic rate of this major source of carbon and 
energy. We also found that none of the fifteen longevity-extending PEs exhibits a statistically 
significant effect on the growth rate and maximum cell yield of WT yeast cultures under non-CR 
conditions (Figure 5.11). Based on this observation, we concluded that each of them extends the 
longevity of chronologically aging yeast not because it slows cell proliferation and, thus, not 




Figure 5.1. PE26, PE39 and PE42, but not PE38, PE40, PE41, PE43 or PE44, increase the 
mean and maximum CLS of WT yeast cultured under non-CR conditions on 2% (w/v) 
glucose. WT cells were cultured in the synthetic minimal YNB medium initially containing 2% 
(w/v) glucose, in the presence of a PE or its absence. The mean and maximum lifespans of 
chronologically aging WT strain cultured under non-CR conditions without a PE or with a PE 
added at various concentrations are shown; data are presented as means ± SEM (n = 6; * p < 0.05, 
** p < 0.01, *** p < 0.001, ns, not significant; the p values for comparing the means of two groups 
were calculated using an unpaired two-tailed t test as described in Materials and Methods). Note 
that PE38 and PE43 can decrease the CLS of WT yeast under non-CR conditions if added at a final 
concentration of 0.5 (w/v) or 1.0% (w/v).  
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Figure 5.2. PE47, but not PE45, PE46, PE48, PE49, PE50, PE51 or PE52, increases the mean 
and maximum CLS of WT yeast cultured under non-CR conditions on 2% (w/v) glucose. 
WT cells were cultured as described in the legend to Figure 5.1. The mean and maximum lifespans 
of chronologically aging WT strain cultured under non-CR conditions without a PE or with a PE 
added at various concentrations are shown; data are presented as means ± SEM (n = 6; * p < 0.05, 
** p < 0.01, *** p < 0.001, ns, not significant; the p values for comparing the means of two groups 
were calculated as described in the legend to Figure 5.1). Note that PE45, PE46, PE48, PE49, PE51 
and PE52 can decrease the CLS of WT yeast under non-CR conditions if added at a final 




Figure 5.3. PE59, but not PE53, PE54, PE55, PE56, PE57, PE58 or PE60, increases the mean 
and maximum CLS of WT yeast cultured under non-CR conditions on 2% (w/v) glucose. 
WT cells were cultured as described in the legend to Figure 5.1. The mean and maximum lifespans 
of chronologically aging WT strain cultured under non-CR conditions without a PE or with a PE 
added at various concentrations are shown; data are presented as means ± SEM (n = 6; * p < 0.05, 
** p < 0.01, *** p < 0.001, ns, not significant; the p values for comparing the means of two groups 
were calculated as described in the legend to Figure 5.1). Note that PE54, PE55, PE56, PE57, PE58 
and PE60 can decrease the CLS of WT yeast under non-CR conditions if added at a final 




Figure 5.4. PE64 and PE68, but not PE61, PE62, PE63, PE65, PE66 or PE67, increase the 
mean and maximum CLS of WT yeast cultured under non-CR conditions on 2% (w/v) 
glucose. WT cells were cultured as described in the legend to Figure 5.1. The mean and maximum 
lifespans of chronologically aging WT strain cultured under non-CR conditions without a PE or 
with a PE added at various concentrations are shown; data are presented as means ± SEM (n = 6; 
* p < 0.05, ** p < 0.01, *** p < 0.001, ns, not significant; the p values for comparing the means 
of two groups were calculated as described in the legend to Figure 5.1). Note that PE61, PE62, 
PE63, PE65 and PE67 can decrease the CLS of WT yeast under non-CR conditions if added at a 




Figure 5.5. PE69, PE72 and PE75, but not PE70, PE71, PE73, PE74 or PE76, increase the 
mean and maximum CLS of WT yeast cultured under non-CR conditions on 2% (w/v) 
glucose. WT cells were cultured as described in the legend to Figure 5.1. The mean and maximum 
lifespans of chronologically aging WT strain cultured under non-CR conditions without a PE or 
with a PE added at various concentrations are shown; data are presented as means ± SEM (n = 6; 
* p < 0.05, ** p < 0.01, *** p < 0.001, ns, not significant; the p values for comparing the means 
of two groups were calculated as described in the legend to Figure 5.1). Note that PE70, PE71, 
PE74 and PE76 can decrease the CLS of WT yeast under non-CR conditions if added at a final 




Figure 5.6. PE77, PE78, PE79, PE81 and PE83, but not PE80, PE82 or PE84, increase the 
mean and maximum CLS of WT yeast cultured under non-CR conditions on 2% (w/v) 
glucose. WT cells were cultured as described in the legend to Figure 5.1. The mean and maximum 
lifespans of chronologically aging WT strain cultured under non-CR conditions without a PE or 
with a PE added at various concentrations are shown; data are presented as means ± SEM (n = 6; 
* p < 0.05, ** p < 0.01, *** p < 0.001, ns, not significant; the p values for comparing the means 
of two groups were calculated as described in the legend to Figure 5.1). Note that PE80 and PE82 
can decrease the CLS of WT yeast under non-CR conditions if added at a final concentration of 




Figure 5.7. Neither PE85, PE86, PE87, PE88 nor PE89 can increase the mean or maximum 
CLS of WT yeast cultured under non-CR conditions on 2% (w/v) glucose. WT cells were 
cultured as described in the legend to Figure 5.1. The mean and maximum lifespans of 
chronologically aging WT strain cultured under non-CR conditions without a PE or with a PE 
added at various concentrations are shown; data are presented as means ± SEM (n = 6; * p < 0.05, 
** p < 0.01, ns, not significant; the p values for comparing the means of two groups were calculated 
as described in the legend to Figure 5.1). Note that PE85, PE88 and PE89 can decrease the CLS 
of WT yeast under non-CR conditions if added at a final concentration ranging from 0.3% (w/v) 










Figure 5.8. 0.5% (w/v) PE26, 0.5% (w/v) PE39, 0.5% (w/v) PE42, 0.3% (w/v) PE47, 0.3% 
(w/v) PE59, 0.1% (w/v) PE64, 0.5% (w/v) PE68 and 1.0% (w/v) PE69 exhibit the highest 
extending effects on the chronological lifespan (CLS) of wild-type (WT) yeast cultured under 
non-CR conditions on 2% (w/v) glucose. WT cells were cultured in the synthetic minimal YNB 
medium initially containing 2% (w/v) glucose, in the presence of a PE or its absence. In the cultures 
supplemented with a PE, ethanol was used as a vehicle at a final concentration of 2.5% (v/v). In 
the same experiment, WT cells were also subjected to ethanol-mock treatment by being cultured 
in the synthetic minimal YNB medium initially containing 2% (w/v) glucose and 2.5% (v/v) 
ethanol. Survival curves (the upper panels in A-H) and the mean and maximum lifespans (the 
lower two panels in A-H) of chronologically aging WT cells cultured without a PE (cells were 
subjected to ethanol-mock treatment) or with a PE (which was added at the concentration optimal 
for CLS extension) are shown. Data are presented as means ± SEM (n = 6). In the upper panels in 
A-H, CLS extension was significant for each of the PEs tested (p < 0.05; the p values for comparing 
each pair of survival curves were calculated using the logrank test as described in Materials and 
Methods). In the lower two panels in A-H, *p < 0.05, **p < 0.01, ***p < 0.001; the p values for 
comparing the means of two in groups were calculated using an unpaired two-tailed t test as 
described in Materials and Methods). Data for mock-treated WT cells are replicated in graphs A-
H of this Figure. Data for WT cells cultured with a PE added at the concentration optimal for CLS 
extension are replicated in Figure 5.1 (for 0.5% (w/v) PE26, 0.5% (w/v) PE39 and 0.5% (w/v) 
PE42), Figure 5.2 (for 0.3% (w/v) PE47), Figure 5.3 (for 0.3% (w/v) PE59), Figure 5.4 (for 0.1% 




Figure 5.9. 0.1% (w/v) PE72, 0.3% (w/v) PE75, 0.5% (w/v) PE77, 0.3% (w/v) PE78, 0.5% 
(w/v) PE79, 0.3% (w/v) PE81 and 0.5% (w/v) PE83 exhibit the highest extending effects on 
the CLS of WT yeast cultured under non-CR conditions on 2% (w/v) glucose. WT cells were 
cultured in the synthetic minimal YNB medium initially containing 2% (w/v) glucose, in the 
presence of a PE or its absence. In the cultures supplemented with a PE, ethanol was used as a 
vehicle at a final concentration of 2.5% (v/v). In the same experiment, WT cells were also 
subjected to ethanol-mock treatment by being cultured in the synthetic minimal YNB medium 
initially containing 2% (w/v) glucose and 2.5% (v/v) ethanol. Survival curves (the upper panels in 
A-G) and the mean and maximum lifespans (the lower two panels in A-G) of chronologically aging 
WT cells cultured without a PE (cells were subjected to ethanol-mock treatment) or with a PE 
(which was added at the concentration optimal for CLS extension) are shown. Data are presented 
as means ± SEM (n = 6). In the upper panels in A-G, CLS extension was significant for each of 
the PEs tested (p < 0.05; the p values for comparing each pair of survival curves were calculated 
using the logrank test as described in Materials and Methods). In the lower two panels in A-G, *p 
< 0.05, **p < 0.01, ***p < 0.001; the p values for comparing the means of two in groups were 
calculated using an unpaired two-tailed t test as described in Materials and Methods). Data for 
mock-treated WT cells are replicated in graphs A-G of this Figure. Data for WT cells cultured with 
a PE added at the concentration optimal for CLS extension are replicated in Figure 5.4 (for 0.1% 
(w/v) PE72 and 0.3% (w/v) PE75) and Figure 5.6 (for 0.5% (w/v) PE77, 0.3% (w/v) PE78, 0.5% 





Figure 5.10. None of the fifteen longevity-extending PEs statistically significantly affects 
glucose consumption by WT yeast cultured under non-CR conditions on 2% (w/v) glucose. 
WT cells were cultured in the synthetic minimal YNB medium initially containing 2% (w/v) 
glucose, in the presence of a longevity-extending PE (which was added at an optimal longevity-
extending concentration) or its absence. Glucose concentration in the extracellular medium was 
















Figure 5.11. None of the fifteen longevity-extending PEs statistically significantly alters the 
growth rate and maximum cell yield of WT yeast cultures under non-CR conditions on 2% 
(w/v) glucose. WT cells were cultured in the synthetic minimal YNB medium initially containing 
2% (w/v) glucose, in the presence of a longevity-extending PE (which was added at an optimal 
longevity-extending concentration) or its absence. Cell number was measured as described in 
Materials and Methods. Data are presented as means ± SEM (n = 3; ns, not significant). 
5.3.2 Each of the fifteen longevity-prolonging PEs mimics longevity extension by CR   
            CR without malnutrition is a low-calorie dietary regimen that extends lifespan in many 
evolutionarily distant organisms and improves healthspan in laboratory rodents and rhesus 
monkeys [11, 15, 488-490]. Certain natural chemicals and synthetic drugs have been shown to 
elicit the CR-like lifespan-extending and healthspan-improving effects even under non-CR 
conditions (i.e., when calorie supply is not limited) [491-496]. These natural and synthetic 
chemical compounds are called CR mimetics (CRMs) if they not only extend longevity under non-
CR conditions but also if they exhibit three other effects. First, CRMs do not impair food intake. 
Second, CRMs have CR-like effects on metabolism and physiology. Third, akin to CR, CRMs 
decrease the susceptibility to diverse stresses [492, 495]. In the present study, we found that each 
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of the fifteen longevity-extending PEs increases yeast CLS under non-CR conditions on 2% (w/v) 
glucose (Figures 5.1-5.6, Figures 5.8 and 5.9) and none of them compromises glucose intake 
during culturing under these conditions (Figure 5.10). Thus, it seems that all these PEs are CRMs. 
This conclusion is further supported by our observations that each of the fifteen longevity-
extending PEs exhibits CR-like effects on several aspects of cell metabolism and stress resistance 
(see below). 
            Of note, we previously reported that if the CR diet is administered by culturing yeast in the 
YNB medium initially containing 0.5% (w/v) glucose, it significantly increases both the mean and 
maximum CLS of S. cerevisiae [461]. In the present study, we investigated how each of the fifteen 
PEs that extends longevity under non-CR conditions influences the longevity of yeast cultured 
under CR conditions on 0.5% (w/v) glucose. We found that eight of the fifteen PEs that prolong 
the longevity of chronologically aging yeast under non-CR conditions do not increase either the 
mean or the maximum CLS of S. cerevisiae under CR conditions (Figures 5.12 and 5.13). These 
PEs included 0.3% (w/v) PE47 (Figure 5.12D), 0.1% (w/v) PE64 (Figure 5.12F), 1.0% (w/v) PE69 
(Figure 5.12H), 0.1% (w/v) PE72 (Figure 5.13A), 0.3% (w/v) PE75 (Figure 5.13B), 0.5% (w/v) 
PE77 (Figure 5.13C), 0.5% (w/v) PE79 (Figure 5.13E) and 0.3% (w/v) PE81 (Figure 5.13F). It 
seems conceivable, therefore, that each of these eight PEs increases yeast CLS because it 
modulates the same or highly overlapping sets of longevity-defining cellular processes under both 
CR and non-CR conditions. 
            We also revealed that seven of the fifteen PEs that extend yeast longevity under non-CR 
conditions also increase both the mean and maximum CLS of S. cerevisiae under CR conditions 
(Figures 5.12 and 5.13). 0.5% (w/v) PE26 (Figure 5.12A), 0.5% (w/v) PE39 (Figure 5.12B), 0.5% 
(w/v) PE42 (Figure 5.12C), 0.3% (w/v) PE59 (Figure 5.12E), 0.5% (w/v) PE68 (Figure 5.12G), 
0.3% (w/v) PE78 (Figure 5.13D) and 0.5% (w/v) PE83 (Figure 5.13G)  were among these PEs. 
Therefore, we hypothesize that each of these seven PEs increases yeast CLS under CR conditions 
because it regulates the sets of longevity-defining cellular processes that differ from (or only 
partially overlap with) the ones it modulates under non-CR conditions. 
            We then compared the efficiency with which each of the fifteen PEs increases yeast CLS 
under non-CR conditions to that under CR conditions. Our comparison revealed that each of these 
PEs extends the longevity of chronologically aging yeast under non-CR conditions significantly 
more efficiently than it does under CR conditions (Figure 5.14). This finding shows that each of 
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the fifteen PEs is a more effective longevity-prolonging intervention in chronologically aging yeast 
not-limited in calorie supply than it is in yeast placed on a CR diet. 
 
  
Figure 5.12. 0.5% (w/v) PE26, 0.5% (w/v) PE39, 0.5% (w/v) PE42, 0.3% (w/v) PE59 and 
0.5% (w/v) PE68 (but not 0.3% (w/v) PE47, 0.1% (w/v) PE64 or 1.0% (w/v) PE69) extend 
the CLS of WT yeast cultured under CR conditions on 0.5% (w/v) glucose. WT cells were 
cultured in the synthetic minimal YNB medium initially containing 0.5% (w/v) glucose, in the 
presence of a PE or its absence. In the cultures supplemented with a PE, ethanol was used as a 
vehicle at a final concentration of 2.5% (v/v). In the same experiment, WT cells were also 
subjected to ethanol-mock treatment by being cultured in the synthetic minimal YNB medium 
initially containing 0.5% (w/v) glucose and 2.5% (v/v) ethanol. Survival curves (the upper panels 
in A-H) and the mean and maximum lifespans (the lower two panels in A-H) of chronologically 
aging WT cells cultured without a PE (cells were subjected to ethanol-mock treatment) or with a 
PE (which was added at the concentration optimal for CLS extension under non-CR conditions) 
are shown. Data are presented as means ± SEM (n = 6). In the upper panels in A-C, E and F, CLS 
extension was significant for each of the PEs tested (p < 0.05; the p values for comparing each pair 
of survival curves were calculated using the logrank test as described in Materials and Methods). 
In the lower two panels in A-C, E and F, **p < 0.01, ***p < 0.001; the p values for comparing the 
means of two in groups were calculated using an unpaired two-tailed t test as described in Materials 
and Methods). In the upper panels in D, F and H, CLS extension was statistically not significant 
for each of the PEs tested (the p values for comparing each pair of survival curves were calculated 
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using the logrank test as described in Materials and Methods). In the lower two panels in D, F and 
H, ns, not significant; the p values for comparing the means of two in groups were calculated using 
an unpaired two-tailed t test as described in Materials and Methods). Data for mock-treated WT 




Figure 5.13. 0.3% (w/v) PE78 and 0.5% (w/v) PE83 (but not 0.1% (w/v) PE72, 0.3% (w/v) 
PE75, 0.5% (w/v) PE77, 0.5% (w/v) PE79 or 0.3% (w/v) PE81) extend the CLS of WT yeast 
cultured under CR conditions on 0.5% (w/v) glucose. WT cells were cultured in the synthetic 
minimal YNB medium initially containing 0.5% (w/v) glucose, in the presence of a PE or its 
absence. In the cultures supplemented with a PE, ethanol was used as a vehicle at a final 
concentration of 2.5% (v/v). In the same experiment, WT cells were also subjected to ethanol-
mock treatment by being cultured in the synthetic minimal YNB medium initially containing 0.5% 
(w/v) glucose and 2.5% (v/v) ethanol. Survival curves (the upper panels in A-G) and the mean and 
maximum lifespans (the lower two panels in A-G) of chronologically aging WT cells cultured 
without a PE (cells were subjected to ethanol-mock treatment) or with a PE (which was added at 
the concentration optimal for CLS extension under non-CR conditions) are shown. Data are 
presented as means ± SEM (n = 6). In the upper panels in D and G, CLS extension was significant 
for each of the PEs tested (p < 0.05; the p values for comparing each pair of survival curves were 
calculated using the logrank test as described in Materials and Methods). In the lower two panels 
in D and G, **p < 0.01; the p values for comparing the means of two in groups were calculated 
using an unpaired two-tailed t test as described in Materials and Methods). In the upper panels in 
A-C, E and F, CLS extension was statistically not significant for each of the PEs tested (the p 
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values for comparing each pair of survival curves were calculated using the logrank test as 
described in Materials and Methods). In the lower two panels in A-C, E and F, ns, not significant; 
the p values for comparing the means of two in groups were calculated using an unpaired two-
tailed t test as described in Materials and Methods). Data for mock-treated WT cells are replicated 




Figure 5.14. Each of the fifteen PEs extends the longevity of chronologically aging yeast 
under non-CR conditions on 2% (w/v) glucose significantly more efficiently than it does 
under CR conditions on 0.5% (w/v) glucose. WT cells were cultured in the synthetic minimal 
YNB medium initially containing 2% (w/v) or 0.5% (w/v) glucose, in the presence of a PE or its 
absence. In the cultures supplemented with a PE, ethanol was used as a vehicle at a final 
concentration of 2.5% (v/v). In the same experiment, WT cells were also subjected to ethanol-
mock treatment by being cultured in the synthetic minimal YNB medium initially containing 0.5% 
(w/v) or 2% (w/v) glucose and 2.5% (v/v) ethanol. The extent to which each of the PE tested 
increases the mean (A) and maximum (B) CLS under non-CR and CR conditions was calculated 
based on the data presented in Figures 5.8, 5.9, 5.12 and 5.13. *p < 0.05, **p < 0.01, ***p < 0.001; 
the p values for comparing the means of two in groups were calculated using an unpaired two-
tailed t test as described in Materials and Methods.  
5.3.3 Each of the fifteen longevity-prolonging PEs is a geroprotector that extends the 
longevity of chronologically aging yeast because it decreases the rate of aging and 
stimulates a hormetic stress response    
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            The rate of biological aging at the demographic level depends on the health of a population 
and can be determined by measuring an age-specific mortality rate of this population [359-361, 
497, 498]. The mortality rates of evolutionarily distant organisms rise with age [359, 361, 367, 
497, 498]. The Gompertz mortality function equation can describe this age-related rise in the 
mortality rate; this equation can be graphically presented as mortality rate data plotted on a semi-
log scale against biological age [359, 361, 366, 367, 498]. Geroprotective interventions (also 
known as geroprotectors) can extend the longevity of organisms across phyla by causing three 
different effects on the Gompertz mortality function. Some geroprotectors can lower a so-called 
“baseline” mortality rate by eliciting an equal decline in the mortality rate at any biological age, 
without affecting a slope of the Gompertz mortality rate [359, 360, 498-500]. This slope is known 
as the coefficient G of the age-specific mortality rate; it is inversely proportional to the rate of 
biological aging [359, 360, 498-500]. Other geroprotectors can decrease the rate of biological 
aging because they lower the value of G, thus raising the value of the mortality rate doubling time 
(MRDT; MRDT = 0.693/G) [359, 360, 368, 498, 501]. The longevity-extending effects of some 
other geroprotective interventions can represent a combination of both the drop in the baseline 
mortality rate and the decline in the value of G (which raises the value of MRDT) [359-361, 498, 
500].  
            We sought to investigate whether each of the fifteen PEs extends yeast longevity by 
lowering the baseline mortality rate, decreasing the rate of biological aging or by altering both 
these rates. Therefore, we conducted the Gompertz mortality rate analysis of WT cells under non-
CR conditions that were either treated with one of these PEs or subjected to mock treatment. We 
found the following: 1) none of the fifteen longevity-prolonging PEs affects the baseline mortality 
rate, and 2) each of them elicits a decline in the coefficient G of the age-specific mortality rate and 
causes a rise in the value of MRDT (Figure 5.15). Based on these observations, we concluded that 
each of these PEs is a geroprotector that lengthens the longevity of chronologically aging yeast 
because it lowers the rate of aging but not because it decreases the baseline mortality rate. 
            Our data allow us to conclude that each of the fifteen longevity-prolonging PEs slows yeast 
chronological aging because it decreases both the extrinsic and the intrinsic rates of aging. This 
conclusion is based on our findings that each of these PEs extends both the mean and maximum 
CLS of yeast (Figures 5.8 and 5.9). The mean lifespans of evolutionarily distant organisms are 
thought to depend on specific environmental (extrinsic) factors to which cells are exposed before 
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they enter the quiescent or senescent state [359, 362-364]. In contrast, the maximum lifespans of 
organisms across species are considered to rely on specific cellular and organismal longevity 
modifiers that operate after cells enter the quiescent or senescent state [359, 362, 363, 365, 366]. 
 
 
Figure 5.15. Each of the fifteen PEs extends the longevity of chronologically aging yeast 
because it decreases the rate of aging but not because it lowers the baseline mortality rate. 
WT cells were cultured in the synthetic minimal YNB medium initially containing 2% (w/v) 
glucose, in the presence of a PE or its absence. In the cultures supplemented with a PE, ethanol 
was used as a vehicle at a final concentration of 2.5% (v/v). In the same experiment, WT cells 
were also subjected to ethanol-mock treatment by being cultured in the synthetic minimal YNB 
medium initially containing 2% (w/v) glucose and 2.5% (v/v) ethanol. Survival curves shown in 
Figures 5.8 and 5.9 were used to calculate the age-specific mortality rates of chronologically aging 
WT yeast populations cultured without a PE (cells were subjected to ethanol-mock treatment) or 
with a PE (which was added at the concentration optimal for CLS extension). The natural 
logarithms of the mortality rate values for each time point were plotted against days of cell 
culturing. The values of the age-specific mortality rates, Gompertz slope (also known as the 
mortality rate coefficient G) and mortality rate doubling time (MRDT) were calculated as 
described in Materials and Methods. Each of the fifteen longevity-extending PEs caused a 
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substantial decline in the value of G and a considerable rise in the value of MRDT. 
 
            Our data also show that the ability of each of the fifteen longevity-prolonging PEs to 
decelerate yeast chronological aging correlates with (and is possibly caused by) its ability to elicit 
a “hormetic” stress response. A characteristic feature of such a response is a nonlinear and biphasic 
(i.e., inverted U-shaped or J-shaped) dose-response curve [112, 116, 254, 502, 503]. As we found, 
the curves that reflect relationships between PE concentrations and mean or maximum yeast CLS 
are inverted U-shaped or J-shaped for all these PEs [Figures 5.1-5.6].   
5.3.4 Each of the fifteen geroprotective PEs intensifies mitochondrial respiration and 
alters the pattern of age-related changes in intracellular ROS  
            A distinct set of cellular processes is known to define the rate of yeast chronological aging 
[15, 17, 31, 32, 41, 59, 185, 238, 504-506]. These processes include coupled mitochondrial 
respiration [15, 17, 24, 32, 62, 118, 122, 125, 185]. We investigated how each of the fifteen 
geroprotective PEs influences an age-related chronology of changes in coupled mitochondrial 
respiration, which we measured as the rate of oxygen consumption by yeast cells. We found that 
each of these PEs causes a statistically significant increase in the rate of mitochondrial respiration 
on days 3 and 4 of culturing in the YNB medium initially containing 2% (w/v) glucose (Figure 
5.16). On these days of culturing in the YNB medium with 2% (w/v) glucose, yeast cells are known 
to enter and proceed through a stationary (ST) phase of culturing [461]. 
            We found that the fifteen geroprotective PEs belong to two different groups regarding their 
effects on the age-related dynamics of changes in coupled mitochondrial respiration under non-
CR conditions. The first group of these PEs includes PE47, PE64, PE69, PE72, PE75, PE77, PE79 
and PE81. Although all these geroprotective PEs allowed the yeast to maintain the rates of 
mitochondrial respiration significantly exceeding those in yeast subjected to ethanol-mock 
treatment, none of them prevented an age-related decline in mitochondrial respiration during the 
ST phase of culturing (Figures 5.16D, 5.16F, 5.16H, 5.16I, 5.16J, 5.16K, 5.16M and 5.16N). Of 
note, all geroprotective PEs from the first group were able to extend yeast CLS only under non-
CR conditions on 2% (w/v) glucose (Figures 5.8D, 5.8F, 5.8H, 5.9A, 5.9B, 5.9C, 5.9E and 5.9F) 
but not under CR conditions on 0.5% (w/v) glucose (Figures 5.12D, 5.12F, 5.12H, 5.13A, 5.13B, 
5.13C, 5.13E and 5.13F). The second group of geroprotective PEs includes PE26, PE39, PE42, 
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PE59, PE68, PE78 and PE83. These PEs increased the rate of mitochondrial respiration and 
sustained it high in ST-phase cultures that were recovered on day 4 (Figures 5.16A, 5.16B, 5.16C, 
5.16E, 5.16G, 5.16L and 5.16O). Noteworthy, all geroprotective PEs from the second group were 
able to extend yeast CLS under both non-CR conditions on 2% (w/v) glucose (Figures 5.8A, 5.8B, 
5.8C, 5.8E, 5.8G, 5.9D and 5.9G) and CR conditions on 0.5% (w/v) glucose (Figures 5.12A, 
5.12B, 5.12C, 5.12E, 5.12G, 5.13D and 5.13G). 
 
 
Figure 5.16. Each of the fifteen geroprotective PEs stimulates mitochondrial respiration in 
yeast cultured under non-CR conditions. WT cells were cultured in the synthetic minimal YNB 
medium initially containing 2% (w/v) glucose, in the presence of a PE or its absence. In the cultures 
supplemented with a PE, ethanol was used as a vehicle at a final concentration of 2.5% (v/v). In 
the same experiment, WT cells were also subjected to ethanol-mock treatment by being cultured 
in the synthetic minimal YNB medium initially containing 2% (w/v) glucose and 2.5% (v/v) 
ethanol. Oxygen uptake by live yeast cells was measured using polarography, as described in 
Materials and Methods. Age-related changes in the rate of mitochondrial oxygen consumption are 
shown. Data are presented as means ± SEM (n = 3; *p < 0.05, **p < 0.01, ns, not significant; the 
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p values for comparing the means of two in groups were calculated using an unpaired two-tailed t 
test as described in Materials and Methods). 
 
            The primary by-products of coupled mitochondrial respiration are several ROS [179, 376, 
507]. These ROS of mitochondrial origin are known for their essential roles in defining the rate of 
aging in organisms across species, including S. cerevisiae [121, 185, 376, 507-513]. 
            We found that all fifteen geroprotective PEs alter the age-related dynamics of changes in 
intracellular ROS (Figure 5.17). Each of these PEs slowed an age-related decline in intracellular 
ROS on days 3 and 4 of culturing, thus enabling a moderate but statistically significant rise in 
intracellular ROS during the ST phase (Figure 5.17). During the post-diauxic (PD) phase on day 2 
of culturing, most of the fifteen geroprotective PEs (other than PE69; Figure 5.17H) elicited a 
modest but statistically decline in intracellular ROS (Figure 5.17).    
            Noteworthy, as described below, we found that there are two different groups of 
geroprotective PEs with respect to their effects on intracellular ROS during the logarithmic (L) 
phase on day 1. 
            PE47, PE64, PE69, PE72, PE75, PE77, PE79 and PE81 did not elicit a substantial change 
in intracellular ROS during the L phase of culturing on day 1 (Figures 5.17D, 5.17F, 5.17H, 5.17I, 
5.17J, 5.17K, 5.17M and 5.17N). Al of them extended yeast CLS only under non-CR conditions 
on 2% (w/v) glucose (Figures 5.8D, 5.8F, 5.8H, 5.9A, 5.9B, 5.9C, 5.9E and 5.9F) but not under 
CR conditions on 0.5% (w/v) glucose (Figures 5.12D, 5.12F, 5.12H, 5.13A, 5.13B, 5.13C, 5.13E 
and 5.13F). 
            In contrast, PE26, PE39, PE42, PE59, PE68, PE78 and PE83 caused a substantial decline 
in intracellular ROS during the L phase of culturing on day 1 (Figures 5.17A, 5.17B, 5.17C, 5.17E, 
5.17G, 5.17L and 5.17O). All these geroprotective PEs stimulated mitochondrial respiration and 
sustained it high in ST-phase cultures (Figures 5.16A, 5.16B, 5.16C, 5.16E, 5.16G, 5.16L and 
5.16O). All of them were also capable of prolonging yeast CLS under both non-CR conditions on 
2% (w/v) glucose (Figures 5.8A, 5.8B, 5.8C, 5.8E, 5.8G, 5.9D and 5.9G) and CR conditions on 






Figure 5.17. Each of the fifteen geroprotective PEs alters the age-related chronology of 
changes in intracellular ROS in yeast cultured under non-CR conditions. WT cells were 
cultured in the synthetic minimal YNB medium initially containing 2% (w/v) glucose, in the 
presence of a PE or its absence. In the cultures supplemented with a PE, ethanol was used as a 
vehicle at a final concentration of 2.5% (v/v). In the same experiment, WT cells were also 
subjected to ethanol-mock treatment by being cultured in the synthetic minimal YNB medium 
initially containing 2% (w/v) glucose and 2.5% (v/v) ethanol. The intracellular concentrations of 
ROS were measured in live yeast by fluorescence microscopy of dihydrorhodamine 123 staining, 
as described in Materials and Methods. Age-related changes in the intracellular concentration of 
ROS are shown. Data are presented as means ± SEM (n = 3; *p < 0.05, **p < 0.01, ns, not 
significant; the p values for comparing the means of two in groups were calculated using an 
unpaired two-tailed t test as described in Materials and Methods). 
5.3.5 Each of the fifteen geroprotective PEs decreases the extent of age-related oxidative 
damage to cellular proteins, and many of them slow the aging-associated buildup of 
oxidatively impaired membrane lipids as well as mitochondrial and nuclear DNA  
            An age-related rise in the intracellular ROS above a toxic threshold has been shown to 
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cause oxidative damage to cellular proteins, lipids and nucleic acids [59, 123, 179, 372-379, 507, 
510-513]. The aging-associated accumulation of these oxidized macromolecules is one of the 
essential contributors to the aging process in yeast and other organisms [59, 123, 179, 372-379, 
507, 510-513]. 
            Each of the fifteen geroprotective PEs perturbed the age-related chronology of changes in 
intracellular ROS (see above). Therefore, we investigated whether each of them also influences 
the aging-associated accumulation of oxidatively impaired proteins, lipids and DNA in yeast cells 
cultured under non-CR conditions on 2% (w/v) glucose. 
            We found that all fifteen geroprotective PEs elicit a statistically significant decline in the 
abundance of oxidatively damaged (carbonylated) cellular proteins in ST-phase cultures recovered 
on day 4 (Figure 5.18). 
            We noticed that these geroprotective PEs belong to two different groups regarding their 
effects on the extent of protein carbonylation in yeast cells taken on day 1, 2 or 3 of culturing. 
            The first group of these PEs includes PE47, PE64, PE69, PE72, PE75, PE77, PE79 and 
PE81, all of which did not cause a statistically significant decline in the abundance of oxidatively 
damaged proteins within yeast cells recovered on day 1, 2 or 3 of culturing (Figures 5.18D, 5.18F, 
5.18H, 5.18I, 5.18J, 5.18K, 5.18M and 5.18N). All geroprotective PEs from the first group 
extended yeast CLS only under non-CR conditions on 2% (w/v) glucose (Figures 5.8D, 5.8F, 5.8H, 
5.9A, 5.9B, 5.9C, 5.9E and 5.9F) but not under CR conditions on 0.5% (w/v) glucose (Figures 
5.12D, 5.12F, 5.12H, 5.13A, 5.13B, 5.13C, 5.13E and 5.13F).  
            The second group of geroprotective PEs includes PE26, PE39, PE42, PE59, PE68, PE78 
and PE83, all of which substantially lowered the abundance of oxidatively damaged proteins in 
yeast recovered on day 1, 2 or 3 of culturing (Figures 5.18A, 5.18B, 5.18C, 5.18E, 5.18G, 5.18L 
and 5.18O). Only for PE78 and PE83 such effects on protein carbonylation were not statistically 
significant in yeast taken on day 1 of culturing (Figures 5.18L and 5.18O). All geroprotective PEs 
from the second group increased yeast CLS under both non-CR conditions on 2% (w/v) glucose 
(Figures 5.8A, 5.8B, 5.8C, 5.8E, 5.8G, 5.9D and 5.9G) and CR conditions on 0.5% (w/v) glucose 






Figure 5.18. Each of the fifteen geroprotective PEs decreases the extent of age-related 
oxidative damage to cellular proteins in yeast cultured under non-CR conditions. WT cells 
were cultured in the synthetic minimal YNB medium initially containing 2% (w/v) glucose, in the 
presence of a PE or its absence. In the cultures supplemented with a PE, ethanol was used as a 
vehicle at a final concentration of 2.5% (v/v). In the same experiment, WT cells were also 
subjected to ethanol-mock treatment by being cultured in the synthetic minimal YNB medium 
initially containing 2% (w/v) glucose and 2.5% (v/v) ethanol. The concentrations of oxidatively 
damaged (carbonylated) proteins were measured as described in Materials and Methods. Age-
related changes in the intracellular concentration (nmoles/mg protein) of carbonylated proteins are 
shown. Data are presented as means ± SEM (n = 3; *p < 0.05, **p < 0.01, ns, not significant; the 
p values for comparing the means of two in groups were calculated using an unpaired two-tailed t 
test as described in Materials and Methods). 
 
            Our analysis of how each of the fifteen geroprotective PEs influences the extent of 
oxidative damage to membrane lipids revealed that PE26, PE39, PE42, PE47, PE59, PE64, PE68, 
PE69, PE72, PE75, PE78 and PE83 statistically significantly decrease it in ST-phase cultures 
recovered on day 4 (Figures 5.19A-5.19J, 5.19L and 5.19O). For PE77, PE79 and PE81, a decline 
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in the abundance of oxidatively impaired membrane lipids in yeast cells taken on day 4 of culturing 
was noticeable but not statistically significant (Figures 5.19K, 5.19M and 5.19N). We also found 
that only those of the fifteen geroprotective PEs that extend yeast CLS under both non-CR and CR 
conditions significantly lower the abundance of oxidized membrane lipids even in yeast recovered 
on day 3 of culturing on 2% (w/v) glucose (Figures 5.19A, 5.19B, 5.19C, 5.19E, 5.19G, 5.19L and 
5.19O for PE26, PE39, PE42, PE59, PE68, PE78 and PE83). In contrast, a decline in the abundance 
of oxidatively damaged membrane lipids on day 3 of culturing on 2% (w/v) glucose was noticeable 
but not statistically significant for any of the geroprotective PEs that increased yeast CLS only 
under non-CR conditions (Figures 5.19D, 5.19F, 5.19H, 5.19I, 5.19J, 5.19K, 5.19M and 5.19N for 
PE47, PE64, PE69, PE72, PE75, PE77, PE79 and PE81). 
 
 
Figure 5.19. Many of the fifteen geroprotective PEs slow the aging-associated buildup of 
oxidatively impaired membrane lipids in yeast cultured under non-CR conditions. WT cells 
were cultured in the synthetic minimal YNB medium initially containing 2% (w/v) glucose, in the 
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presence of a PE or its absence. In the cultures supplemented with a PE, ethanol was used as a 
vehicle at a final concentration of 2.5% (v/v). In the same experiment, WT cells were also 
subjected to ethanol-mock treatment by being cultured in the synthetic minimal YNB medium 
initially containing 2% (w/v) glucose and 2.5% (v/v) ethanol. The concentrations of oxidatively 
damaged membrane lipids were measured as described in Materials and Methods. Age-related 
changes in the intracellular concentration (equivalents of nmoles H2O2/mg protein) of oxidatively 
damaged membrane lipids are shown. Data are presented as means ± SEM (n = 3; *p < 0.05, ns, 
not significant; the p values for comparing the means of two in groups were calculated using an 
unpaired two-tailed t test as described in Materials and Methods).  
 
            We also examined how each of the fifteen geroprotective PEs influences the extent of 
oxidative damage to mitochondrial DNA (mtDNA) and nuclear DNA (nDNA). The oxidative 
damage to each of these two types of DNA molecules is known to cause an aging-associated 
buildup of mutations in mtDNA and nDNA [514-518]. Therefore, we investigated the effect of 
each of the fifteen geroprotective PEs on the frequencies of spontaneous point mutations in the 
RIB2 and RIB3 genes of mtDNA [32, 110] as well as the frequencies of spontaneous point 
mutations in the CAN1 gene of nDNA [32 110]. We found that all fifteen geroprotective PEs 
statistically significantly decrease the incidences of rib2 and rib3 mutations in mtDNA of yeast 
recovered from the ST phase on day 4 but not on any other day of culturing (Figure 5.20). 
Furthermore, PE26, PE39, PE42, PE59, PE64, PE69, PE75, PE78, PE79 and PE81 caused a 
statistically significant decline in the frequencies of can1 mutations in nDNA of yeast cells that 
were taken from the ST phase on day 4 of culturing only (Figures 5.21A-5.21C, 5.21E, 5.21F, 
5.21H, 5.21J and 5.21L-5.21N). In contrast, neither PE47, PE68, PE72, PE77 nor PE83 elicited a 
significant change in the incidences of these mutations in nDNA of yeast recovered on any day of 




Figure 5.20. Each of the fifteen geroprotective PEs decreases the frequencies of rib2 and rib3 
mutations in mitochondrial DNA (mtDNA) of yeast cultured under non-CR conditions. WT 
cells were cultured in the synthetic minimal YNB medium initially containing 2% (w/v) glucose, 
in the presence of a PE or its absence. In the cultures supplemented with a PE, ethanol was used 
as a vehicle at a final concentration of 2.5% (v/v). In the same experiment, WT cells were also 
subjected to ethanol-mock treatment by being cultured in the synthetic minimal YNB medium 
initially containing 2% (w/v) glucose and 2.5% (v/v) ethanol. The incidences of spontaneous point 
mutations in the RIB2 and RIB3 genes of mtDNA were measured as described in Materials and 
Methods. Age-related changes in the frequencies of these mtDNA mutations are shown. Data are 
presented as means ± SEM (n = 3; *p < 0.05, ns, not significant; the p values for comparing the 
means of two in groups were calculated using an unpaired two-tailed t test as described in Materials 











Figure 5.21. PE26, PE39, PE42, PE59, PE64, PE69, PE75, PE78, PE79 and PE81 (but not 
PE47, PE68, PE72, PE77 or PE83) cause a statistically significant decline in the frequencies 
of can1 mutations in nuclear DNA (nDNA) of yeast cultured under non-CR conditions. WT 
cells were cultured in the synthetic minimal YNB medium initially containing 2% (w/v) glucose, 
in the presence of a PE or its absence. In the cultures supplemented with a PE, ethanol was used 
as a vehicle at a final concentration of 2.5% (v/v). In the same experiment, WT cells were also 
subjected to ethanol-mock treatment by being cultured in the synthetic minimal YNB medium 
initially containing 2% (w/v) glucose and 2.5% (v/v) ethanol. The incidences of spontaneous point 
mutations in the CAN1 gene of nDNA were measured as described in Materials and Methods. Age-
related changes in the frequencies of these nDNA mutations are shown. Data are presented as 
means ± SEM (n = 3; *p < 0.05, ns, not significant; the p values for comparing the means of two 
in groups were calculated using an unpaired two-tailed t test as described in Materials and 
Methods). 
5.3.6 Each of the fifteen geroprotective PEs increases cell resistance to long-term 
oxidative and thermal stresses   
            Genetic, dietary and chemical interventions that decrease cell susceptibility to chronic 
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(long-term) oxidative and/or thermal stresses have been shown to decelerate the aging process and 
extend longevity in yeast and other organisms across species [15, 17, 32, 68, 112, 178, 179, 254, 
380-382, 501, 503]. Therefore, we investigated the effect of each of the fifteen geroprotective PEs 
on the susceptibility of chronologically aging yeast cells to these two types of chronic stresses.  
            To examine aging-associated changes in cell susceptibility to these long-term stresses, we 
recovered aliquots of yeast cells on days 1, 2, 3 and 4 of culturing under non-CR conditions in 
liquid YNB medium with 2% (w/v) glucose. To assess cell susceptibility to chronic oxidative 
stress, we spotted serial dilutions of these cell aliquots on solid YEP medium with 2% (w/v) 
glucose and 5 mM hydrogen peroxide and incubated them for 3 days. To assess cell susceptibility 
to chronic thermal stress, we spotted serial dilutions of these cell aliquots on solid YEP medium 
with 2% (w/v) glucose, incubated at 60oC for 60 min, transferred the plates to 30oC and incubated 
at this temperature for 3 days. 
            We found that each of the fifteen geroprotective PEs makes yeast cells more resistant to 
chronic oxidative and thermal stresses, especially cells in ST-phase cultures recovered on days 3 




Figure 5.22. Each of the fifteen geroprotective PEs makes yeast more resistant to chronic 
(long-term) oxidative and thermal stresses. WT cells were cultured in the synthetic minimal 
YNB medium initially containing 2% (w/v) glucose, in the presence of a PE or its absence. In the 
cultures supplemented with a PE, ethanol was used as a vehicle at a final concentration of 2.5% 
(v/v). In the same experiment, WT cells were also subjected to ethanol-mock treatment by being 
cultured in the synthetic minimal YNB medium initially containing 2% (w/v) glucose and 2.5% 
(v/v) ethanol. Spot assays for examining cell resistance to chronic oxidative (B) and thermal (C) 
stresses were performed as described in Materials and Methods. (A) In control samples, serial 10-
fold dilutions of cells recovered on different days of culturing were spotted on plates with solid 
YEP medium containing 2% (w/v) glucose. All pictures were taken after a 3-d incubation at 30oC. 
(B) In samples subjected to long-term oxidative stress, serial 10-fold dilutions of cells recovered 
on different days of culturing were spotted on plates with solid YEP medium containing 2% (w/v) 
glucose and 5 mM hydrogen peroxide. All pictures were taken after a 3-d incubation at 30oC. (C) 
In samples subjected to long-term thermal stress, serial 10-fold dilutions of cells recovered on 
different days of culturing were spotted on plates with solid YEP medium containing 2% (w/v) 
glucose, incubated at 60oC for 60 min and then transferred to 30oC. All pictures were taken after a 





            We discovered fifteen PEs that extend the longevity of chronologically aging budding 
yeast. All these PEs originate from plants used in traditional Chinese and other herbal medicines 
or the Mediterranean and other long-established diets. However, none of these PEs has been 
previously known for its ability to prolong lifespan in yeast or other organisms.     
          Our data indicate that each of the fifteen longevity-extending PEs prolongs yeast CLS not 
because it slows the metabolism of glucose, the only source of carbon and energy added to the 
growth medium. We also revealed that the longevity-extending ability of each of the fifteen PEs 
is not caused by its negative effect on the proliferation of yeast cells. Thus, it seems likely that 
none of these PEs can prolong yeast CLS because it slows the formation and release of harmful 
products of cell proliferation. 
           Our study provides evidence that each of the fifteen longevity-extending PEs satisfies all 
the criteria previously proposed for a CRM. CRMs are chemical interventions that can mimic the 
CR-like lifespan-increasing and healthspan-improving effects even if calorie supply is not limited 
[491-496]. Indeed, we uncovered the following. First, each of the fifteen PEs prolongs yeast CLS 
under non-CR conditions. Second, none of these PEs impairs glucose uptake and metabolism. 
Third, each of them exhibits CR-like effects on specific aspects of metabolism and physiology; 
these effects include an increased rate of coupled mitochondrial respiration, an altered chronology 
of changes in intracellular ROS, and a decline in the oxidative damage to cellular proteins, 
membrane lipids and mtDNA. Fourth, each of them makes cells more resistant to long-term 
oxidative and thermal stresses. Of note, PE26, PE39, PE42, PE59, PE68, PE78 and PE83 can 
prolong yeast CLS even under CR conditions, when all cellular processes that limit longevity under 
non-CR conditions are likely to be suppressed. Therefore, it seems conceivable that each of these 
seven PEs may stimulate the longevity-extending cellular processes and/or may suppress the 
longevity-shortening cellular processes that operate only under CR conditions. 
            Our analyses of the Gompertz mortality rates and dose-response curves have led us to the 
following two conclusions. First, each of the fifteen PEs prolongs yeast CLS because it is a 
geroprotective agent that decreases the rate of chronological aging but has no effect on the baseline 
mortality rate. Second, each of these PEs promotes a hormetic stress response in chronologically 
aging yeast.  
            In this study, we discovered that the fifteen geroprotective PEs differently affect three 
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groups of cellular processes in chronologically aging yeast, as summarized below.  
            First, each of the fifteen geroprotective PEs significantly increases the rate of coupled 
mitochondrial respiration and slows a decline in intracellular ROS (known to be the primary 
products of mitochondrial respiration) within yeast cells that enter and proceed through the ST 
phase of culturing.  
            Second, each of them substantially suppresses oxidative damage to cellular proteins and 
mtDNA in ST-phase yeast cells that enter day 4 of culturing. We noticed that twelve of these 
geroprotective PEs also significantly decrease oxidative damage to membrane lipids in ST-phase 
yeast cells on day 4, whereas PE77, PE79 and PE81 cause a statistically insignificant decline in 
oxidized membrane lipids within these cells. We also found that ten of these geroprotective PEs 
significantly reduce oxidative damage to nDNA, while neither PE47, PE68, PE72, PE77 nor PE83 
exhibits such effect on nDNA.  
            Third, each of them significantly decreases cell susceptibility to long-term oxidative and 
thermal stresses, especially the susceptibility of yeast cells that enter and proceed through the ST 
phase of culturing. 
5.4.1 Future perspectives 
            Our goals for the future research of the fifteen geroprotective PEs described here are 
outlined below. 
            First, we are interested in investigating and understanding the molecular and cellular 
mechanisms through which each of these PEs slows yeast chronological aging. We have recently 
described mechanisms underlying the aging-delaying action of PE21 [519], an extract from the 
white willow Salix alba we discovered in our previous screen for geroprotective PEs [461].               
            Second, we would like to explore how each of the fifteen geroprotective PEs may 
coordinate the information flow through a longevity-defining network of signaling pathways and 
protein kinases operating in budding yeast and other organisms. This network incorporates the pro-
aging TORC1, PKA and PKH1/2 pathways as well as the pro-aging serine/threonine-protein 
kinase Sch9 [11, 15, 17, 477]. This network also integrates the anti-aging SNF1 and ATG pathways 
as well as the anti-aging serine/threonine-protein kinase Rim15 [11, 15, 17, 477]. Our recent study 
has revealed that each of the six geroprotective PEs we discovered in the previous screen [461] 
slows yeast chronological aging through different functional modules of this longevity-defining 
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signaling network [477]. Of note, pairwise mixes of these six geroprotective PEs slow the process 
of yeast chronological aging in a synergistic or additive manner only if they include the PEs that 
target different modules of this network [520]. Therefore, we are interested in investigating how 
different combinations of the fifteen geroprotective PEs described here influence the extent of 
yeast chronological aging delay. We will be looking for the combinations of geroprotective PEs 
that exhibit synergistic or additive effects on the extent of yeast chronological aging delay.  
            Third, the Health Canada government agency defines thirteen of the fifteen geroprotective 
PEs described here as the ones that are safe for human consumption [476]. The agency 
recommends using eight of them as health-improving supplements with clinically proven benefits 
to human health [476]. Among these health-improving PEs are PE26, PE47, PE59, PE64, PE69, 
PE75, PE77 and PE83 [476]. For each of them, Health Canada provides a detailed description of 
the source material, routes of administration, doses and dosage forms, uses or purposes, durations 
of use, risk information, cautions and warnings, contraindications, known adverse reactions, non-
medicinal ingredients, specifications, references cited and reviewed, examples of appropriate 
dosage preparations, and frequencies of use [476]. Our ongoing collaborative research aims to 
investigate which of the eight geroprotective PEs recommended by Health Canada as healthspan-
extending dietary additives for humans can increase the replicative lifespan of cultured human 
fibroblasts or for delaying the onset of aging-associated human diseases. These diseases include 
arthritis, diabetes, heart disease, kidney disease, liver dysfunction, sarcopenia, stroke, 
neurodegenerative diseases (including Parkinson's, Alzheimer's and Huntington's diseases), and 
many forms of cancer [11, 23, 26, 50, 56, 114-116, 335, 338, 339, 342, 359, 460, 469-472, 474, 











6 General discussion 
            In studies presented in this thesis, we used a robust cell viability assay to conduct two 
screens of commercially available plant extract libraries in search of those plant extracts (PEs) that 
can delay chronological aging and prolong the longevity of the budding yeast S. cerevisiae. Many 
of the PEs in the library have been used for centuries in traditional Chinese and other herbal 
medicines or the Mediterranean and other customary diets. Of note, none of these PEs was 
previously tested for its ability to slow aging and extend the longevity of any organism. Our screens 
have allowed us to discover twenty-one PEs that significantly prolong the longevity of 
chronologically aging yeast cells that are not limited in calorie supply. We provided evidence that 
each of these longevity-extending PEs is a geroprotector that lowers the rate of yeast chronological 
aging and elicits a hormetic stress response. Our findings demonstrated that the efficiencies of 
aging delay and longevity extension by many of these geroprotective PEs significantly exceed 
those for any of the chemical compounds previously known for their abilities to slow aging and 
prolong lifespan in yeasts, filamentous fungi, nematodes, fruit flies, daphnias, mosquitoes, honey 
bees, fishes, mammals and cultured human cells. Our findings also revealed that each of the 
twenty-one geroprotective PEs mimics the aging-delaying, longevity-extending, stress-protecting, 
metabolic and physiological effects of a caloric restriction diet in yeast cells that are not limited in 
calorie supply. We also demonstrated that the discovered geroprotective PEs elicit partially 
overlapping effects on a distinct set of longevity-defining cellular processes. Such processes 
include the coupled mitochondrial respiration, maintenance of the electrochemical potential across 
the inner mitochondrial membrane, preservation of the cellular homeostasis of reactive oxygen 
species (ROS), protection of cellular macromolecules from ROS-inflicted oxidative damage, 
maintenance of cell resistance to oxidative and thermal stresses, the efficiency of the lipolytic 
cleavage of neutral lipids deposited and stored in lipid droplets (LDs). We provided evidence that 
some of the discovered geroprotective PEs slow yeast chronological aging because they target 
different hubs, nodes and/or links of the longevity-defining network integrating specific 
evolutionarily conserved signaling pathways and protein kinases. 
            A challenge for the future is to characterize the individual chemical compounds responsible 
for the ability of each of the discovered geroprotective PEs to postpone the onset and decrease the 
rate of yeast chronological aging. Such characterization is already underway in our laboratory. 
Furthermore, the other future challenge is to investigate and understand the molecular and cellular 
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mechanisms through which each of the discovered geroprotective PEs slows the chronological 
mode of aging in S. cerevisiae. Moreover, our ongoing collaborative research aims to investigate 
which of the thirteen (out of twenty-one)  geroprotective PEs recommended by Health Canada as 
healthspan-extending dietary additives for humans can increase the replicative lifespan of cultured 
human fibroblasts or for delaying the onset of aging-associated diseases in mice models. These 
diseases include arthritis, diabetes, heart disease, kidney disease, liver dysfunction, sarcopenia, 
stroke, neurodegenerative diseases (including Parkinson's, Alzheimer's and Huntington's 
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